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Abstract:
Prostatic  Intraepithelial  Neoplasia  (PIN)  is  a  putatitive  precursor  of prostate 
carcinoma  (CaP).  PIN  is  defined  as  an  abnormal  proliferation  where  the 
cellular changes  exhibit  the  cytological  changes  of cancer,  but  retain  a  basal 
cell  layer.  Using  radical  prostatectomy  specimens  we  have  studied  the 
relationship between PIN and carcinoma of the prostate.
Method:
This study was divided into two parts:
1)  Step sections from 76 consecutive radical prostatectomy specimens 
were examined prospectively.  Using planimetry software  the  total 
volume  of the  gland,  the  volume  of cancer,  the  volume  of benign 
tissue, and the volume of PIN was calculated.  These volumes were 
compared to serum PSA.
2)  The expression of P5 3, bcf. baxaiPha, and Ki-67  was measured using 
semi  quantitative  immunohistochemistry  in  92  hormone  naive 
specimens as well  as specimens from  14 patients who had received 
androgen  ablation.  Benign  prostate  specimens  obtained  from  19 
patients  were  used  as  controls.  This  was  carried  out 
retrospectively.
Results:
The  mean  weight  of the  prostate  gland  was  61.3  (range  =  26  -   173)  g,  the 
mean  calculated  total  volume  of the gland  was  50.9  (range  19.4 -155.5)  mis, 
the mean  volume of cancer was 2.5  (range = 0.09 -   15) mis, the mean volume 
of PIN was 0.53 (range = 0 - 2.7) mis, and the mean volume of benign tissue in 
each gland was 47.5 (range =  13.3 -   153.4) mis.  The mean value for the PSA=
9.1  (range = 3-45) ng/ml.
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The  calculated  volume  of the  gland  correlated  with  the  weight  of the  gland 
(p<0.0005, r=0.9353). The cancer volume also had an inverse correlation with 
the  benign  and  the  total  volume  of  the  gland  (p<001).  The  volume  of PIN 
correlated with the total volume of the gland.
Prostate  weight,  volume  and  cancer  volume  independently  correlated  with 
serum PSA.  The  volume of PIN did not correlate with  serum  PSA.  1   gram of 
benign  tissue  correlated  with  0.07  ng/ml  of  serum  PSA,  and  one  gram  of 
malignant correlated with 0.8 ng/ml of serum PSA.
The expression  of p.s.i increased  in a stepwise manner, 0/19  benign, 5/92  PIN, 
and  9/92  CaP,  but  the  increase  was  not  significant.  Bcb  was  expressed  in 
75/92  PIN  specimens,  27/92  Ca  P  and  0/19  benign  specimens  (p<0.05). 
Baxa|pa  expression  was  ubiquitous,  but  staining  intensity  increased  when 
comparing benign  with  PIN  or CaP (p<0.05).  Ki-67 expression  was absent  in 
benign  tissue  and  expressed  in  91/92  PIN  specimens,  and  92/92  with  CaP 
(p<0.05).  In  the  subset  of  patients  treated  with  androgen  ablation  areas  of 
cancer were compared with specimens from the hormone naive group. P53 was 
expressed  in  4/14  pts  (p=0.07),  bcl-2  expression  occurred  in  9/14  (p<0.05), 
baxaipa-staining  intensity  decreased  (p<0.05),  and  the  number  of  cell 
expressing Ki-67 decreased (p<0.05).
Conclusions:
PIN  volume  correlates  directly  with  gland  volume,  the  volume  of  cancer 
correlates  inversely  with  the  volume  of  benign  tissue.  1  gram  of  malignant 
tissue  correlates  with  eleven  times  as  much  serum  PSA  when  compared  to 
benign  tissue.  The  volume  of PIN does  not  have  any  relationship  with  serum 
PSA.
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P53  expression  is  infrequent  and  may not  be  important  in  the  early genesis of 
CaP. BcP expression  increases from benign to PIN and decreases in CaP.  It is 
expressed  in  the  luminal  cells,  and confers  relative  immortality,  resistance  to 
cytotoxics  and  androgen  ablation.  Therefore,  PIN  luminal  cells  may  have  the 
survival  advantage  required  for  progression  from  PIN  to  CaP,  and  are 
relatively  resistant  to  intervention.  These  cells  may  also  represent  the 
precursors of androgen  resistant clones.  The  increased  intensity of baxaipha  in 
CaP,  allows  it to be amenable to therapeutic  intervention.  Ki-67 positive cells 
shift from  basal  to luminal  as one progresses from  benign to  malignant tissue. 
This implies increasing cell production in areas of malignant tissue.
Androgen  ablation  leads  to  a  decrease  in  Ki-67  staining,  an  increase  in  the 
proportion of specimens expressing bcl2 and P5 3, and a decrease in the staining 
intensity for baxaipha.  Therefore LHRH decreases the production of cells,  may 
use  p5 3-mediated  pathways  for apoptosis  and  by  up  regulating  the  expression 
of bcbmay cause the selection of androgen resistant immortal clones.
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Chapter 1: Introduction
l.I  Embryology and Foetal Pre-Pubertal Histology
The  male foetus under the control of the product of the SRY gene from the Y 
chromosome  produces  the  SRY  protein.  The  SRY  protein  initiates  a 
developmental  cascade  which  results  in  the  formation  of  the  testis,  male 
genital  ducts,  and associated glands,  the male external genitalia,  and the entire 
constellation of male secondary sex characteristics.
In  the  third  month  the  indifferent pelvic  urethra is  transformed.  The  prostate
1  T
begins development from the mesenchyme surrounding the urogenital  sinus  “. 
Its  development  depends  upon  dihydrotestosterone,  which  is  produced  from
g c
foetal  testosterone by the enzyme 5-alpha reductase  in the  urogenital  sinus  . 
Epithelial  buds invaginate from the posterior urogenital sinus on either side of 
the verumontanum.  Simultaneously the mesonephric (Wolfian) ducts develop 
into  the  seminal  vesicles,  epididymis,  vas  deferens,  and  ejaculatory  ducts, 
which  are  stimulated  by  foetal  testosterone.  By  16  weeks  of  gestation  the 
basic structure of the prostate is complete.
The glandular buds,  in the foetal prostate, develop as solid outgrowth of cells. 
Small  lumina  develop  lined  by  cuboidal  or  columnar  epithelium  m .  These 
glands  are  simple  tubular  structures  without  significant  branching,  and  areProstatic Intraepithelial Neoplasia and Prostate Cancer.
lined  by  multiple  layers  of  immature  cells  with  round  nuclei  and  scant 
cytoplasm.
1.2  Gross Anatomy of the prostate.
The non-pathological prostate in the post pubescent male weighs  12-20g and is 
the  shape  of an  inverted cone.  The  size of the prostate enlarges  with  age,  in 
those  that  are  over  40,  the  average  prostate  is  the  size  of  a  walnut  and 
measures  approximately  4.0-4.5cm  (transverse  diameter),  2.5-3.0  cm  (a-p 
diameter), and 3.0-4.0cm  (cephal-caudal diameter).
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________________
Fig.l:  A  prostatectomy  specimen  obtained  from  a  retropubic  radical 
prostatectomy.
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A  pseudo  capsule  that  is  indistinct  from  the  surrounding  fascial  tissue 
surrounds  the  prostate.  The  surgical  capsule  is  not  a  histological  entity,  but 
consists of an extension of prostatic parenchyma with dense fibrous tissue and 
smooth  muscle  that connect  with  the  muscular  layers  of the prostatic  urethra 
and cannot be separated from the prostate without tearing the glandular tissue. 
This  tissue  is  thicker  anterior  and  thins  as  it  surrounds  the  prostate  laterally 
and posterior.  The pseudo-capsule has a number of areas of weakness:
i.  The insertion of the neurovascular bundles
ii.  The insertion of the ejaculatory ducts
iii.  The insertion of the internal sphincter
iv.  At the apex and in the region of the levator ani
v.  And at the base where the bladder impinges  upon the prostate.
At  the  apex,  skeletal  muscle  is  often  mixed  with  prostatic  glands  and  so  the 
boundary  is often obscure.  This vagueness as  to  what constitutes  the edge of 
the  prostate  has  important  implications for assessing extra prostatic  extension 
by carcinoma or whether the capsule has been cut into.
The prostate  is  superior to the  levator ani  and is separated anteriorly from the 
pubic symphysis and the pubic bones by the veins of Santorini, fat,  lymphatic, 
nerves  and  fascial  tissues.  Laterally  the  prostate  is  bound  by  the  obturator 
internus.  Posteriorly  areolar  tissue  and  Denonvillier’s  fascia  separate  the
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prostate from the rectum.  Cranially the prostate is attached to the bladder; the 
paired  seminal  vesicles  are  situated  on  the  postero-superior  aspect  of  the 
prostate separating the bladder from the rectum.
The caudal tip of the prostate, the apex, is where the urethra exits the prostate. 
The anterior aspect of the prostate  is attached to the pubic  symphysis  and  the 
pubis  bones  by  the  puboprostatic  ligaments.  The  posterior  surface  of  the 
prostate  contains  a  central  furrow  the  median  sulcus.  The  prostatic  urethra 
runs  from  the  bladder  to  the  prostate  via  the  horse  shoe  shaped  internal 
sphincter,  which  is  at  the  base  of the  gland.  It  exits  the  horseshoe  shaped 
external  sphincter  at  the  apex  of  the  prostate  where  it  becomes  the 
membranous urethra.  The prostatic urethra does not follow a straight line as it 
traverses  the  gland  but  bends  anteriorly  approximately  35  degrees  at  the 
verumontanum.  There  are  two  bilaterally  paired  ejaculatory  ducts  that  pass 
from  the  junction  of  the  medial  vas  and  the  lateral  seminal  vesicles,  and 
anteriorly and inferiorly as they join the prostatic urethra at the verumontanum.
The  internal  sphincter  is  in  the  region  of the  proximal  prostatic  urethra  and 
consists of urethral musculature with incorporation of both collagen and elastic 
fibres.  The  external  sphincter at  the  level  of the  levator  ani  is  composed  of 
striated  muscle.  It  surrounds  the  membranous  urethra  and  extends  into  the 
prostate.
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There are two significant groups of vessels in close relation to the prostate, the 
neurovascular  bundles  (described  by  Walsh)  and  Santorini’s  plexus. 
Santorini’s  plexus  has  minimal  perforating  vessels  involving  the  prostate 
capsule.  Its major feeding vessels are the deep vein of the penis,  but there are 
some  small  tributaries  from  the  prostate.  The  neurovascular  bundle,  as  its 
name  implies,  is  a  mixture  of  the  arteries,  veins  and  nerves.  These  are 
bilateral,  paired  and  run  from  the  apex  of the  gland  towards  the  tips  of the 
seminal  vesicles  and  the  bladder.  The  bundles  perforate the prostate capsule, 
and  so  allow  a  conduit  for  the  spread  of tumour  at  these  potential  sites  of 
capsular weakness.  The bundles were initially thought to be discrete structures 
at the base of the gland that could be dissected off.  However recent work has 
suggested that this may be the case in the foetus, but in the adult as the prostate 
grows  the  ejaculatory  nerves  along  with  the  prostatic  fascia  form  a  concave 
curtain around the prostate234.
During  surgery  for  the  prostate  the  neurovascular  bundles  have  a  major 
implication  with  respect  to  the  management  of  cancer  and  the  potential 
morbidity associated with the operation.  The other arterial structures are:
i)  A  basilar  branch  of  feeding  vessels  course  inferior  to  the  seminal 
vesicles, enter the prostate at the base of the gland along the ejaculatory
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ducts, and then courses to the level of the verumontanum.
ii)  An apical  branch,  which enters the  inferior portion of the prostate and 
courses to and feeds the surgical capsule.
iii)  Urethral  and  inner  gland  flow  is  from  a  combination  of  the 
anterolateral  and  posterolateral  vessels,  coursing  through  the  outer 
gland.
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1.3  Lowsley’s (lobar) anatomy:
The  traditional description of the prostate divided it into five major lobes 23’.
i)  The  anterior  lobe,  which  is  between  the  prostatic  urethra  and  the
anterior aspect of the prostate.  This area arises from  the  ventral  walls 
of the urethra.
ii)  The  median  or middle  lobe,  which  is  defined  as  the  area  between  the
prostatic  urethra anteriorly  and  the ejaculatory ducts posteriorly.  This 
area arises from  the rectal  surface of the urethra and the  lies above the 
orifices of the ejaculatory ducts.
iii)  The  posterior lobe which extends anteriorly from  the ejaculatory ducts
to the posterior surface of the gland.  This area arises  from  the urethra 
below the ejaculatory ducts.
iv)  and  v) the two lateral  lobes which are relatively symmetrical  and arise
from the lateral walls of the urethra.
The Lowsley classification  is used everyday in clinical  urology,  however it  is
limited in its use as a means of interpreting histological anatomy.
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1.4  McNeal’s (Zonal) Classification:
^48 This separates the prostate into the following four zones "  :
i)  The peripheral (outer -  posterior and lateral)
ii)  The central,
iii)  The  preprostatic  region  which  encompasses  the periurethral  ducts  and
the transition zone
iv)  The anterior fibro muscular stroma.
The anterior fibro muscular stroma consists of 33% of the prostate;  it contains 
very few  glands  and consists of smooth  muscle  and dense  fibrous tissue. The 
anterior fibro muscular stroma blends with the internal sphincter of the bladder 
neck proximally and  the  striated  muscle of the external  sphincter at the  apex. 
The  central  zone  surrounds  the  ejaculatory  ducts  with  its  apex  at  the  veru 
montanum; this region is thought to originate from the mesonephric (Wolfian) 
duct,  similar  to  the  seminal  vesicle.  The  peripheral  and  central  zones  are 
glandular  (acinar),  the  majority of the  prostate  is  composed  of the  peripheral 
region (75%). The peripheral zone is distal to the central zone and corresponds 
to  a  horseshoe  shaped  structure  extending  posteriorly,  posteriolaterally  and 
laterally.  The  majority  of  tumours  arise  in  the  peripheral  zone,  and  the 
majority  of  benign  disease  occurs  in  the  transition  zone  of  the  preprostatic 
region.  The  periurethral  region  consists  of  cylindrical  smooth  muscle
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sphincter surrounding the urethra and extending from the verumontanum to the 
bladder neck.  The transition zone consists of ducts,  which extend  laterally in 
the region of the verumontanum.  The transition zone in health consists of only 
5%  of the  normal  prostate  but  it  may grow  considerably  in  benign  glandular 
stromal hyperplasia.
This zonal classification is often simplified to a two-zone concept i.e.
i)  inner (transition) zone, and
ii)  outer (central and peripheral) zone.
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Transition zone
Central zone
Anterior fibromuscular stroma
Peripheral zone
Uay'or Coi'ege ot Med*one 1990
Figure2: McNeals Zonal Classification.
The  transition  zone  surrounds  the  urethra  proximal  to  the  ejaculatory 
ducts.  The  central  zone  surrounds  the  ejaculatory  ducts,  and  the 
peripheral  zone  consists  of  apical,  posterior  and  lateral  regions  of  the 
prostate248.
28Prostatic Intraepithelial Neoplasia and Prostate Cancer.
1.5  Histology:
The  prostate  consists  of  stromal  (smooth  muscle  cells,  fibroblasts  and 
endothelial cells) and epithelial cells. The epithelial cells line the alveoli.  The 
epithelial  cells  consist  of  columnar  secretory  cells,  basal  cells  and  neuro 
endocrine cells.  The tall columnar cells are secretory and are attached to each 
other  by  cadherins  and  to  the  basement  membrane  by  integrins  attached  to 
laminin and fibronectin.  These cells are terminally differentiated.
The basal cells lie beneath the secretory cells, and lie parallel to the basement 
membrane.  The cells  are  elongated  and  are  less differentiated  than  secretory 
cells.  Basal  cells  are  thought  to be  the  progenitors  of secretory cells.  Basal 
cells are absent in adenocarcinoma of the prostate.
Neuroendocrine  cells  are  present  within  the prostatic  ducts  and  acini,  and  in 
the  urothelium  of  the  prostatic  urethra  3.  These  cells  may  function  by 
endocrine,  paracrine,  neurocrine,  and  lumencrine  mechanisms.  They  play  an 
important  regulatory  role,  both  during  growth  and  differentiation  of  the 
prostate and also in the secretory process of the mature gland.
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1.6  Prostate Cancer
Fig 3: General Norman Schwarzkopf on the cover of Time, April 1996, 
having been diagnosed with prostate cancer.
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1.61  Epidemiology
In 2002, 8277 deaths occurred due to carcinoma of the prostate in England and
->87
Wales- the second commonest cancer related cause of death"  Data from the 
Office  of Population  Censuses  and  Surveys  (OPCS)  has  recorded  an  increase 
in  the  incidence from  34.0 per  100,000 in  1980 to  79.3  per  100,000  in  2002. 
The OPCS  believe  that the  increase  in  the  incidence  is not only due to  better 
detection  but  also  the  underlying  prevalence  of  the  prostatic  carcinoma  is 
increasing.  An  ageing  population  coupled  with  an  increased  awareness 
amongst  the  medical  profession  and  the  lay  public  are  also  contributory 
factors.  However an  obvious  disparity exists  between  the  number of patients 
with carcinoma of the prostate and the number that succumb to the disease.
1.62  Aetiology
A number of risk factors have been implicated, age is the most important, 95% 
of cases occur between 45  and 89 years, the median age of presentation being 
72;  90%  of deaths  occur  after  65  at  a  median  age  of 77  years.  Post-mortem 
studies  have  revealed  40%  of  90-year-old  patients  have  carcinoma  of  the 
prostate.  Race  is  a  risk  factor,  blacks  are  affected  more  than  whites  and 
Oriental’s  have  the  lowest  prevalence.  The  highest  prevalence  is  amongst 
black men in Washington DC71.
An  individual’s  risk  is  increased  three  fold  if  a  first-degree  relative  has
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carcinoma of the prostate.  A group from the University of Utah is undertaking
^ 52 genealogy studies with the large Mormon population in Utah"  and a group at 
the Royal Marsden  is studying familial  prostate cancer111.  A high fat diet has 
also  been  implicated,  as  have  androgens.  Androgens  are  essential  for  gland 
proliferation  and  in  experimental  models  induce  carcinoma  of  the  prostate. 
There  is  no clear relationship between  serum  testosterone  levels  and prostatic 
carcinoma but patients with low levels have a poor response to treatment.
1.63  Presentation
Carcinoma of the  prostate  presents  principally  in  four ways.  Patients  present 
with  symptoms  of  bladder  outlet  obstruction  (this  used  to  be  the  majority), 
secondly an incidental finding upon histopathological examination of prostatic 
chips,  thirdly  patients  may  present  with  metastatic  disease,  and  finally 
screening  whether  it  is  specifically for carcinoma of the  prostate  or a routine 
examination. Among men with newly diagnosed carcinoma of the prostate one 
third  have  distant  metastasis,  10-15%  have  locally  extensive  tumour  (about 
half  have  lymph  node  metastasis),  and  50-60%  have  clinically  localised 
disease  (a  third  have  lymph  node  metastasis).  Thus  two-third  of  newly 
diagnosed patients have disease which is not localised and so is amenable only 
to palliation 34(> .
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1.64  Diagnosis
Fig 4: The digital rectal examination still remains important.
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Three primary diagnostic tests exist to initiate histological or cytological tissue 
sampling:  digital  rectal  examination  (DRE),  trans-rectal  ultrasound  (TRUS), 
and prostate specific antigen (PSA).  The clinical  impression of the examining 
urologist correlates well with the positive predictive value of DRE.  On biopsy 
samples from clinically normal prostates a positive predictive value of 2% was 
calculated, compared to 83% on those with marked induration 363.
Transrectal  ultrasound  is the commonest modality used to  image the prostate. 
It  is  of  limited  benefit  with  a  distinctly  palpable  lesion.  However  when  the 
DRE is unremarkable  and the PSA  is raised the positive predictive  value of a 
TRUS guided biopsy is  16.4%.  If the PSA is normal and the DRE is abnormal 
it  is  13%,  and  if  both  tests  are  unremarkable  it  falls  to  9.3%88.  If  DRE  is 
abnormal and a digitally guided biopsy result is benign then in the same cohort 
a TRUS guided biopsy will be positive in 53% of patients  l64.  The addition of 
sextant biopsies  further improves  the detection  rate  165  and  more  recent  work 
has  shown  that  increasing  the  number  of  biopsies  as  a  factor  of  the  gland 
volume leads to further improvements in detection rate104 237.  Up to six sets of 
biopsies may be necessary to rule out cancer of the prostate324.
Prostate  specific  antigen  is  the  best  marker  for  prostatic  carcinoma  and 
probably  the  best  tumour  marker  currently  available.  It  is  an  established
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immunohistochemical  marker and  is  used  to monitor patients.  It can  also  be 
used  to  aid  staging  and  diagnosis,  and  proponents  of  screening  strongly 
advocate its use as a screening tool.  PSA is a serine protease secreted into the 
ductal system of the prostate where it is thought to catalyse the liquefaction of 
the  seminal  coagulum  after  ejaculation.  However,  it  does  not  explain  the 
clotting  and  liquefaction  of  semen,  which  is  so  important  for  reproduction. 
Any  process  that  disrupts  the  normal  architecture  of  the  prostate  allows 
diffusion of PSA  into the  stroma;  here it gains access  to the  blood  stream  via 
the  stromal  micro  vasculature.  Elevated  levels of serum  PSA  are detected  in 
prostatitis,  infarcts,  benign  prostatic  hypertrophy,  transiently  after  prostatic 
manipulation  and  with  prostatic  adenocarcinoma.  Cancer  produces  less  PSA 
per cell  than  benign epithelium  but the greater number of malignant cells and 
the  stromal  disruption  associated  with  cancer  account  for  the  clinically 
important  elevation  in  serum  PSA  levels  u .  The  higher  the  grade  of  the 
cancer,  the  less  differentiated  the  cells  and  the  less  PSA  is  produced  with 
Gleason grade 5 tumours contributing relatively little PSA to the serum PSA5
A  number of PSA  parameters  have  been described  to  improve  its  sensitivity, 
specificity, and clinical utility.  The normal range of PSA is less than 4.0ng/ml, 
however in 20% of patients with newly diagnosed prostatic carcinoma the PSA 
levels are less than 4.0 ng/ml.  PSA may increase with age as a result of benign 
hypertrophy.  Therefore,  age  specific  reference  ranges  (Table  1)  have  been
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introduced  and appear to increase the sensitivity of PSA in  men younger than 
60 years and the specificity in men older than 60 290.
36Age yr. 
PSA ng/ml
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40  45  50  55  60  65  70  75  80
2.0  2.4  2.8  3.3  3.8  4.5  5.3  6.2  7.2
TABLE 1: Age-specific reference  ranges for PSA.
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PSA  density,  i.e.  serum  PSA  divided  by  the  volume  of  the  prostate,  was 
introduced to adjust for contribution of benign prostatic hypertrophy to serum 
PSA levels,  it was found to be a better predictor of pathological stage than the 
Gleason grade 26:347.  Others have not found this parameter useful51'290.
A  PSA  velocity,  i.e.  the  rate  of increase  of PSA  over time,  greater than  0.75 
ng/ml  per  year  is  an  accurate  predictor  of cancer  identifying  72%  of cancer 
cases with a specificity of 90% 69.  In cohort studies serum PSA correlates with 
cancer volume, tumour grade and pathological  stage300 34, but it is not reliable 
on an individual basis.
If PSA  is used  as  the  initial  test  in  asymptomatic  men  more  than  50 years  of 
age, then with the aid of TRUS guided biopsies 22% of men with a PSA of 4.0 
-  9.9  ng/ml  are  diagnosed  as  having  carcinoma  of the  prostate.  This  figure 
increases to 67% in men with PSA >  lO.Ong/ml72.
Any of the three primary investigations can lead to a tissue biopsy, but PSA is 
the most sensitive single parameter 72 and the positive predictive value of DRE 
and TRUS can be increased with a raised PSA.
1.65  Staging of Prostate Cancer.
Once the diagnosis of prostatic carcinoma is made,  staging is carried out with
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radiological  imaging,  a  nuclear  bone  scan  and  TRUS.  As  part  of the  WHO 
consensus  conference  on  imaging  it  was  concluded  that  MRI  is  superior  to 
other  modalities  in  the  assessment  of  local  tumour  stage,  particularly  if  an 
endorectal  coil  was  used  l67,242.  The  majorities  of  lesions  arise  in  the 
peripheral  zone  and  are  seen  as  low  signals  on  T2-weighted  images.  The 
accuracy  of  MRI  in  differentiating  invasive  from  localised  disease  is  well 
established.  A  peripheral  zone  defect  of  1cm  or  greater  with  an  ill  defined 
border and of low signal proved to be  100% sensitive 306 and 54%  specific  309 
for extra capsular spread (fig. 5).
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Fig 5a  Fig5b
Fig 5: Trans abdominal MRI of the prostate, a large left sided cancer can 
be seen in the peripheral zone.  Fig 5a shows a T2 cancer and Fig 5b a T3 
lesion. Although the images obtained  with transrectal  MRI  were  initially 
better, improvement in  MRI technology  has allowed extra corporal  MRI 
to supersede this.
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The  value  of  MRI  in  detecting  nodal  disease  was  limited  to  evaluation  of 
lymph node size and its accuracy, i.e. 80-90%, has not exceeded that of CT 31. 
Any node greater than  1.5cm  is  likely to be  malignant.  However more recent 
work  with  ultra  small  particles  of  iron  oxide  -   ferumoxtran-10,  in  pelvic 
malignancies  has  shown  that the  sensitivity may be  increased  with  no loss  of 
specificity  "  .  It remains to be seen if this is of any benefit in the detection of 
pelvic lymph nodes in patients with prostate cancer.
Ultrasound  imaging of the  prostate  via the  abdominal  approach  is  unreliable, 
the use of the transrectal probe has allowed excellent high resolution images of 
the peripheral  zone  where 70%  of the carcinomas arise 243,  however it should 
be  remembered  that  24%  of prostatic  tumours  are  isoechoic  95.  Transrectal 
ultrasound detection of local extension is operator dependent and the accuracy 
varies from 60 to  100% 322;339.
The  utility of CT  is  diminishing.  It  may  have  a  use  in  situations  where  MRI 
scans are inconclusive, e.g. the assessment of para-aortic nodes.
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Fig 6: Lymph nodes obtained by surgical dissection.
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Anterior Posterior
Fig 7: A positive bone scan in a patient with multiple metastasis.
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The  axial  skeleton  is  the commonest site of haematogenous  metastasis.  Bone 
metastasises  are  assessed  with  scintigraphy  (fig.7)  that can  point  to  the  need 
for plain  radiographs.  Routine radiographic  surveys  have no place in  imaging 
for  skeletal  involvement;  it  is  costly,  time  consuming  and  involves  a 
significant  dose  of radiation.  Furthermore  there  must  be  a 50%  loss  of bone
O '} 1
density  before  a  lesion  is  visible  and  23%  of patients judged  to  be  free  of 
bone metastasises by radiography have metastatic disease by scintigraphy 303.
The mainstay of assessing chest involvement is a chest radiograph 242.
The  level  of serum  prostate  specific  antigen  is determined  by prostate cancer 
volume  and  by the  percentage  of high-grade cancer  l88.  Therefore,  the  use  of 
serum  PSA coupled  with  tumour grade  and clinical  stage  has  been  advocated 
by Partin et al as a staging tool 302.  In a series of pelvic lymphadenectomies if 
the PSA < 6ng/ml  and the Gleason score < 5  all  the pelvic lymph nodes were 
tumour free (n=142), but if the PSA <  10 ng/ml and the Gleason score < 6 then 
1% of the pelvic lymph adenectomies were positive  (n=388) 28’.
Once  the  localised  tumour  has  been  staged  using  the  TMN  classification, 
(Table2)  the  patient  is  a  candidate  for one  of the  three  management  regimes 
available:
i)  watchful waiting 
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ii) active surveillance,
iii) radiotherapy - external beam
brae hy  therapy
iii)  radical prostatectomy-  retro pubic,
perineal, and 
laparoscopic.
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TABLE 2: Staging of Localised Prostate Cancer (UICC 2002).
T Primary Tumour
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
T1 Clinically inapparent tumour not palpable or visible by imaging.
Tla Clinically inapparent tumour not palpable.
Tib Tumour incidental histological  finding in more than 5ck  of the tissue.
Tic Tumour identified by needle biopsy.
T2 Tumour eonfined within the prostate or invading the apex.
T2a Tumour involves one half of one lobe or less.
T2b Tumour involves more than half of one lobe, but not both lobes.
T2c Tumour involves both lobes.
T3 Tumour extends through the prostatic capsule.
T3a Unilateral or bilateral extra capsular extension.
T3b Tumour invades the seminal vesicles.
NO No regional  lymph node metastasis.
MO No distant metastasis.
Nx Regional lymph nodes not sampled.
NO No positive regional  lymph nodes.
N1 Regional lymph node metastasis
MX Distant metastasis cannot be assessed.
MO No distant metastasis.
Ml Distant metastasis.
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1.66  Management:
Watchful Waiting.
Patients  are  initially  followed  without  treatment  and  receive  subsequent 
treatment  for  symptoms  e.g.  androgen  ablation  for  metastatic  disease  or 
transurethral resection for outlet obstruction.  Limited data is available from 4 
studies about the outcome of watchful waiting (Table 3).
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TABLE 3:
Localised  prostate  cancer,  deferred  therapy:  Progression,  Metastatic 
Rate, and Prostate Cancer Death.
5 years/%
Author No. of Mean Prog. Met. Death
patients. age
George126 120 75 84 11 20
Johansson184 223 72 31 9 8
Whitmore415 75 67 69 37 0
Adolfsson4 122 68 55 14 1
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These studies demonstrate that within 5 years 31-84% of patients will progress 
and that metastasis will occur in 9 to 37% of patients.  A pooled analysis of six 
non randomised studies, which included three of the four studies listed in table 
3  4:184:4 L \   concluded  at  10  years  the  disease  specific  survival  for  low  grade 
disease  (grade  1+2)  was  87%  with  a metastasis  free  survival  rate  of 81%  for 
grade  1,  and  58%  for  grade2.  The  figures  for  high-grade  (grade  3)  disease
cp
were 34 % and 26% respectively ".
A  more  recent  study  from  Denmark  of 2,570  patients  with  newly  diagnosed 
clinically  localised  prostate  cancer  treated  with  watchful  waiting;  radical 
prostatectomy was not performed in Denmark before  1995, and external beam 
radiotherapy  was  only  rarely used;  demonstrated  an  annual  mortality of  13%, 
with an  increased in  mortality for all  ages at follow up.  Follow up was at  10-
49 14 yrs,  15-19 yrs,  and greater than 20 years after diagnosis  .  Additionally the 
results  of the  Medical  Research Council  immediate  versus deferred  treatment 
study for carcinoma of the prostate have demonstrated more rapid progression 
and death in the deferred treatment group for all stages 94.
1.67  Management: Active surveillance.
The  rational  behind  this  management  option  is  that  the  majority  of patients 
have  a  disease  which  is  indolent  and  will  not  progress,  and  to  treat  these 
patients with curative intent would lead to unnecessary morbidity without any
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survival  benefit.  Therefore  active  surveillance,  to  paraphrase  Whitmore, 
attempts to separate the pussycats from the tigers. Patients with localised organ 
confined disease  are followed up with  three  monthly reviews  including PSAs 
DREs,  and  repeat  biopsies,  as  part  of  a  study  protocol,  no  intervention  is 
required unless there is evidence of disease progression -  progression in PSA, 
Gleason score, or clinically.
If there  is  evidence  of progression  or  it  is  felt  that  the  patient  is  not  suitable 
(high Gleason score) for active surveillance, the patient is referred for curative 
therapy.  This  is  distinct  from  watchful  waiting,  which  relies  on  the  use  of 
palliative intervention for symptomatic progression157291.
1.68  Management: Radiotherapy - External Beam:
The Stanford series consists of 1119 patients (from October  1956 to December 
1990) treated with external beam irradiation derived from a mid to high-energy 
linear accelerator (range,  6-25  mV).  673  patients  had disease confined to  the 
prostate  l4.  These  authors  found  survival  to  be  inversely  proportional  to 
clinical stage and pathological grade. At  15 years the survival rates for the best 
prognosis  tumours  were equivalent to that of an  age  matched cohort  i.e.  50% 
at  15  years,  however the poorer prognosis tumours had a survival  rate of  18% 
at  15 years.  Age had no influence on outcome.
50Prostatic Intraepithelial Neoplasia and Prostate Cancer.
More recently the use of adjuvant androgen blockade along with external beam 
radiotherapy has been championed.  In a randomised study, androgen ablation 
was  started  at the time of the first dose of irradiation  and continued for three 
years  after.  In  patients  with  locally  advanced  disease,  there  was  a  survival 
advantage and decreased  local  progression  in  the group  on  androgen ablation
. *  37:38 therapy
1.69  Management: Radiotherapy - Brachytherapy:
In  this  form  of  radiotherapy,  radioisotopes  are  inserted  directly  into  the 
prostate. It has been used for the management of other malignancies arising in 
organs  accessible  to  this  type  of delivery  system  including  the  brain  and  the 
gynaecological tract. The Seattle group has data from 634 consecutive patients 
who have undergone brachytherapy36, with  10 year follow up available on  125 
patients140.  The  initial  results  appear  to  be  similar  to  those  obtained  for 
external beam radiotherapy or surgery.  Brachytherapy is not a benign form of 
management.  5-10%  of  patients  develop  short  term  urinary  retention36,  the 
Seattle group report incontinence rates of less than  1% and potency rates of 75 
to  90%  after  treatment36.  Other  series  have  not  been  so  flattering  reporting 
40%  of patients  developing  urinary  incontinence,  with  18%  reporting  having 
used  a  pad  in  the  last  week  378.  The risk of incontinence  appears  to  increase 
with time and 83% of men who had had a previous TURP were incontinent378. 
The incidence of total  impotence is 45%, with 68% of men having an erection
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178 inadequate for penetration
1.70  Management: Radical Total Prostatectomy.
Surgery is curative only if the entire tumour is removed.  Two approaches are 
advocated for open surgery, retro-pubic or perineal, the results are comparable. 
Precise  control  of  bleeding  from  the  dorsal  vein  complex  allows  anatomic 
dissection  of the  apex,  and  thus  identifies  the  branches  of the  pelvic  plexus 
which innervate the corpora and so preserves sexual function 409.  Incontinence 
(6-10%) and impotence (30%) are serious side effects.
Laparoscopic  radical  prostatectomy  is  slowly  gaining  favour  in  the  United 
Kingdom.  Richard  Gaston  developed  the  initial  technique  in  Bordeaux; 
however this remains an unpublished series. The procedure was popularised by 
Guillonneau  and  Vallencienl4314\   The  Montsouris  group  advocated  a 
transperitoneal  approach.  This  technique  is  based  on  the  primary  incision  of 
the  peritoneum  above  the  recto-vesicle  cul-de-sac  followed  by  dissection  of 
the seminal vesicles. This approach does not adhere to the basic laparoroscopic 
tenet  of  replicating  the  open  operation.  Therefore,  an  alternative  extra 
peritoneal approach has been developed39.
Whichever approach  is adopted, open or laparoscopic, perineal  or retro pubic, 
transperitoneal  or  extra  peritoneal,  oncological  cure  coupled  with  acceptable
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functional  results remains the imperative.  To this end, data from the Virginia 
Mason  Clinic  for  patients  with  localised  disease  revealed  a  15  year  crude 
survival of 64% and after  10 years the disease specific mortality was 2%  with 
the  cause  specific  survival  curve  plateau  at  17  years  with  no  further  disease 
specific  mortality  128.  The  group  from  Duke,  Durham  demonstrated  a 
significant difference in the failure and death rates between patients with organ 
confined,  specimen  confined,  and  margin positive disease,  i.e.  failure rates of 
12%, 30%, 60%, and death rates of 8%,  12%, and 30% at  10 years respectively 
3()4.  A  more  recent series has shown that the grade of the  tumour also affects 
the rate of progression1 1  \  Therefore cancer control after surgery is affected by 
tumour  grade,  and  whether  the  tumour  was  organ-confined,  specimen- 
confined,  or not confined  to the  specimen  m .  PSA can  also be a measure of 
recurrence  however  biochemical  PSA  failure  may  not  manifest  itself  as
I  1  1 clinical progression in the patient
Other  novel  approaches  have  also  been  advocated,  such  as  high  intensity 
focussed ultrasound 35 and cryotherapy28, but long term data is awaited.
Advocates  of screening  in  Britain  suggest there  may be  a potential  benefit  in 
terms  of  survival  if  screening  is  adopted  298,  however  there  is  considerable 
opposition  to  this  in  this  country.  In  the  USA  early  detection  programmes 
detect organ-confined disease  in  a younger cohort of patients  34*.  Long-term
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follow up of these patients is required to determine if there is an improvement 
in  survival.  A  study  comparing  two  large  fixed  cohorts  of  male  Medicare 
patients, Seattle n = 94,900 and Connecticut n =  120,621, exposed to different 
screening regimens concluded that more intensive screening over a eleven year 
period  is  not  associated  with  lower prostate cancer specific  mortality "  A 
recent  randomised  study  from  Denmark  compared  surgery  with  watchful 
waiting and initially demonstrated a significant improvement in cancer specific 
survival  in  the  surgery  arm  but  no  improvement  in  overall  survival  l69,  a 
further update has now shown a decrease in local progression and a decrease in 
the development of distant metastasis in the patients randomised to surgery33.
Using  the  SEER  (surveillance,  epidemiology,  and  end  results)  data  base  a 
study  of  104,577  patients  with  localised  prostate  cancer  concluded  that  1) 
treatment  is  associated  with  lower disease  specific  and overall  mortality,  and
2)  advanced  age  and  black  race  are  markers  of disease  specific  and  overall 
mortality.  No conclusion was drawn about the optimal treatment modality 2 < )(\
A second study using the SEER database and an intention to treat analysis i.e. 
patients  with  lymph  node  dissection  and  radiotherapy  or  radiotherapy  alone 
were  assigned  to  the  radiotherapy  group,  and  those  with  a  lymph  node 
dissection  alone  or  radical  prostatectomy  were  classified  into  the 
prostatectomy group.  The advantage of this type of analysis is that it includes
54Prostatic Intraepithelial Neoplasia and Prostate Cancer.
patients in the prostatectomy group who have been deselected by pathological 
staging.  The  disadvantages  are  that  co-morbidity  and  tumour-related
variables, e.g. tumour size and PSA, are not controlled for.  The data suggested 
that treatment was most useful for high grade tumours, patients with low grade 
tumour did better than the general population, and the data for surgery may be
flattering  because  surgeons  were  the  selecting  best  patients  when  analysing
? 1 , ^
data by treatment received “  .
The Prostate Cancer Clinical Guidelines Panel has recently published its report 
on  the  management  of  clinically  localised  prostate  cancer  "  .  The  report 
concluded  that  the  published  data  to  date  was  inadequate  for  a  valid 
comparison  of the  treatment  options  and,  all  patients  with  newly  diagnosed, 
clinically localised cancer should be informed of all the treatment options. The 
appropriate patient for total prostatectomy should have organ confined disease, 
an expected  longevity that is  longer than  the natural  history of the cancer i.e. 
15  years,  no  significant  surgical  risk  factors  and  a  preference  to  undergo 
surgery.  The major advantage  is the potential  for removal  of the cancer.  The 
downside  includes  genitourinary  dysfunction  and  disease  progression.  The 
patients  most  likely  to  benefit from  radiation  therapy  would  have  a relatively 
long  life  expectancy.  No  significant  risk  factors  for  radiation  toxicity  and  a 
preference for radiation therapy.  In favour of radiotherapy is the fact it is well 
tolerated and a potential  for cure exists.  The adverse effects include radiation
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cystitis, proctitis, and erectile dysfunction.  The prostate is still  in place and so 
disease progression  may occur.  Patients with  a short life expectancy and/or a 
low-grade  tumour  are  likely  to  be  suitable  for  surveillance.  Disease 
progression  is  likely  with  only  a  marginal  compromise  to  disease  specific 
survival at 5 and  10 years 257.
The  absence  of hard  data  is a constant  source  of embarrassment to  all  health 
professionals  involved  in  the  management  of  localised  carcinoma  of  the 
prostate.  The  Department  of  Veterans  Affairs  and  the  National  Cancer 
Institute's  Cancer  Therapy  Evaluation  Programme  Co-operative  Study  (407)- 
the  Prostate  Cancer  Intervention  Versus  Observation  Trial  (PIVOT)  -  is  a 
randomised  trial  designed  to determine the benefits of early  intervention  with 
radical  prostatectomy  compared  to  surveillance418.  PIVOT  will  enrol  2000 
patients  over a three  year period  and follow  up  will  be  for a  minimum  of  1 2  
years.  Radiotherapy has not been included as a third treatment arm because of 
sample size, cost, and  feasibility.  This study should hopefully answer some of 
the questions.
In the United Kingdom, the three arm randomised ProtecT (prostate testing for 
cancer and treatment) randomised study is currently recruiting  107.  This study 
has  demonstrated  the  negative  connotation  patient’s  place  on  the  phrase 
watchful  waiting,  patients  interpreted  this  as  no  treatment,  and  has  replaced
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this with the acceptable concept of active monitoring.
The peculiar biology of this disease has contributed to the lack of a consensus 
about  the  management  of  localised  prostate  cancer.  The  median  time  of 
detection  of this  disease  is  72  years,  the  median  age  of death  due  to  prostate 
cancer  is  77  years,  since  the  average  life  expectancy  is  74.2  years,  and  it  is 
evident that the most men will die in spite of the disease rather than because of 
it.
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The  increasing  focus  of the  public  has  generated  considerable  interest  in  the 
management  of  prostate  cancer.  This  in  turn  has  resulted  in  screening 
programmes  being  established;  not  only  have  these  programmes  detected 
prostate  cancer  but  they  have  detected  an  increasing  number  of  men  with 
atypical  epithelial  proliferation  the  most  common  being  prostatic  intra­
epithelial neoplasia.
2.1  Prostatic intra-epithelial neoplasia
Bostwick and Brawer 46 introduced the term Prostatic Intraepithelial  Neoplasia 
(PIN) in  1987, and although  initially it was divided into three grades it rapidly 
evolved  into a two tier system -  high  and  low grade  l37.  Low grade PIN is of 
no clinical relevance and the generic term PIN exclusively refers to high grade 
PIN.  In  a  model  analogous  to  Vogelstein’s  for colorectal  cancer,  it  has  been 
proposed  that  PIN  refer  to  the  precancerous  end  of  the  morphological 
spectrum.  PIN  is  defined  as  an  abnormal  proliferation,  where  the  cellular 
changes  within  the  prostatic  ducts,  ductules  and  acini  exhibit  the  cytological 
changes  of  cancer  i.e.  progressive  loss  of  the  markers  of  secretory 
differentiation,  increasing  nuclear  and  nucleolar  abnormalities,  increasing 
proliferative  index,  neovascularisation,  genetic  instability,  and  variation  inProstatic Intraepithelial Neoplasia and Prostate Cancer.
DNA, but retain a basal cell  layer (intact or fragmented).  PIN is a spectrum of 
atypical  cytological  features  ranging  from  minimal  change  to  those  that  are 
indistinguishable from prostate cancer.  The most striking features are nuclear 
and  nucleolar enlargement,  and  are  often  regarded  as  diagnostic  of PIN.  The 
absence of a basal cell  layer distinguishes cancer from PIN.  The generic term 
PIN usually refers exclusively to high grade PIN.  Low grade PIN is no longer 
thought to be clinically relevant.
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Figure  8 :  The  continuum  of change from  benign  to  malignant  proposed 
by  Bostwick  and  Brawer  46.  The  loss  of  the  basal  cell  layer  is 
pathognomonic of cancer, but the the cytological changes of cancer occur 
in  prostatic  intraepithelial  neoplasia which  has an  intact basal cell  layer. 
The  presence  of  the  basal  cell  layer  can  be  confirmed  with  the  use  of 
antibodies against high molecular weight cytokeratins.
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There  are  four  main  architectural  types  of  high  grade  PIN:  tufting,  micro 
papillary, cribriform, and flat45.
Fig 9: Tufting PIN (low power) Fig 10: Micropapillary(low power),
Fig  11: Cribriform PIN (low power)  Fig  12: Flat PIN (low power).
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These  different  architectural  types  do  not  appear  to  have  any  clinic
pathological  significance.  PIN  spreads  through  the  prostatic  ducts  in  three 
different patterns 44:
i)  Neoplastic cells replace the normal  luminal secretory cells,
ii)  Direct invasion of the duct wall,
iii)  Pagetoid spread, the cells grow between the secretory and basal cells.
Clinical  studies  suggest  that PIN  precedes carcinoma by  ten  years,  with  low- 
grade PIN first emerging in men in the third decade 331  and the peripheral zone 
is the most common  location for PIN.  The frequency of PIN in prostates with 
adenocarcinoma is much greater than in prostates without cancer 31'.
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Low-grade PIN 
(PIN 1)
High grade PIN 
(PIN 2 and 3)
Cancer
Architecture Epithelial  cell 
crowding  and 
stratification, 
with  irregular 
spacing.
More  crowding  and 
stratification.
Four  patterns:  tufting, 
micro  papillary, 
cribriform, and flat
Crowding with stratification
Cytology:
Nuclei
Enlarged  with 
size variation
Enlarged  with  size  and 
shape variation.
Hyper chromatic nuclei with macro 
nucleoli.
Cytology:
Chromatin
Normal Increased  density  and 
clumping
Increased density and clumping
Cytology:
Nucleoli
Rarely
prominent
Frequently  large  and 
prominent
Large and prominent
Basal  Cell 
Layer
Intact May  show  some 
disruption
Absent
Basement
Membrane
Intact Intact Absent
Table  4:  Summary  of  relationship  between  prostatic  intraepithelial 
neoplasia and cancer.
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2.2  Incidence of high-grade PIN  in  benign prostate tissue (biopsy and 
TURP)
The incidence of PIN varies in benign needle biopsy specimens between 0.7% 
and  16.5%.  In TURP specimens it is between 2.8% and 3.2%.  The incidence 
of  PIN  is  lower  in  screened  populations  than  in  patients  presenting  for 
urological assessment.
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Ref./Y  ear No of Patients Tissue Specimen Patient Incidence  of
PIN /%
2IS/ 1989 256 14 G needle biopsy Non-screening 11
25 71991 330 18 G needle biopsy Screening 5.2
< 2 71994 163 18 G needle biopsy Non-screening 8 .6
4S/1995 2 0 0 18 G needle biopsy Non-screening 16.5
4X / 1995 2 0 0 18 G needle biopsy Non-screening 9.5
2'71996 1275 18 G needle biopsy Non-screening 4.4
4171997 439 18 G needle biopsy Non-screening 5.5
,< S (V  1997 79 14 G needle biopsy Non-screening 7.6
m/ 1997 148 18 G needle biopsy Non-screening 14.1
M / 1 9 9 7 1009 18 G needle biopsy Non-screening 1.5
|W/1997 158 TURP Non-screening 3.2
2% /1997 570 TURP Non-screening 2 .8
■ ”71998 2219 18 G needle biopsy Non-screening 4.0
l77l998 388 18 G needle biopsy Non-screening 8 .0
■ 427l998 795 18 G needle biopsy Non-sereening 7.4
"97 1998 62537 18 G needle biopsy Non-screening 4.1
2s7/ 1999 15753 18 G needle biopsy Non-sereening 3.9
1  *71999 8763 18 G needle biopsy Screening .7
U ’/2 0 0 0 3891 18 G needle biopsy Non-screening 5.4
7 2 0 0 0 485 18 G needle biopsy Non-screening 6 .8
l7(l/2 0 0 l 1474 18 G needle biopsy Screening 4.7
o
o
(
N 1961 18 G needle biopsy Screening 4.7
' 72004 1086 18G needle biopsy Non-sereenining 4.0
2fl7/2005 1 188 18G needle biopsy Non-sc reenining 2.7
Table 5:  The incidence of PIN according to recent studies.
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The  incidence  and  extent  of  PIN  appears  to  increase  with  age,  it  is  more
1  ">0 prevalent and extensive in patients of African origin  “  . PIN is also detected a
I ^0 decade earlier in men of African origin compared to Caucasians  “  .
2.3  Location of PIN
PIN  lesions  are  often  multifocal,  and  bilateral,  as  is  prostate cancer.  PIN  and 
prostate cancer are principally  located  in  the peripheral  zone of the gland.  In 
radical  prostatectomy specimens with cancer, high grade PIN  is present  in the
transition  and  peripheral  zone  simultaneously  in  36%  of cases,  and  is  found
^ 1  1 exclusively in the transition zone in  1  % of cases  .
2.4  PIN and serum PSA levels
This  is  a  contentious  area;  a  study of 81  men  undergoing  surgery  for benign 
disease  found  that  in  men  with  PIN  alone  the  mean  serum  PSA  fell  between 
the  levels  for  men  with  benign  and  malignant  disease50.  The  same  authors 
found similar results for patients with BPH, PIN, and cancer on TRUS sextant 
biopsy 52.  However,  Ronet et al  326 and Alexander et al6 did  not confirm  this 
finding.  In a recent study of 8 1   consecutive men who have undergone radical 
retro pubic prostatectomy it was  shown that PIN did not contribute to total  or 
percent  free  PSA  levels269.  Using  grid  counting  to  calculate  the  volume  of 
tumour,  PIN,  and  benign  disease,  in  a study of  194 patients  PIN  volume wasProstatic Intraepithelial Neoplasia and Prostate Cancer.
shown  to  correlate  to  PSA,  this  result  was  interpreted  by  the  authours  as  an 
artefact  and  they  concluded  that  PIN  did  not  to  contribute  to  it6. 
Immunohistochemical studies reveal that the expression of PSA in PIN is less 
than that observed in BPH and cancer249.  The explanation for a lower PSA in 
patients  with  PIN  is  that PIN  is  an  abnormality within  pre-existing ducts  and 
acini,  and  cytoplasmic  secretory  products  would  be  expected  to  wash 
downstream rather than escape into the stroma and blood vessels.
2.5  PIN and Radiotherapy.
A  study  of  29  patients  who  underwent  salvage  prostatectomy  after 
radiotherapy  demonstrated  PIN  in  only  two  of  the  specimens.  After 
radiotherapy  the  basal  cell  layer  in  PIN  becomes  more  prominent  and  the
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presence of cytoplasmic blebs distinguishes secretory cells from basal cell.
2.6  Clinical Significance of PIN
High  grade  prostatic  intraepithelial  neoplasia has  a high  predictive  value  as  a 
marker  for  adenocarcinoma,  Davidson  et  al  evaluated  this  in  a  retrospective 
case  control  study  of  100  patients  with  needle  biopsies  with  high  grade  PIN 
and  112  biopsies  without  PIN  matched  for  clinical  stage,  patient  age,  and 
serum  PSA.  Adenocarcinoma  was  identified  in  35%  of  the  subsequent 
biopsies  with  PIN  compared  with  13%  in  the  controls.  The  likelihood  of 
adenocarcinoma increased with time, 32% at one year, and 38% after one year.
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The  presence  of  high  grade  PIN  and  a  raised  PSA  are  associated  with
19^ adenocarcinoma  in  51%  of cases  in  repeat  biopsies  “.  Others  studies  have 
found cancer detection rates of 28%  216 and 47% 35°.
The incidence of prostate cancer after an initial diagnosis of PIN increases if a 
patient  has  repeat  biopsies207.  In  a  series  of  245  patients  with  an  initial 
diagnosis  of  PIN,  cancer  was  diagnosed  in  24.5%  of  patients  on  the  initial 
repeat biopsy and a total of 32.2% after the second repeat biopsy 207.
Recent  work  has  also  highlighted  the  importance  of  second  biopsies  with  a 
diagnosis of PIN. In a cohort of 190 men diagnosed with PEN and having serial 
repeat biopsies the overall  incidence of prostate cancer on repeat biopsies was 
30.5%,  but if there was a second biopsy with PIN detected, the risk of cancer 
increased  to  41%,  compared  to  only  18%  if  the  second  biopsy  had  benign
135
t i s s u e   .
PIN  is  often  associated  with  moderately  to  poorly  differentiated 
adenocarcinoma  of  the  prostate;  it  is  not  often  associated  with  low-grade 
prostate cancer or cancer arising in the transition zone 263.
2.7  Evidence linking PIN and Cancer.
There  is  no  disruption  of the  basal  cell  layer  in  benign  disease,  where  as  in
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cancer the  basal  layer  is  absent.  In  PIN  there  is  partial  disruption.  There  is 
increased  expression  of the proteolytic  enzyme type  IV  collagenase  in  cancer 
and PIN compared to benign disease264.
The  number of stromal  micro vessels in PIN is greater than in benign or BPH 
tissue, but less than  in  adenocarcinoma.  The micro vessels in PIN are shorter 
than  those  in  benign  epithelium,  with  irregular contours  and  open  lumina,  an 
increase  in  the  number  of endothelial  cells,  and  a  greater  distance  from  the 
basement membrane264.
The doubling time of PIN  is at an  intermediate  level  when compared to BPH 
and  cancer  265  and  there  is  a  progressive  increase  in  the  number  of  mitotic 
figures and apoptotic bodies from BPH through to PIN and finally cancer266.
The cell  kinetics of PIN have been studied.  It has been shown that PIN, which 
is not associated with carcinoma, shows a down regulation in apoptosis, which 
is  common  with  prostate  cancer,  but  distinct  from  PIN  which  is  associated 
with prostate cancer 200
Many  markers  of differentiation  are  down  regulated  in  PIN  and  cancer,  e.g. 
neuroendocrine  cells47,  prostatic  acid  phosphatase,  and  prostate  specific96 
antigen.  Benign  prostate  has  most cells  with  neuroendocrine  differentiation.
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Others  are  up  regulated  e.g.  fatty  acid  synthetase277,  glycoprotein  A-80136, 
glycoprotein TAG-7254, and Lewis X and Lewis Y antigen276.
Using micro array analysis  hepsin  is up regulated  in PIN,  and prostate cancer 
but  is  absent  in  benign  tissue101,  in  hormone  refractory  disease  it  has  an 
intermediate  level  of  staining.  Hepsin  has  been  shown  to  be  a  predictor  of 
relapse101.  PIM1  kinase  was  up  regulated  in  all  stages  of prostate  cancer  but 
absent in PIN and benign disease101.
Transgenic  mice  have been  used  to study the pathogenesis of prostate cancer. 
The  most extensively used  model  is the TRAMP (transgenic  adenocarcinoma 
mouse prostate) model130  138.  The simian virus 40 (SV40) early region tumour 
antigens have the ability to induce transformation in vivo.  The large T antigen 
(Tag)  interacts  with  the  retinoblastoma  gene  (Rb)  and  p.53,  and  the  small  t 
antigen interacts with a protein phosphatase.  The loss of wild type Rb and  p.33 
was used in this  model.  Probasin was used to target the SV40 to the prostate. 
Probasin  encodes  for  an  androgen  and  zinc  related  protein  specific  to  the 
dorsolateral  epithelium  of the prostate.  A  probasin  SV40 Tag  construct  was 
used to target the prostate of mice  138. The expression of SV40 early genes in 
the  prostate  of  the  mice  results  in  mice  displaying  progressive  forms  of 
prostate  disease.  The  mice  develop  prostatic  hyperplasia  at  10  weeks  and 
invasive  adenocarcinoma  by  18  weeks  of age.  By  10  to  12  weeks  TRAMP
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I ^9 mice reproducibly displayed evidence of high grade PIN  "  .  By 30-36 weeks 
all  TRAMP  mice  developed  metastases130.  This  model  has  therefore 
facilitated in the understanding and characterisation of the sequence of events, 
which  may  occur  in  the  initiation,  and  progression  of prostate  cancer.  This 
model  is  however  open  to  criticism,  since  in  the  human  form  of the  disease 
benign prostatic hyperplasia does not progress  to adenocarcinoma.
2.8  Differential diagnosis of PIN
There  are  several  benign  conditions  that can  mimic  PIN;  these  include  atypia 
induced  by  inflammation,  infarction, or radiation; transitional  cell  metaplasia; 
basal  cell  hyperplasia;  clear  cell  cribriform  hyperplasia;  normal  ejaculatory 
duct  and  seminal  vesicle  epithelium.  Malignant  lesions,  which  have  to  be 
distinguished  from  PIN,  include  high  grade  transitional  cell  carcinoma 
involving  the  prostate  ducts  and  acini,  and  cribriform  acinar,  and  cribriform
i i   •   " > 9 9 ductal prostatic carcinoma"  .
Despite its major impact as the most common cancer in men, prostate cancer is 
relatively  poorly  understood  at  the  genetic  level.  It  is  hypothesised  that,  as 
with  other  neoplasms,  mutations  of  proto-oncogene  and  tumour  suppressor 
genes  contribute  in  some  way  to  the  genesis  of prostate  cancer.  The  use  of
molecular  markers  to  supplement  clinical  information  concerning  the 
biological  aggressiveness  of  a  carcinoma  may  allow  better  selection  for
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different management strategies.  Alternatively, they may be used after surgery 
to  stratify  men  into groups  whereby those  with  poorer prognosis  may receive 
adjuvant  treatment,  perhaps  providing  an  advantage  of  improved  disease 
specific survival.
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Chapter 3: P5 3. Bcl2, Bax-aipha, and Ki-67.
3.1  P53
The  P53  gene  is  located  on  the  short  arm  of chromosome  17  (17p 13.1).  The 
gene  is composed of  11  exons.  The P53 gene product is a 53Kda (393-amino 
acid) nuclear phosphoprotein 203, which inhibits the advancement of cells from 
the G1  to the S phase.  Lane and Crawford first identified this in  1979 214.
The  DNA  tumour  virus  SV40  expresses  two  antigens,  small  t  and  largeT. 
These  are  essential  for  the  virus  to  transform  cells.  Lane  and  Crawford 
demonstrated that the T antigen binds to a 53 Kd host protein, and precipitated 
this  out.  They  postulated  that  this  protein  was  not  virally  coded  and  that  it 
could  be  detected  in  cells  transformed  by  other  viruses,  radiation,  chemical 
carcinogens,  or  even  in  untransformed  cells.  They  further  precipitated  the 
protein from  polyoma virus transformed cell  line.  The  authors postulated that 
this protein  may  have  an  important role  in the  modulation  of the  transformed 
state,  and  it  may  normally  act  as  a  regulator  of cellular  functions  related  to 
growth.  Lane  and  Crawford  concluded  that  it  is  of  prime  importance  to 
determine the level  of this protein in untransformed cells or normal  tissue and 
to  see  if  it  is  induced  by  other  carcinogens  2I4.  The  importance  of  this 
discovery  was  not  clear  early  on,  since  these  viruses  do  not  cause  human
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cancers.
From its humble beginnings, the influence of p53 rapidly grew. The number of 
publications  with  p.53  in  the  leading  role  increased  exponentially  every  year 
from  1979.  In  1993  P53  was  named  as  Science  magazines  Molecule  of  the 
Year203.  In  the  editorial  Dr Koshland commented  that  the  early detection  of 
P53 may lead to treatment by known methods such as surgery, and stressed the 
importance of basic  research  -  “Basic research does not mean of no practical 
value’’203.  This is also the aspiration of this piece of research.
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Figl3: Cover of Science Dec 1993.
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A  mutant P53  gene  synthesises  a defective P53  protein  that  lacks  the  ability to 
regulate  cell  proliferation.  The  p.33  protein  is  found  in  small  quantities  in 
normal  cells,  but  in  large  quantities,  5  to  100-fold  increase,  in  transformed 
cells  both  in  vivo  and  vitro.  Inactivation  of p.53  is  the  single  most common 
mutation  in  human  cancer  224.  The  presence  of  P53  nuclear  reactivity  is  a 
predictor of recurrence  after definite  local  therapy  i.e.  radiotherapy or radical 
prostatectomy142.  P53  and  Ki-67  have  been  shown  to  be  independent 
prognostic markers of recurrence 274.
3.11  Function of P53 -Guardian of the genome 213.
The  wild  type  p.33  is  capable  of  forming  a  homo  oligomer,  which  binds  to 
specific  DNA  sequences  and  act  as  a transcription  factor.  Insults  to  cellular 
DNA, such as exposure to ultraviolet light, or radiation results in an increased 
levels  of the  p.53  protein  in  normal  cells  leading to  arrest  in  the  G1 phase (the 
growth  phase  of  the  cell  cycle  after  mitosis  and  prior  to  DNA  synthesis), 
allowing repair of the  DNA  prior to replication of the DNA in the  S-phase of 
the cell cycle.  If DNA repair cannot be accomplished, programmed cell  death 
(apoptosisj may occur.  Thus P53  is thought to ensure genomic  integrity.  The 
P53  gene  does  not  directly  establish  integrity  of  the  genome  but  acts  as  a
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transcription  factor to  increase expression of other genes  that  will  initiate  the 
cell  cycle arrest  and/or apoptosis.  Apoptosis  is  genetically programmed cell 
death program,  which functions as a suicide pathway wherein  individual cells 
kill  themselves  when  triggered  to  do  so.  Apoptotic  death  is  distinct  from 
necrotic death.
It has been suggested that p53  regulates the transcription of at least two sets of 
genes;  one  is responsible  for transient cell  arrest  in G1  and the other controls 
the  initiation  of  apoptosis.  Both  of  these  processes  eliminate  potential 
oncogenic  mutations,  either  by  DNA  repair or  by  inducing  damaged  cells  to 
commit suicide.
This response has been lost in many tumour cells as their p53 genes have either 
been  mutated or had its activity neutralised through the production of proteins 
that bind to it and neutralise it.  Lack of ps3 function in tumour cells is thought 
to  be  responsible  for  the  observed  genomic  instability  of  these  cells  as 
manifested  by  aneuploidy  and  the  ability  to  undergo  gene  amplification. 
However,  the pS3  gene does  not seem  to be essential  for normal  development 
but  lack  of p53  function  confers  an  elevated  risk  of  developing  cancer  -   Li 
Fraumeni syndrome (see next section).
Initially the ps3 gene  was  thought to be an oncogene  but  later studies  showed
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t h a t   t h e   p 5 3  c l o n e s   t h a t   h a d   b e e n   s t u d i e d   w e r e   in   f a c t   m u t a t e d   v e r s i o n s   o f   t h e  
g e n e ,   a n d   t h e s e   m u t a n t   a l l e l e s   h a v e   p r o p e r t i e s   w h i c h   a r e   d i f f e r e n t   f r o m   t h o s e  
o f   t h e   w i l d   t y p e   P 53  g e n e .   C u r r e n t   e v i d e n c e   s u p p o r t s   its   c l a s s i f i c a t i o n   a s   a  
t u m o u r   s u p p r e s s o r  g e n e .
3.12  Evidence supporting wild type P53 as a tumour suppressor gene:
1)  T h e   m u r i n e   w i l d   t y p e   P 53  g e n e   c a n   s u p p r e s s   t h e   t r a n s f o r m a t i o n   o f   r a t  
e m b r y o   f i b r o b l a s t s   in   c e ll   c u l t u r e   b y   k n o w n   o n c o g e n e s   e .g .  m s  a n d  
a d e n o v i r u s   E 1 B .   T h e   i n t r o d u c t i o n   o f   w i l d   t y p e   g e n e   o r   c D N A   i n t o   a  
t r a n s f o r m e d   c e ll   c u l t u r e   s t o p s   c e l l   g r o w t h   a t  t h e   G1  p h a s e   o f   t h e   c e ll  
c y c l e   f o l l o w i n g   m i t o s i s   134.
2 )   T h e   w i l d   t y p e   p .33  g e n e   is   c a p a b l e   o f   r e v e r t i n g   t h e   t r a n s f o r m e d  
p h e n o t y p e   o f   h u m a n   c a n c e r   c e l l s   a n d   o s t e o s a r c o m a   c e l l s   in   a n   a n i m a l  
m o d e l 280.
3 )   M u t a t i o n s   a n d   a l l e l i c   l o s s   o f   t h e   p .33  g e n e   h a v e   b e e n   a s s o c i a t e d   w i t h  
t u m o u r s   f r o m   a   w i d e   v a r i e t y   o f   h u m a n   o r g a n s   a n d   t i s s u e s ,   e .g .   c o l o n 67,
181  70  18  ^0^
l u n g   ,  o e s o p h a g u s   ,  b r e a s t   ,  o v a r y ““  ,  b r a i n   ,  a n d   h a e m a t o p o i e t i c  
t i s s u e .
4 )   T h e   L i - F r a u m e n i   f a m i l i a l   c a n c e r   s y n d r o m e 400,  c h a r a c t e r i s e d   b y   d i v e r s e  
m e s e n c h y m a l   a n d   e p i t h e l i a l   n e o p l a s m s   a t  m u l t i p l e   s i t e s   -   b r e a s t   a n d  
a d r e n o c o r t i c a l   c a r c i n o m a s ,   s a r c o m a s   o f   s o f t   t i s s u e   a n d   b o n e ,   b r a i n  
t u m o u r s   a n d   l e u k a e m i a ,   is  a s s o c i a t e d   w i t h   t h e   p r e s e n c e   o f   g e r m   l i n e
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mutations in the p.53 gene400.
5)  Transgenic  mice  deficient  for  p53  or  carrying  altered  p53  gene  are 
significantly  more prone  to  the  spontaneous  development of a variety 
of neoplasms416.
6)  Oncoproteins from  several  DNA tumour viruses e.g.  the SV40 large T 
antigen, the adenovirus EIB, and papilomavirus E6 protein, were found 
to  functionally  inactivate  p.33  by  binding to or degrading the  wild  type
*  •   87 P53 protein  .
3.13  Mechanism of action of ps3.
1)  Up  regulation  of transcription of the bax  gene and down  regulation  of
u   1   261
bcb  .
2)  Up  regulation  of  IGF-BP3  gene  expression.  IGF-BP3  blocks  IGF
induced  signalling  by  binding  to  IGF.  Inhibiting  IGF  promotes 
apoptosis64.
3)  Up  regulation  of  FAS/APO-1  gene  expression.  The  cell  surface
receptor Fas mediates apoptosis “  .
4)  Activation  of  G  proteins.  Cdc42  is  a  GTPase,  and  p.33  promotes
apoptosis  through  up  regulation  of  cdc42  mRNA  and  protein,  up 
regulation  was  followed  by cytoplasmic  to  membrane  translocation  of 
this  G  protein.  One  action  of  Cdc42  is  phosphorylation  and  so 
inactivation of Bcb386.Prostatic Intraepithelial Neoplasia and Prostate Cancer.
3.14  Inactivation of P53 function
A mutation of p.33 gene is the most common mechanism  of inactivation of p.33 
function  l68.  DNA mutation can result from external environmental  factors or 
internal errors  in  mechanisms involved in nucleic  acid metabolism 361.  In the 
first  case,  the  mutagenic  agent  determines  the  nature  of  the  lesion.  In  the 
second case,  mutations appear to be spontaneous.  Analyses of the mutational 
spectrum of P53  in  human  tumours revealed that the majority of p5 3  mutations 
in  human cancers  are  missense  mutations, giving rise  to  an  altered  protein 75. 
At least four mutation  "hot spots,"  have been  identified  in a variety of human 
neoplasms.  Mutations  in  these  hot  spot  codons  account  for  approximately 
30% of all pS3 mutations.
In  addition  to  mutation,  inactivation  of  p.33  function  can  occur  by  other 
mechanisms,  including  binding  of  p.53  to  another  protein  or  increased 
degradation  of p.5 3.  The  EIB  protein  of adenovirus  binds  to  p .33  and  prevents 
P53 activated transcription.  The E6 protein of some types of human papilloma 
virus (HPV) binds to P5 3, causing P53 to be marked for degradation  17'.  Thus, 
HPV  infection  can  lead  to  increase  p.33  degradation.  Only  E6   proteins  from 
those  strains  of  HPV  that  have  been  strongly  associated  with  anogenital 
cancers (HPV  16 and HPV  18 are the most common) result in accelerated P53 
degradation.
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Another mechanism by which P53 is inactivated is interaction with endogenous 
cellular  proteins.  In  sarcomas,  there  is  amplification  of the  MDM2  (mouse 
double  minute)  gene,  located  at  chromosome  12q 13-14,  resulting  in  high
^91 levels of its 90-kD nuclear protein product"  .  Binding of the MDM2 protein 
to  P53  is  thought  to  inactivate  its  transcriptional  activity  262.  The  binding 
occurs at a site distinct to the T Ag binding site, and in tumours where there is 
up  regulation  of  MDM2,  mutation  of  wild  type  p.33  is  not  necessary  for 
transformation 21 \
3.15  Detection of P53 gene and product
The  methods  currently  used  in  the  detection  of  P53  alterations  are  outlined 
below.  Different methods have different advantages and disadvantages, which 
are discussed.
3.16  Immunohistochemical analysis
In  1982 Benchimol et al  ‘  demonstrated by radio-immununological  assay that 
the  ps3  protein  was  specifically  over-expressed  in  transformed  cells  and 
'undetectable'  in  normal  cells.  Numerous  studies  have  confirmed  these 
observations and proved that p.33 protein accumulation  is a consequence of its 
stabilisation.  Wild type p.53 (normal) product has a short half-life of about 6-20 
min and normally does not accumulate in amounts detectable by conventional 
immunoprecipitation  or  immunohistochemical  methods  18.  Mutations  in  the
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gene  result  in  a product  (mutant p.3 3)  with  a  much  longer  half-life  of up  to  6  
hours  224.  Therefore,  the  findings  of  intense  nuclear  staining  with  anti-p? 3 
antibody is  indicative of a point mutated  p.33  18.  Early data from  direct DNA 
sequencing confirms  that mutations  were present in cases  that over expressed 
the protein and were absent in tumours that did not over express the protein  18
24:146
Immunostaining  studies  of  tumour  cells  require  antibodies  with  very  high 
specificity,  absence  of  cross-reactivity  with  another  cellular  protein,  high 
affinity for the antigen regardless of the method of tissue fixation.  Almost all 
archival  tissue  in  histopathology  departments  all  over  the  world  is  preserved 
by  formaldehyde  and  embedded  in  paraffin  blocks.  This  has  led  to  the 
production  of  a  new  panel  of  monoclonal  antibodies  (MAbs)  specific  for 
human  p .53,  such  as  DOl,  D07  and  HR231  2 1 9 4 0 7  which  are  very efficient on 
this  type of material.  All  these  monoclonal  antibodies  are currently available 
commercially.
At  present,  immunohistochemistry  is  the  most  widely  used  technique  for 
assessing  p.33  alterations  in  human  cancers  because  it  is  simple  and  rapid  36'. 
From the clinical  standpoint p 53  immunohistochemistry appears to be the most 
practical  and  useful  method  for  detection  of p53  alterations  in  pre-cancerous 
lesions  and  carcinomas.  This  technique  allows  precise  localisation  and
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identification of the cells that exhibit P53  alterations,  however it cannot detect 
the complete  loss of p.33 or non-sense mutations that introduce premature stop 
codons  into the gene75.  Moreover point  mutations in  the p.33  gene  are  not the 
only  mechanism  by  which  the  p.33  protein  can  be  stabilised.  The  normal  p.33 
protein  can  be  stabilised  by  the  action  of  viral  and  cellular  oncoproteins. 
Treatment  of  cells  with  DNA-damaging  agents  (preoperative  radio  and 
chemotherapy)  increases  the  level  and  stability of the  P53  protein  as  well  l53. 
Therefore,  interpretation of immunohistochemically positive  staining with  p.33 
must include consideration of the mechanisms that underlie stabilisation of the 
P53 protein.
A comparative study carried out on  19 archival specimens of colorectal cancer 
and  comparing  six  commercially  available  antibodies  -   Bp53-12(BioGenex), 
1801  (Oncogene  Science),  D07  (Novocastra),  240(Novocastra),  CM1 
(Novocastra),  and  Signet  (Signet)  with  results  obtained  by  PCR  and  double­
stranded  DNA  sequencing  demonstrated  that  D07  gave  significantly  the  best 
results.  When  D07  was  used  with  an  antigen  retrieval  system  and  the cut of 
for high expression was a labelling index of 30%  the sensitivity was 67%, the 
specificity  was  90%,  the  positive  predictive  value  was  8 6 %,  the  negative 
predictive  value  was  75%,  and  the  efficiency  was  79%.  If the cut of for the 
labelling  index  was  lowered  to  1%  the  sensitivity  was  89%,  the  negative 
predictive  value  was  8 6 %,  specificity  was  60%,  and  the  positive  predictive
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value was 67%, with an efficiency of 74%13.
3.17  Molecular analysis (DNA sequencing)
DNA  sequencing determines  the exact mutational  event that  modified the p.33 
gene.  This knowledge is mainly of use in molecular epidemiological analysis. 
It  is  generally  assumed  that  a  decrease  in  genetic  stability  of the  genome  is 
involved  in  the accumulation of a  multitude of genetic changes  leading to the 
formation of a neoplastic cell.  As  mentioned  before, the type of p.33  mutation 
depends  on  the  event,  which  affects  the  DNA  (external  or internal).  Genetic 
assay is the most accurate technique for identification of P53 mutations but it is 
generally laborious and requires specially equipped molecular laboratories.
3.18  Serological analysis
Several  studies  have  demonstrated  the  presence  of  P53  auto  antibodies  in 
patients  with  carcinomas  68 9 L 9 8 -4 19  The  immune  response  was  found  only 
when P53 accumulation  was detected in  the tumour cell,  but mutation or over­
expression did not automatically lead to a p.33  immune response and there was 
no  correlation  with  the  location  of the  mutation  212:342.  Several  laboratories 
have  developed  ELISA  procedures.  Despite  this,  serological  analysis  of P53 
alterations in human cancers is still in its infancy 36'.  Progress in this field will 
be  of  great  importance,  because  this  technique  can  be  easily  performed  for
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routine diagnosis and does not require tumour samples.Prostatic Intraepithelial Neoplasia and Prostate Cancer.
3.20  P53 and human cancers
Mutations in the  p.53  gene are now regarded  as one of  the commonest specific
genetic  changes  found  in  human  cancer73.  More  than  a  half  of  human
malignancies  derived  from  the  epithelial,  mesenchymal,  haematopoietic,  and 
lymphoid tissues, as well as the central nervous system, analysed thus far, have 
an  altered  p.33  gene  l7:89; 146:168  T h i s   has  led  to  a  concentration  of efforts  to 
uncover  the  value  of P53  as  an  independent  marker for  tumour detection  and 
diagnosis, prognosis and progression.
3.21  P53  as  an  independent  marker  for  tumour  detection  and  early
diagnosis
Mutated P53 protein might be a good target for cancer detection and diagnosis. 
As discussed before this is primarily due to many missense mutations inducing 
changes  which  prolong  the  half-life  of  the  p.33  protein  allowing
immunohistochemical  detection.  P 5 3   positive  immunostaining  has  been 
observed  in  pre-cancerous  lesions  of  the  colorectum  190-307  stomach  357 
bronchus  288 362  larynx  103  oesophagus  23-410  and  in  head  and  neck
4^0
premalignancies  “  .  Although  P53  mutation  seems  to  occur  at  the  earliest 
clinically  detectable  stages  of  the  neoplastic  process  in  some  cancers,  the 
fraction of tumours with an altered p?3 gene is generally higher in the late stage 
of tumours  114-119.
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3.22  P 5 3   as an independent marker for tumour prognosis
Altered  P53  function  has  been  examined  as  potential  prognostic  factors  in  a 
variety  of cancers.  An  ever  increasing  number  of studies  are  reporting  that 
altered  P53  is  an  independent  predictive  factor  of  unfavourable  prognosis. 
Aberrant  forms  of p.33  protein  are  correlated  with  more  aggressive  tumours, 
early metastasis and lower 5-year survival rates.
In  breast  cancer  P53  over  expression  (with  either  demonstrated  or  presumed 
mutation)  has  been  associated  with  late  stage,  metastatic  spread,  and  low 
progesterone  receptor  content  97.  In  other  studies  it  was  associated  with  a 
shortened  survival  I8 2 -3 2 7 -3 3 6 -3 5 9 -3 7 3 -390  ancj  shortened  metastasis  free  survival 
391.  A  consistent  picture  is  now  also  emerging  correlating  the  loss  of  p.33 
function  with  shortened  survival  in  patients  with  cancers  of  the 
colon6 7 '2 7 2 '3 8 0 4 2 7 lung  ,8 1 -268 oesophagus  70 stomach  118 ovaries  223 and bladder 
349 as well as soft tissue sarcomas 108.
3.23  P53 as an independent marker for tumour progression
The role of P53  mutations  in the progression of astrocytomas  to glioblastomas 
l47'358,  in  the  evolution  of chronic  myelocytic  leukaemia  to  blast  crisis  119:408 
and  in  primary  as  compared  with  metastatic  cervical  cancers  92  has  been 
demonstrated.  Genetic analysis showed the presence of p.33 mutant cells in low 
numbers  in primary tumours  and  the  largely mutant composition  of the  more
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advanced tumours as well as their metastases  147J58-408<   jn the pathogenesis of 
colon  carcinoma  point  mutations  typically  arise  during  the  conversion  of  a 
benign  adenoma  to  an  invasive  adenocarcinoma  114.  The  molecular 
mechanisms that underlie tumour progression are thought to include the clonal 
expansion of cells that previously acquired a mutation in cancer-related genes. 
A cell that carries a specific change in a critical gene might acquire a selective 
growth  advantage  and  become  the  dominant  cell  type  as  the  tumour 
progresses.  This hypothesis is also supported by the repeated discovery of the 
mutant  p ^   preferentially  in  anaplastic  and  undifferentiated  tumours  l06:183:l8t) 
e.g.  in  thyroid carcinomas  in  which  the p.53  mutants  are primarily confined  to 
undifferentiated tumours.  The colorectal  tumour progression model continues 
to be the paradigm for all tumour progression.Prostatic Intraepithelial Neoplasia and Prostate Cancer.
3.3  P53 and Prostate Cancer.
A  literature  review  was  carried  out  using  the  Medline  database.  The  initial 
keyword  used  was  P53  and  the  second  was  prostate  neoplasms.  For the  first 
keyword a total  of  16282 references  were detected  and for the second  32852. 
Theses  two  searches  were  combined  and  more  manageable  297  references 
were detected.  These were further limited to English language and human and 
the number of references coned down to 280.  The abstracts were reviewed and
those  that  were  felt not  to  be  pertinent  were omitted,  a total  of 90 references 
were reviewed in detail  «0:II:IW1:29:32:42:55:56:60:63:65:66:74:7.5:78: 79:81:100:103:110:112:121:  
123:139:142:151:161:162:173-176:180:187:193:194:201:209:210:215:220:236:238:238-241:251:254:259:273:274 
:278:283;295;312:314;315:334:341:364:368:369;371:372;374:375:377:387:389:396:397:399:406:4 i 3:423:425:426
Fifteen  years  ago  the  first  study  linking  the  inactivation  of the  pS3  gene  and 
prostate cancer was published  l8°. Since this study there has been an explosion 
in  research  activity  associated  with  p.33  and  prostate  cancer.  In  this  seminal 
study by Isaacs et al  it was reported that mutations occurred in the p.33 gene in 
prostate  cancer  cell  lines  and  human  tissue  specimens.  Sequence  analysis  of 
exons  5-8  of the  P53  gene  reveals  that  three  of five  prostate  cancer cell  lines 
contain  mutations  which  alter  the  base  sequence  of this  portion  of the  gene. 
One  of  two  primary  prostatic  cancer  specimens  examined  also  contained  a 
mutation  in  this  region.  Transfection  of  the  wild-type  p.53  gene  versus  a 
mutated  P53  gene  into  two  cell  lines  with  p.33  mutations  results  in  reduced
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colony formation.  Immunocytochemical  data indicate that prostate carcinoma 
cells expressing the transfected wild-type p.33 gene are growth arrested because 
they exhibit a reduced level of thymidine incorporation into DNA.
The  first  paper  linking  p.33  and  prostate  cancer  specimens  from  a  patient 
appeared  in  1992  from  the  group  from  North  Carolina112.  Using  PCR 
techniques  they  detected  P53  mutations  in  a  patient  with  T4N 1M0  prostate 
cancer  who  had  initially  been  treated  with  a  multimodality  combination  of 
radiotherapy  and  hormonal  therapy.  The  patient  14  years  after  the  initial 
treatment  went on  to  have a TURP and  radical  cystoprostatectomy. The areas 
of  the  primary  tumour  and  the  lymph  nodes  were  examined  with  PCR 
techniques.  Although the mutations in p.53  were heterogeneous in the primary 
tumour, the same mutations were detected both  in the primary tumour and the 
nodal deposits.
3.31  P53 in patients who have undergone surgical treatment.
Radical  prostatectomy has become the main  stay for the surgical  management 
of  localised  prostate  cancer;  however  it  is  only  successful  if  the  patient  is 
cured.  P 5 3   has  been  advocated  as a predictor of outcome.  One of the earliest 
studies of the incidence of pS3 in patients with prostate cancer consisted of 150 
patients.  The  study  group  consisted  of  8 8   men  who  had  had  a  radical 
prostatectomy, 52 cases had a TUR, and  10 cases had a TUR for palliation of
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recurrent disease.  P53  was detected using immunohistochemistry  in  17 of the 
140 primary tumours,  and  in two patients  with recurrence42.  It is noteworthy 
that  an  antigen  retrieval  system  was  not  used  in  this  earlier  study. 
Immunostaining  was  significantly  related  to  stage.  The  immunhistochemical 
findings  were  confirmed  in  14  cases  by  DNA  amplification  and  screening 
between exons 4-9.  20 negatively staining cases were used as controls and no 
mutations  were  detected  in  these cases.  The authors  used  the fact that single 
strand  conformational  polymorphism  may  not  be  1 0 0 %  sensitive,  and  P53 
accumulation  may  occur  without  p.33  mutation  as  an  explanation  for  the 
discrepancy in the results obtained between  immunohistochemistry and single 
strand  conformational  polymorphism.  The  authors  also  commented  upon  the 
fact that compared to other tumours -  breast, lung, colon, and oesophagus, the 
frequency of P53 mutation and accumulation was rather low42.
In  a retrospective  study of 49  patients  with  clinically  localised  (T 1.2  Nx  Mo  , 
PSA  < 20,  bone  scan  negative)  moderately differentiated  (Gleason  score 5-7) 
carcinoma of the prostate treated with radical prostatectomy and with a follow 
up  of  at  least  5  years,  Yang  et  al  425  showed  that  P53  determined  by 
immunohistochemical  was  present  in  10/16  patients  which  had  a  recurrence 
compared to 7/33  in the non-recurrent group.  P53 was significantly associated 
with cancer recurrence.  It is interesting to note that in this report 22 out of the 
49  patients  that  had  extra  capsular  disease  and  the  incidence  of  nodal
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involvement is not mentioned.
In a study of 93 patients from Memorial Sloan-Kettering Cancer Centre,  19/93 
(20%) demonstrated  nuclear immunostaining  n .  Of the 93  tumours, 48  were 
primary  tumours,  29  were  lymph  nodes  involved  with  tumour,  and  16  were 
specimens  from  patients  who  had  presented  with  pathological  fractures.  Of 
the  48  primary  tumours,  9  were  organ  confined,  18  had  seminal  vesicle 
involvement, at the time of the operation  11  had lymph node involvement, and 
10  were  from  patients  with  disseminated  hormone  refractory  disease.  Apart 
from  the  1 0  patients  with  metastatic  disease  who  had  undergone  palliative 
TURPs, the remaining 38 primary tumours were from patients who had under 
gone radical prostatectomy.  9 out of the 48 primary tumours stained positively 
for  P5 3,  of these  9,  8  had  Gleason  scores  above  8 .  Only  one  of the  primary 
tumours  with  a Gleason  score of less than  7  was observed  to accumulate p.3 3. 
None of the specimens  with organ confined disease stained positively for p.33, 
but  1  out  of the  18  with  seminal  vesicle  involvement,  and  2   out  of  the  11 
patients with pelvic lymph node metastasis stained positively for p.5 3. Eight out 
of the  16 bone specimens compared to two out of the 29  lymph nodes stained 
positively  for  p.3 3.  Therefore  p.53  accumulation  significantly  correlated  with 
high Gleason score, stage, hormone refractory disease, and was more common 
in  bone  metastasis  than  lymph  node  metastasis.  A  study of  100 consecutive 
radical prostatectomy specimens confirmed the low incidence of p.33 mutations
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in  localised carcinoma  i.e.  one  in  67 cases,  compared  to 5  out of 33 cases  in 
locally  invasive  carcinoma  27\   This  study  also  demonstrated  a  good 
correlation  between  immunohistochemically  detected  P53  over  expression 
compared  to  p5 3  mutations  detected  by  polymerase  chain  reaction 
amplification  and  single  strand  conformation  polymorphism.  The  DO-1 
antibody  detected  5  out  of  6   mutations  in  P53  and  an  additional  mutation  in
77 ^
exon 6  was detected by molecular biology '  .
A  further  study  of 73  radical  prostatectomy  specimens  demonstrated  that  34 
specimens  stained  positively for P53  l62.  It  is  interesting  to  note  that only 28 
out of the  73  prostatectomy  specimens  were  in  fact organ  confined  i.e.  39%. 
24  out  of the  28  pT2 or  less  lesions  were  P53  negative,  thus  staining  for  p5 3 
correlated  with  high  stage.  In  addition  p.53  staining correlated  with  increased 
PSA,  Gleason  score  and  increased  tumour  volume.  This  correlation  is  not 
surprising  since  high  stage  disease  is  associated  with  increased  PSA,  high 
Gleason  score and high tumour volume.  Follow up was not an aspect of this 
study  and  this  paper  did  not  comment  upon  whether  p.33  staining  was  an 
independent  marker  for  recurrence.  A  further  study  of  137  consecutive 
prostate  specimens  obtained  by  radical  prostatectomy  detected  11  specimens 
(8 %) with P53 over expression, ten out of the  11  specimens were pT3, nine out 
of the  11  were  high  grade  i.e.  Gleason  score  >7.  P53  over  expression  was 
associated  with  increased  Ki-67  labelling  index  implying  rapid  tumour
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proliferation 60.
A  study  of  85  prostate  carcinoma  specimens  obtained  from  a  mixture  of 
radical  prostatectomy  specimens  and  TURP  specimens  analysed  by 
immunohistochemistry and DNA analysis demonstrated only 3 specimens with 
aberrant P53 expression i.e.  3.5% 406.  No information was given regarding the 
stage of the disease; the Gleason score of the specimens was  6 ,  7,  and  8 . The 
authors concluded that the presence of aberrant p.33  appears to be an infrequent 
event.  The  infrequency  of  P53  in  localised  prostate  cancer  was  further 
confirmed  on  a  study  of  tissue  obtained  from  37  patients  with  localised 
carcinoma  of  the  prostate  and  subsequently  treated  with  external  beam 
radiotherapy, only one of the 37 specimens stained positively for P53  15’.  This 
study  went  on  to  compare  immunohistochemistry  with  PCR  using  both 
positive  and  negative  samples  and  found  complete  concordance.  These 
authors  concluded  that  the  presence  of  p.33  mutation  was  a  late  step  in  the 
progression of prostate cancer and was a late step in the progression of prostate 
cancer  and  associated  with  advanced  disease,  dedifferentiation,  and  the 
acquisition of androgen independence.
The  studies  so  far  mentioned  in  this  section  have  largely  concentrated  upon 
detecting  the presence  of p .3 3 ,  and  correlating  it  with  known  markers  of poor 
outcome,  i.e.  high Gleason score, high tumour volume/stage.  The group from
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Walter Reed  Army Medical  Centre,  Washington,  then published  the outcome 
of their series of radical prostatectomy operations  19:2()-274.  The series consisted 
of  175  patients  who  had  had  radical  prostatectomy  over  a  seven-year  period 
and who they had archival material available on. Using immunohistochemistry 
114 of the  175  patients (65%) were positive for p.5 3, a much higher proportion 
than  previously  detected.  Expression  correlated  with  higher  stage,  Gleason 
score, and nuclear grade.  P53 positivitey did correlate with a higher incidence 
of recurrence,  i.e.  51.1%  in  p.53  positive  patients  versus  2 2 %  in  P53  negative 
patients.  This  was  an  independent prognostic  marker  19.  Over expression of 
bcf  was detected  in 47  patients  (26.9%),  the combination  of p.53  positive and 
bcE positive was highly significant at predicting recurrence when compared to 
P53  negative and bcf  negative patients.  Similar results  have been reported by 
others, in a series of 40 radical prostatectomy specimens, 32 (80%) stained for 
P53  and  of  these  20  (62.5%)  progressed,  none  of  the  p.33  negative  patients 
progressed.  P53  immunoreactivity was an independent predictor of recurrence 
374.  In a British series of 76 radical prostatectomies carried out by the Bristol 
group  with  a  mean  follow-up  of 38  months,  aberrant  p.53  was  detected  in  39 
(57%) of patients.  19 of these patients had recurrence of prostate cancer, where 
as in the group with normal expression of p5 3 only three out of 23 patients had 
evidence  of recurrent  disease.  Therefore  the  authors  concluded  that  aberrant 
P53  does  predict  recurrence  5\   In  a  further  series  of  76  radical 
prostatectomies,  aberrant  P53  was  detected  in  18  patients  (2 0 %  positive
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staining)  and  this  significantly correlated  with  poor survival  in  a  multivariate 
analysis 209.
A  heterogeneous  series  of patients  treated  with  radical  prostatectomy,  some 
having had LHRH therapy preoperatively, from the Memorial Sloan-Kettering 
demonstrated  a  strong  link  between  p.33  over  expression  and  recurrence  29\  
However  they  also  found  that  some  tumours  expressed  P2 1.  There  was  no 
relationship  between  P21  and P53  status, this  is  interesting since p2 i  is thought 
to be a downstream messenger of P53, and one would expect only patients with 
wild  type  P53  to  have expression  of P2 1.  The  authors  postulated  that p2 i  may 
also be activated by a p.33 independent pathway 295.
A  study  from  New  South  Wales  carried  out  on  263  consecutive  radical
prostatectomy attempted to quantify the relationship between p5 3 and outcome
^ 1 ^ after  surgery  The  authors  compared  the  number  of cell  with  aberrant p.33 
with outcome, and also compared clustering of p.33 i.e. the presence of a cluster 
of P53 positive tumour cells within a 2 0 0  x  magnification field, with outcome. 
They  concluded  that  their  data  supported  the  relationship  between  outcome 
and p5 3 immunohistochemistry at thresholds of no nuclear accumulation versus 
any accumulation; and the presence of clusters of P53 positive cells versus their 
absence/and  between  >20%  positive  cells  and  <20%staining.  In  predicting 
early  death  from  prostate  cancer  p53  positivity  in  >2 0 %  of  nuclei  defines  a
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group  of patients  with  highly  aggressive  disease,  all  six  of  the  patients  that 
died  during  the  follow  up  period  of  the  study  (4.9  to  123  months,  mean 
55.5months) fell in to this group 312.
A recent study investigated  the usefulness of p.33  in  locally advanced prostate 
cancer 22().  This study group consisted of 72 patients with a median follow up 
of 5.4  years  (range  .5  to 6.4).  Biochemical  failure,  local  failure,  or  systemic 
failure  occurred  in  29  of the patients.  The group compared  the usefulness of 
P53  positive  staining  at the  10%  level  with  Gleason  score,  PSA,  pathological 
stage, volume of extraprostatic tumour extension, and total  volume of tumour. 
Using  a  multivariate  analysis,  which  contained  P5 3,  only  p.33  predicted 
outcome,  and  when  it  was  added  to  the  statistical  model  for  predicting 
outcome it improved the predictive ability of the model  “  .
Other studies  have  not shown p.53 to be so useful.  A study evaluating the role 
of P5 3,  Ki-67,  and  apoptotic  index  in  predicting  recurrence  in  a  series  of 47 
patients demonstrated that  16 of the specimens had clustered immunopositivity 
for P5 3.  17 of the 47 patients had evidence of disease recurrence at 5 years and 
the conclusion of these authors was that although both p.53 and apoptotic index 
may predict recurrence  using a multivariate  analysis only the  apoptotic  index 
reaches significance in the final  logistic regression 368.  A further study of 208 
consecutive  radical  prostatectomy  specimens,  75  with  localised  intracapsular
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disease,  123  extra  capsular  locally  invasive,  and  8  of these  had  lymph  node 
involvement.  P53 at the >5% level was detected in 79 specimens, and although 
this  did  correlate  with  tumour  volume,  P53  expression  levels  were  not 
associated  with  differences  in  recurrence  free  survival  194.  A  study  of  134 
patients  also  showed  that  P53  was  not  helpful;  this  report did  not  indicate  the
397
method of treatment
3.32  P53 and watchful waiting
The  Scandinavian  countries  have  adopted  watchful  waiting  as  their  mainstay 
for the  management of asymptomatic  carcinoma of the prostate.  The rational 
for  this  has  been  discussed  previously  (see  section  1.66).  In  a  study  of  186 
patients  diagnosed  by  TURP  and  treated  with  watchful  waiting  163  patients 
died, 79 from prostate cancer, during the follow up.  Nineteen patients stained 
for aberrant p.33,  the mean survival for p.33  positive patients was 52 months and 
for  P53  negative  patients  it  was  123  months.  There  was  a  significant 
correlation between tumor stage, tumor grade, metastasis, age and p53 staining. 
However  in  a  Cox  multiple  regression  analysis  of tumor  stage,  tumor grade, 
metastasis, age and p.5 3, p.33 lost its significance. The authors concluded that the 
prognostic  value  of p.33  appears  to depend  upon  its association  with  advanced 
stage  and  high  grade,  and  they  did  not  feel  it  would  be  a  good  prognostic 
marker in early prostate cancer369
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A  further  study  from  Scandinavia  of 221  men  diagnosed  with  carcinoma  at 
TURP  and  followed  up  for  a  median  of  15  years  showed  that  all  tumors 
expressed some degree of staining for p53.  There was a significant association 
between  p53  staining,  local  tumor  stage  and  grade.  The  patients  that  were 
highly  immunoreactive  for  p33  did  significantly  worse  than  the  patients  with 
low immunoreactivity for p33 43.
3.33  P53 and radiotherapy.
Radiation  causes  cellular  DNA  damage  which,  if  irreparable  can  lead  to 
apoptosis in a cell expressing wild type p33. Cells with an aberrant p33 can not 
enter  cell  cycle  arrest  at  the  Gl/S  or  Go/M  checkpoints,  as  would  cells 
expressing  the  wild  type  p33  gene.  In  a  series  of  33  patients  who  had  failed 
radiotherapy  and  had  pre  and  post  radiotherapy  specimens  no  significant 
difference  in  p33  immunostaining  was  found  between  the  failures  (67%)  and
17 3 the  successes  (75%)  of radiation  therapy  .  However,  the  sample  size  was 
small  and  the  follow  up  period  was  short  at  3  years.  A  further  study  of 38 
patients  also  failed  to show  any relationship between p33  over expression and 
recurrence 315.
A large study was commissioned under the auspices of the Radiation Therapy 
Oncology Group.  The protocol,  8610, consisted of cytoreduction pre and peri 
radiotherapy  for  locally  advanced  prostate  cancer.  One  hundred  and  twenty
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nine patients were analysed in this sub set analysis with a median follow up of 
5  years  (range  1.17 -  7.14 years).  23  patients  stained for aberrant p53  with  > 
2 0 %  positive  nuclei,  1 2  in  the  radiotherapy  alone  arm  and  1 1  in  the 
radiotherapy  plus  cytoreduction  group.  Using  Cox  regression  analysis 
abnormal  p.33  expression  was  an  independent  prognostic  indicator  for 
significantly shortened survival, increased incidence of distant metastases, and 
a reduced progression free survival  l39.
A  study  of 55  patients  with  recurrent  disease  despite  radiotherapy,  who then 
underwent  salvage  radical  prostatectomy,  p.33  staining  was  detected  in  50
7 0
specimens  .  Over  expression  of  P53  was  associated  with  an  increased 
proliferative activity as measured by Ki-67 labelling index.  It is not clear from 
this  study  whether  the  over  expression  of  p.33  developed  overtime  or  was 
always present.  Additionally radiotherapy can lead to stabilisation of the wild 
type  P53  and  so  this  may  be  detected  by  immunohistochemistry.  An  older 
study  of  18  radiotherapy  failures  patients  also  showed  a  high  level  of  p53 
accumulation  (72%  -  13  patients) 3I°.  In this  study group the authors  had pre 
radiotherapy tissue specimens of  1 0 patients and in these specimens there was 
also  a  high  level  of p.53  expression,  implying  longstanding ps3  alteration.  The 
authors also tested  the  validity of p.53  immunoreactivity with  PAb  1801  in  ten 
post  irradiation  patients,  five  with  positive  staining.  Using  single  strand 
conformational  polymorphism  they  could  only  demonstrate  abnormalities
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between  exons  5   to  8  in  three  out  of the  five  p53  positive  staining  patients. 
None of the negative staining specimens demonstrated any abnormalities.  The 
authors  attributed  this  discrepancy  to  less  than  1 0 0 %  sensitivity  of  single 
strand  conformational  polymorphism,  false  positive  staining  with 
immunohistochemistry, or the ps3 mutations may lie outside exons 5 to 8  31°.
The  alteration  in  the  phenotype  and  the  genotype  of recurrent  tumours  after 
definitive  therapy  was  investigated  in  32  patients  142.  18  patients  had
recurrence  after  radical  prostatectomy,  and  13  had  recurrence  after 
radiotherapy.  In both groups of patients there was a significant increase in the 
Ki-67  labelling  index,  and  p33  nuclear  reactivity  in  tissue  obtained  from 
recurrences when compared with primary lesion.  The nuclear reactivity was of 
the  clustered  type,  which  may  represent  a  more  aggressive  phenotype  425. 
There was also an increase in the Gleason scores of the recurrent lesions in the 
radiotherapy  group.  This  would  suggest  that  a  more  aggressive  phenotype. 
The  authors  suggested  a  number  of  explanations  for  this;  tumour  cells  are 
genetically unstable  and therefore the first cells to relapse are the ones  with  a 
selective  growth  advantage.  An  alternative explanation  may  be  by  removing 
the primary tumour,  a growth inhibitor is removed.  There is therefore growth 
acceleration  of the  residual  tissue  as  is  the case  in  the  Lewis  lung carcinoma 
model 289.
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3.34  P53 and pre-treatment biopsies.
The  ability  to  detect  preoperatively  those  patients  that  would  benefit  from 
radical  surgery would  be  a considerable aid to the  surgeons.  In a series of 76 
patients who had undergone radical prostatectomy and had preoperative TRUS 
guided  biopsies  it  was  shown  that  the  risk  of  relapse  was  24%  higher  if 
aberrant p.33  was  detected  on  the pre-operative  biopsies.  Using  a  multivariate 
analysis  the presence of aberrant P53  and  Gleason  score  > 7  was  shown  to  be 
independent  predictors  of  relapse  in  patients  undergoing  radical 
prostatectomy55.
A study comparing biopsies with  106 radical prostatectomy specimens that had 
neoadjuvant  androgen  ablation  prior  to  definitive  surgery  did  not  show  a 
correlation  between  preoperative  expression  of p.53  and  outcome  74.  In  this 
study,  with  respect  to  radical  prostatectomy  specimens,  the  aberrant  p.53  was 
detected  in  32  cases  prior  to  antigen  retrieval  and  in  77  cases  after  antigen 
retrieval.  Only  77  biopsies  were  available  for  analysis  and  after  antigen 
retrieval  only  eight  were  positive.  The  expression  of  aberrant  p.33  in  radical 
prostatectomy  specimens  correlated  with  poor  outcome,  however  in  a 
multivariate  analysis  this  was  not  an  independent  prognostic  factor.  Biopsy 
expression of p5 3 did not relate to outcome 74.  The increase in the levels of P53 
may be explained by the effect of androgen ablation on the expression of p .3 3 .
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A  retrospective  review  of  the  pre-treatment  biopsies  of  49  patients  who 
underwent definitive radiotherapy for the treatment of localised carcinoma was 
carried out.  A surrogate end point for relapse was used; this was a PSA nadir 
of  l.Ong/ml.  The  biopsies  of  17  patients  stained  positively  for  p.3 3,  of these 
patients  15  (88.2%)  did  not  reach  a  PSA  nadir  of  1.0.  32  patients  stained 
negatively  for  P5 3,  of  these  23  reached  the  surrogate  end  point.  Logistic 
regression  analysis  showed  that  P53  was  an  independent  predictor  of relapse 
after definitive radiotherapy 341.  The results of this study could be interpreted 
as  showing  that  increased  p?3  is  common  in  patients  with  advanced  possibly 
extraprostatic disease not amenable to radiotherapy.
A  comparison  of pre-treatment  biopsies  and  survival  was  carried  out  on  60 
patients 37'.  This  was  a retrospective  study,  with  the  majority of patients not 
receiving  any  pre-treatment  hormonal  manipulation.  The  group  of  patients 
consisted  of 36  patients  with  T2  or  below  disease  and  18  patients  with  stage 
T3-T4  disease.  Six  patients  were  Tx,  i.e.  not  staged;  the  local  staging  was 
carried out with  digital  rectal  examination.  15 patients underwent lymph node 
dissection,  and  five  of these  were  positive.  59  patients  had  had  a bone  scan 
which  was  negative.  P53  immunostaining  was  carried  out  with  an  antigen 
retrieval  system, overall positive staining occurred in  15 tumours, surprisingly 
and  in  Contrast  to  other  studies  a  greater  proportion  of  lower  stage  tumours 
stained positively. The survival of the P53 positive group appeared to be better
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than  the  p.33  negative  group.  The  authors  concluded  that  no  survival 
disadvantage was seen in patients with P53 im mu noreactive tumours, implying 
aberrant P53  does  not confer radio resistance  and  that alternative pathways  to 
apoptosis  may  be  more  important.  This  study  is  incomplete  in  many  ways. 
There is no mention of PSA, and no imaging of the lymph nodes was carried. 
It  is  not  incomprehensible  to  suspect  that  many  of these  patients  may  have 
advanced  disease  since  in  the  15  patients  suitable  for  radical  surgery  a  third 
had disease beyond the prostate and mean survival of the patients was only 75 
months (range 8.5 -  172).37'.
3.35  P 5 3  and metastatic prostate cancer
A  study of ten  lymph  node  specimens  with  prostate cancer showed  that only 
one stained positively for P 5 3 4 0 6 .  A further study of 56 patients with metastatic 
lymph node disease and a median follow up of 3.8 years was carried out 238.  In 
this study 26 patients had material available from both the primary tumour and 
lymph  nodes,  a  further  15  had  material  available  from  the  primary  tumours 
only,  and  15  patients  had  only  lymph  node  samples.  P 5 3   was  detected  in  5 
primary tumours, and in 7 lymph node specimens. The median Ki-67 labelling 
index  was  8.4%  in  the primary  tumours  and  8.7%  in  the  lymph  nodes.  The 
median  Ki-67  labelling  index  was  significantly  higher  in  the  P53  positive 
patients.  TJsing a multivariate analysis the Ki-67  labelling index  and Gleason 
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with positively staining lymph nodes the presence of bone metastasis was also 
a prognostic  factor 238.  Although patients  staining positively for P53  and  bcf 
tended to have a poorer outcome this did not reach significance 238.  A study of 
36 primary prostate cancers,  17 patients with nodal  involvement, and  14 cases 
of  bone  metastasis,  demonstrated  a  greater  proportion  of  the  specimens 
obtained from  metastasis  showed aberrant staining for p.5 3;  i.e.  only ten of the 
primary tumours,  ten  of the lymph nodes with  metastasis, and six of the bone 
metastasis  174.  Interestingly there was no correlation between P53 expression in 
the primary tumour and metastasis.
The  difference  in  p53  staining  between  treatment  naive,  metastatic  and 
hormone refractory prostate cancer was  investigated in 61  patients161.  The 61 
patients  consisted  of 27  patients  with  recurrence  after either  radiotherapy  or 
hormonal  intervention  or both  and  tissue  was  obtained  by TURP  and  in  one 
case  by  prostate  biopsy;  8  patients  with  metastatic  lymph  node  disease  and 
tissue  was obtained from  the  lymph nodes;  and 27 primary untreated tumours 
and  tissue  was prostate biopsies.  The  authors demonstrated  an  increase  in  p.33 
in  the  hormone  refractory  group  i.e.  20  out  of  the  26  cases  (76%)  stained 
positively for P53 compared to 4 out of the  8 (50%) metastatic, and 6  out of 27 
(22%)  in  the  untreated  group.  The  authors  concluded  that  this  study 
demonstrated  an  increase  in  p.53  from  untreated  primary  tumour  to  hormone 
refractory disease161.  However there  are  several  points  in  this  paper,  which
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are  not  that  clear.  The  group  of  patients  with  refractory  disease  was  rather 
heterogeneous,  and  it is not clear whether all  the patients  in  the relapse group 
actually  relapsed  using  PSA  criteria  or  needed  a  TURP  for  non-malignant 
outlet obstruction. The abstract of the paper claims that 94%  of the patients in 
this group were p.33 positive, where as in the body of the paper only 76% i.e.20 
out  of  26  stain  positively  for  In  addition  it  is  worth  noting  that  five 
patients  in  the  relapsed  group  had  cytoplasmic  staining  for  p.33,  the  authors 
graded these as positive161.
A  study of bone  marrow  biopsies obtained  from  the  iliac crests of 43  patients 
with  hormone  refractory  metastatic  carcinoma of the  prostate  showed  that  2 2  
(51%)  exhibited  immunohistochemical  positivity  for  P53  245.  Eight  cases 
exhibited positive staining for bcb and P5 3, and six cases were positive for just 
bcK  The expression of either of these proteins did not influence outcome and 
so  it  was concluded  that these genetic  mutations are  not essential  for the  fatal 
progression  of prostate  cancer.  There  must  be  multiple  pathways  of tumour
">43
p r o g r e s sio n   in   p r o sta te   c a n c e r   "  .
3.36  The effect of castration on P53.
In  a  retrospective  study,  Stattin  et  al  studied  the  effect  of  castration  on  28 
patients  with  carcinoma  of the  prostate  372.  The  28  patients  consisted  of  15 
responders and  13  non-responders, 3 patients were initially stained for p.33 and
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further  3  responders  stained  after  LHRH  therapy.  P53  immunoreactivity  did 
not correlate with outcome after castration 372.
Increased  p.33  was  also  detected  in-patients  who  had  had  neoadjuvant  LHRH 
therapy prior to radical prostatectomy.  All the patients in this cohort who had 
expression  of  p.53  relapsed.  The  authors  concluded  that  the  finding  of  an 
aberrant p.33 could be due to the advanced stage at which the patients presented 
and  were selected  for treatment using neoadjuvant LHRH, since an altered psi 
may  lead  to  resistance  to  castration  induced  apoptosis  and  so disease  relapse. 
Therefore  the  presence  of  an  aberrant  P53  may  be  an  early  event  in  the 
evolution  of hormone  refractory disease  in clinically  localised prostate cancer 
29\   This  relationship  between  aberrant  P53  after  neoadjuvant  therapy  and
relapse  was  further  commented  upon,  when  19  out  of  21  patients  with  P53
^ 1 ^ clustering relapsed within 36 months of definitive treatment
This  relationship  between  the  presence  of  aberrant  p5 3  detected 
immunohistochemically  after  LHRH  treatment  was  further  strengthened  in  a
subset analysis of 263  radical prostatectomies carried out in  New South Wales
^ 1  ^ in  Australia  ".  39  patients  in  this  cohort  of  263  had  received  neoadjuvant 
LHRH  treatment  prior  to  definitive  surgery.  23  patients  in  this  group  of 39 
had  relapsed.  A  total  of  21  patients  were  p.33  cluster  positive,  and  90%  (19 
patients)  of the  cluster  positive  patients  relapsed.  P 5 3   cluster  status  was  the
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strongest  predictor  of  recurrence  in  a  multivariate  analysis  comparing  p.5 3, 
pretreatment PSA, Gleason score, and pathological stage 3I2.
In a study of 26 patients with prostate cancer that had relapsed despite first line 
therapy -  radiotherapy or hormonal or both, a total of 2 0  patients demonstrated 
P53  staining  and  in  4  of  these  the  staining  was  cytoplasmic  161.  The 
significance of cytoplasmic  staining of a nuclear protein  is  at  present unclear. 
However the authors counted these tumors as P53 positive.
The  relationship  between  aberrant  p.53  expression  and  androgen  receptor gene 
amplification  was  studied  in  30  patients  with  hormone  refractory  disease. 
Comparing  primary  untreated  tumours  with  hormone  refractory  specimens 
obtained  from  the  same  patient,  the  immunostaining  for  P53  increased  from 
17%  to  40%  respectively.  The  tumours  with  aberrant  p.33  expression  were 
more  likely  to  have  androgen  receptor  gene  amplification,  suggesting  that 
tumours  with  an  aberration  in  P53  were  more  likely  to  become  hormone 
refractory and so survive in lower androgen concentrations201.
3.37  Site of P53 mutations
Micro  dissected  DNA  selectively  extracted  from  paraffin-embedded  sections 
of prostate cancer and PIN has shown a high frequency of p.53  mutations in the 
lesions dissected from the peripheral zone lesions when compared to those that
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were  dissected  from  the  transition  zones.  For the cancer lesions  the  incidence 
was 33.3% in the peripheral zone versus 4% in the transition zone, and for PIN 
the  incidence  was  14.7%  and  5.6%  respectively.  In  areas  of  benign  tissue 
adjacent  to the PIN  or cancer there  were  mutations detected  in  p.3 3.  The  point 
mutations detected in  PIN and cancer were not identical  the  authors attributed 
this  to  the  polyclonality  of prostate  cancer.  In  addition  the  authors  found  a 
higher  incidence  of  P53  mutation  in  T3  carcinomas  of  the  prostate  when 
compared  to  T2  lesions.  The  authors  conclude  by  stating  that  their  findings 
indicate  that  that  the  p.33  gene  mutations  are  involved  in  prostatic 
carcinogenesis and explain why the non-transition zone is the predominant site
C  377 or cancer  .
3.38  Racial differences
A heterogeneous group of 62 archival  samples of prostate tumor obtained from
•   •   X I Asians  of  non-Japanese  origin  were  examined  .  The  specimens  were 
obtained  by  TURP  and  the  patients  were  staged  with  a  CT  scan  of  the 
abdomen  and pelvis, only  2   patients’  expressed  p.33,  both of these  patients had 
metastatic disease.  The authors concluded that the expression of p.33 mutation 
in Asian cohorts is significantly lower.
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Table 6 (cont.): The incidence of P53 in patients with prostate cancer.
27X 1994 Rad  Pros 
tumour  (28), 
Rad  Pros  PIN 
(16)  metastatic 
primary  (16). 
lymph  nodes 
(18).
78 28 • > 16+18 1HC 2/28 localised carcinoma p53+, 
1/16 PIN p53+.
9/16 metastatic p53+.
10/18 lymph nodes p53 +.
Increasing  p53  in  pts  with 
mets.
32 1994 Microdiseetion 
of  benign 
lesions close to 
malignant 
tissue
21 6 12 3 PCR
SSCP
1/21  benign  lesion  close  to 
Gleason  7  lesion  showed 
alteration in p53.
P53  alteration  may  be  an 
early change in the genesis of 
prostate cancer.
161 1995 TURP  + 
Biopsies
61 ?0 26+27 8 IHC
PCR
6/27 treatment naive p53+, 
20/26  androgen  refractory 
p53+,
4/8 metastatic were p53+.
Progression  in  p53  alteration 
from  untreated  to  hormone 
refractory disease.
151 1995 TURP  + 
biopsies.
37 26 11 0 IHC
PCR
1/37 p53 +
P53 positive on IHC confirmed 
by  PCR.  7  negative  patients 
had PCR. no p53 mutation.
IHC  is  reliable,  and 
correlates  well  with  PCR. 
The  authors  concluded  p53 
mutations  detected  by  IHC 
are  a  late  step  in  the 
progression  of  prostate 
cancer  and  are  associated 
with  advanced  disease, 
dedifferentiation,  and  the 
acquisition  of  androgen 
independence.
310 1996 Salvage 
prostatectomy 
(15)  or  TURP 
(3)  for  relapse 
post DXT.
18 • > ■ 7 0 IHC  + 
PCR
13/18  (12%)  +  in  relapse 
group, 20 %  + in control  (Non 
irradiated advanced Ca P)
P  53  aberration  common  in 
patients  with  relapse  post 
DXT.Table 6: The incidence of P53 in patients with prostate cancer.
Ref. Year of 
pub
Type  of 
specimen
No  of 
cases
No  with 
intracapsular 
disease
No with extra
capsular
disease.
No  with 
metastasis
Method Results of P53 staining Conclusion
406 1994 85  prostate 
(Rad  pros  + 
biopsies )-t- 
10  lymph 
nodes
85 +  10 ■ > 0 10 IHC +
Polymerase 
chain  reaction 
single
stranded
polymorphism
(PCR-SSCP)
3/85  p53  +  in  primary 
prostate  cancer  and  1/10 
p53 + in lymph nodes.
P53  mutations appear to 
be  of  low  frequency  in 
prostate cancer.
162 1994 Rad  pros 73 28 45 IHC 4/28 localised p53 +
31/45 extracapsular p53 +
P53  correlated  with 
more  advanced  tumour 
stages.  with  higher 
Gleason  grades,  and 
with  larger  total  and 
high-grade  tumour 
volumes.
11 1994 Radpros, 
TURP. 
Primary, 
lymph nodes. 
Mets
93  (48 
prostates 
29  lymph 
nodes.  16 
bone 
mets).
9 18 1  1   rad  pros  in 
pts with lymph 
node
involvement 10 
TURP
29  lymph 
node
16 Bone mets
IHC 0/9  p53+ in localised 
1/18 p53+ in extra capsular 
2/11  p53+in pts with lymph 
node+
6/10  p53+  in  hormone 
refrae CaP
2/29  p53+  in  lymph  node 
met
8/16p53+ in bone mets.
P53 correlates with high 
grade.  hormone 
refractory  tumours,  and 
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Table 6 (cont.): The incidence of P53 in patients with prostate cancer.
4H 1997 Rad  Pros. 
TURP.  Pros 
Biopsy
36 22 0 14 IHC 5/22  (239c)  p53  positive 
localised.  1/14  (7%)  metastatic 
positive.
Follow  up  only  12  months, 
no  relationship  between 
outcome and p53 status
2 7': < 1997 Radical
prostatectomy
100 67 33 29 IHC
PCR-
SSCP
1/67 localised p53 +
5/33 extra capsular p53 +
5/6 mutations detected by IHC 
6/6 detected by PCR - SSCP.
P53  mutations are a rare late 
event in prostate cancer.
66 1997 Biopsy
TURP
40 15 24 21 T, _ 2=5/15 p53 +
T,_j = 14/24 p53 +
17/19 p53+ pts progressed 
12/21  p53 - pts progressed
P53  positive  tumours higher 
grade  and  quicker 
progression.  No correlation 
between  p53  and  p21  or 
waf 1.
797 1998 Not Stated 134 51 27 56 IHC 11/51  p53+Localised 
7/27 p53+  Extra capsular 
15/56 p53+ With extra prostatic 
disease.
P53  did  not predict outcome 
(Mode  of  treatment  not 
stated)
79 1999 Salvage 
Radical 
prostatectomy 
in  post-DXT 
relapse.
53 • > ■ ) IHC 50/55  P53 + High  incidence  of  p53+  in 
patients  who  relapsed  post 
DXT.
X I 2000 62 TURP 62 13 4 36 IHC
PCR
2 p53+ Lower  p53  expression  in 
Asians
IV) 2004 Rad Prost 98 • > • > 9 IHC 55/98 Positive by IHC No  prognostic  data,  but 
compared  IHC  with  PCR. 
IHC  generated  27/55  false 
positive,  and  15/42  false 
negative.Prostatic lntraepithelial Neoplasia and Prostate Cancer.
Table 7: The relationship between P53 watchful waiting
Ref. Year  of 
pub
Type  of 
specimen
No  of 
cases
No  with 
intracapsular 
disease
No  with  extra
capsular
disease.
No  with 
metastasis
Method Results of P53 staining Conclusion
W 19% TURP 186 159 27 23 IHC TO = 6%  M0 = 9% 
T1  =  13%  Ml  =22% 
T2 =  10%  Mx  =  14% 
T3 = 25%
T4 = 38%
P53  correlates  with  stage, 
grade,  metastasis,  but  in 
multiple  regression  analysis  it 
is  not  an  independent 
predictor.
4< 2000 TURP 221 131 90 60 IHC P53 staining correlated with stage. P53  was  an  independent 
adverse prognostic indicator.
111Prostatic Intraepithelial Neoplasia and Prostate Cancer.
Table 8 : The relationship between P53 and outcome in patients who have had radical prostatectomy.
Ref. Year  of 
pub
Type  of 
specimen
No  of 
cases
No
localised
No  locally 
invasive
No  lymph 
nodes/mets
Method Results Conclusion.
4: 1993 Rad  Pros 
+TURP
150 38 36 69 IHC + 
PCR
Stage 0  1/12  p53 +
Stage  1   0/26  p53 +
Stage 2 2/36  p53 +
Stage 3 8/36  p53 +
Stage 4 8/33  p53 +
Un staged 0/7 p53 +
{Treatment  was  radical 
prostatectomy  (88).  TURP  (52), 
hormonal manipulation (10)}
19/150 p53 +
P53 + related to stage.
1 4 1995 Rad Pros 139 57 81 1 IHC 28/57 localised p53 + 
56/81  extracapsular p 53 +
P53  was  an  independent 
marker for progression. ■  4 y. ■
1996 Rad Prost 49 29 20 ‘ 7 10/16  with  recurrence,  compared 
to 7/33 in non-recurrent group.
P53  staining  associated  with 
recurrence.
274 1996 Rad Pros 162 
mean 
follow  up 
4.5yrs
62 99 •7 IHC 38/62 localised p53 + 
73/99 extraapsular p53 +
In  a  multivariate  analysis  p53 
and  Bcl-2  independent 
prognostic  markers.  P53  +  = 
112  (69.1%).  bcl-2  =  44 
(27.2), Ki-67 = 62 (38.3%)
20 1996 Rad Pros 175pts 
with
mean  fu 
4.6yrs
174 1 ‘7 IHC 1  13/174 localised p53 + 
1/1  extracapsular p 53 +
In  a  multivariate  analysis  p53 
and  Bcl-2  independent 
prognostic  markers.  Bcl2+  = 
26.9%.  p53+  =  65%. 
multivariate  analysis  p53  and 
bcl2 independent predictors of 
disease.
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Table 8  (cont.): The relationship between P 5 3  and outcome in patients who have had radical prostatectomy.
60 1996 Rad Pros 137 44 93 34 IHC 1/44 localised p53 +
10/93 extra capsular p53 +
3/34  node  +  pts  were  p53  +  in  the 
primary tumour.
P53  +  tended  to  worse 
prognosis but not significance. 
Bcl2  pT3  (31%)  >  pT2  (5%) 
significant.  Combined  analysis 
of Ki67,  LI. and  Bcl-2 allowed 
the  distinction  of three  groups 
with different clinical outcome. 
Prognosis  was  best  in  Bcl-2- 
negative  tumours  with  low 
Ki67  LI.  worst  in  Bcl-2- 
positive  tumours  with  high 
Ki67 LI.
174 1996 Rad Pros 40 0 40 9 IHC 32/40 p53 + 20/32  p53  +  progressed.  P53 
was  an  independent  marker for 
progression.
204 1998 Rad Pros 76 42 34 6 IHC 18 >20%  p53 + >20%  p53  +  only  variable 
associated with decreased long­
term  survival  in  multivariate 
analysis.
144 1998 Rad Pros 208 75 123 8 IHC 79 p53 + P53  and  Rb  did  not  predict 
recurrence,  but  p53  did 
correlate  with  tumour  volume. 
MIB-1  and  Bcl-2  correlated 
with progression.
[42 1998 Rad Pros 18 11 7 5 IHC 1/18 Primary p53 + 
7/18 Recurrent p53+
Increased  p53  in  recurrences, 
genotype  of recurrence  is  more 
aggressive.
m 1998 Rad prost 47 47 0 0 IHC 10/17  p53+  in  relapse  group  @ 
5yrs
6/30  p53+  in  non-relapse group  (s>  
5 vr.
In  multivariate  analysis  only 
apoptotic  index  and  clustered 
p53  added  info,  in  regression 
model only AI reached stat sig.
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Table 8  (cont.): The relationship between P 5 3  and outcome in patients who have had radical prostatectomy.
5? 1999 Rad  Prost  +
pre-op
biopsies.
76 37 39 ■ > IHC 39 p53+ P53  predicted  recurrence. 
Aberrant  p53  led  to  a  24% 
higher  risk  of  relapse.  P53 
expression was more frequently 
observed  in  biopsy  specimens? 
difference  in  fixation? 
difference  in  tumour  due  to 
multifocality.
2 < J 5 1999 Rad Prost 86 51 35 ■ ) IHC 6/86 >20% p53 + P53 -i-ve relapsed quicker.
No  correlation  between  p53  + 
and  preop  PSA,  tumour  stage, 
or grade.
Also  stain  for  mdm2  and  p21 
which  was  positive  in  50%  of 
cases  and  postulated  that  p21 
activation  due  to  an  alternative 
mechanism  other  than  p53 
activation.
< 1 2 2(W)0 Rad Pros 263 114 144 5 IHC 132 (50.2%) (nuclear clustering) 
>0 to <2%  33 (12.2%)
>2 to <5% 35 (13.3%)
>20% 34(12.9%)
P53+ve  (Clustering  or  nuclear 
accumulation)  was  an 
independent  predictors  of 
relapse,  as  was  pre  treatment 
PSA.  tumour  stage,  tumour 
grade,  and  lymph  node  status. 
In pts treated with preop LHRH 
p53  clustering  predicted 
relapse.
::o 2000 Rad  Pros  in 
locally 
advanced 
disease.
72 0 70 23 IHC 28 >10% p53 + P53+  predicted  biochemical, 
local. & systemic failure.
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Table 8  (cont.): The relationship between P53 and outcome in patients who have had radical prostatectomy.
74 2000 Rad  Pros 
Biopsies  after 
neoadjuvant 
treatment.
106 57 31 17 IHC 77/106 p53 +
8/77 biopsies p53 +
P53+  increased  after  hormonal 
Tx.  and  correlated  with  grade, 
stage,  biochemical  progression 
and  short  survival.  P53+  from 
pre  LHRH  biopsies  did  not 
show any correlation.
4 5ft 2004 Rad Prost 98 • > ■ > ■ > IHC 55/98 Positive by IHC No  prognostic  data.  but 
compared  IHC  with  PCR.  IHC 
generated  27/55  false  positive, 
and  15/42 false negative.
17 7 2005 Rad Pros 52 14 38 0 IHC 20 p53 + 13  p53+  relapsed,  7  p53- 
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Table 9: The relationship between P53 and outcome in patients who have had radiotherapy.
Ref. Year  of 
pub
Type  of 
specimen
No  of 
cases
No
localised
No  locally 
invasive
No  with  lymph 
nodes/mets
Method Results Conclusion.
3 71 1996 Pre-DXT
Biopsies.
60 36 18 5 IHC Localised =  12/36 p53+. 
Locally invasive = 3/18 p53+
P53  correlated  with  stage,  not 
grade.  P53  did  not  predict 
relapse.
139 1997 Pre-DXT
Biopsies
129 129 IHC 23/129 (18%) with p53+ >20%. 
6/23 p53+  progressed 
27/106 p53- progressed 
12/23 p53+ died at 4 yr.
43/106 p53- died at 4 yr.
P53 + prognostic indicator for 
survival,  decreased 
progression  free  survival, 
decreased overall  survival  and 
distant  metastasis. 
Independent of Gleason  score 
and stage.
142 1998 Pre-DXT 
biopsies  & 
post-DXT 
biopsies.
13 13 IHC Primary p53 + = 1/13 (8% ) 
Recurrent p53 + = 7/13 (54% )
Genotype  of  recurrence  is 
more  aggressive  than  primary 
lesion.
173 1998 Pre-DXT 
biopsies  & 
post-DXT 
biopsies.
33  pt. 
who 
relapsed 
after DXT
‘7 ‘7 ‘7 IHC P53 + pre DXT  = 24/33 
P53 + post DXT = 20/33
P53  did  not  increase  post 
DXT,  and  could  not  predict 
DXT failures.
7 4 1 1999 Biopsies 49 49 IHC 17/49 p53+ 
32/49 p53-
15/17 p53+ did not reach PSA 
nadir of 1.0
23/32  p53-  did  reach  PSA 
nadir of 1.0.
Pre  DXT  p53  status  predicts 
response to DXT.
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Table 10: P 5 3  in patients treated with hormonal manipulation.
Ref. Year  of 
pub
Type of specimen No of cases No localised No  locally 
invasive
No mets Method P53
4115 1992 TURP = 44 
Biopsy= 75 
Open Spec  =  18
137 51 82 36 IHC T1  + T2 =2 %   MO = 2% 
T3 =  2%  Ml  =  11% 
T4=  12%
Pts  treated  with  hormonal 
manipulation  (n=97),  DXT. 
and surgery.
High  level  staining 
correlates with early relapse, 
poor  survival,  and  high 
grade.
47: 1998 Biopsies  before  & 
after LHRH
28 7 21 0 IHC 3 (6 after LHRH) p53 +ve. P53+ve  could  not  predict 
response  to  LHRH 
treatment,  but  increased  in 
responders.
241 2000 Biopsies  pre
hormonal
manipulation.
73 0 0 73 IHC P53 + =  14/73 (19.2%). 
6/14 P53+ progress 
8/59 p53- progress
P53  positive  patients 
correlated with early relapse.
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Tablell: The relationship between P53 and outcome in patients with extra prostatic disease.
Ref. Year  of 
pub
Type  of 
specimen
No  of 
cases
No
localised
No  locally 
invasive
No  with 
metastasis
Method P53 Conclusion
245 1998 43  patients 
with  hormone 
refractory 
disease.
43 IHC 22/43  (51%)  p53+  in  bone 
marrow'.
Did  not  correlate  with 
outcome
24X 1998 Lymph  nodes 
+ Rad Prost
56 39 17 56  nodes
19Bone
metastasis.
IHC 5/41  Primary tumours  p53+ 
7/41  lymph nodes p53+
P53+  had  no  prognostic 
significance.
7X 1999 Rad  Pros  + 
Lymph nodes
220 0 0 220 IHC 109 Rad Pros p53+
83 Lymph nodes p53+
The  majority  of patients then  had 
LHRH.
P53  expression  in  the  primary 
tumour  was  concordant  with 
p53  presence  in  nodes.  The 
presence  of p53  expression  in 
the  nodes  was  an  adverse 
prognostic factor for survival.
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Table 12:  The relationship between P53 in pre op biopsies and outcome.
Ref. Year Specimen Number Method Stage Results Conclusion
2.W 1997 Pre treatment biopsies 
Mean  follow  up  35.5  (range  1   -132 
months).  Treatment  with  Rad  pros 
(49).  hormonal  therapy  (89).  or 
surveillance (8 ).
146 IHC TI.:N(IM()=50. 
T,.N()Mn=28. 
T1„ 4N1M,,=9. 
Ti.4N1Mi =59.
T^NoM,, p53 + =  10/50. 
T,.N„M0  p53 + =8/28.
T,.4N,M„  +  T,.4N,M|  p53  +  = 
2 2 /6 8 .
P53+ =  107r staining +
P53  positive  correlates  with  shorter 
progression  free  survival.  Bel2  positivity  an 
independent indicator of poor prognosis.
62 1998 Pre-tx biopsies.
Follow  up  5  years,  heterogeneous 
treatment  with  Rad  pros.  DXT. 
hormonal  therapy.  TURP,  or 
surveillance.
1 1  1 IHC ■ ) \b% p53 positive. 
2 0 c/c bel2 positive. 
7.59c  Ki67 positive.
P53 + correlated with high-grade tumour. 
Univariate  analysis  showed that high Gleason 
score,  high  percentage  of tumour,  high  Ki-67 
LI,  and  p53  positive purports high percentage 
of  death.  But  multivariate  high  Ki-67  only 
independent predictor.
55
1999 Pre  treatment  biopsies  and  radical 
prostatectomy specimens.
Mean  follow  up38  months  (range  6  to 
114  months).  Treatment  with  radical 
prostatectomy.
76 IHC T,.2N()M0 =37.
T,.N„M„=39.
19/22  with  relapse  are  p53+  on 
biopsy.
20/40  relapse  free  are  p53+  on 
biopsy.
Biopsy  p53  +  in  multivariate  analysis 
correlated with poor outcome.
Aberrant p53  observed  more often in  biopsies 
than in radical prostatectomy specimens.
264 1999 Comparison  of  needle  biopsies  (129) 
with rad prostatectomy! 199) specimens
129 IHC •y Rad Pros  132/193 p53+ 
Needle biopsy 64/129 p53+
Immunostaining  of biopsies  not  predictive  of 
recurrence.
Poor  correlation  between  biopsy  and  rad 
prostatectomy  specimens,  but  as  the  editorial 
suggests  the  biopsies  were  done  at  many 
institutions  and  this  may  be  a  technical 
problem.
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Table 13: The relationship between aberrant P53 and prostatic intra epithelial neoplasia.
Ref. Year Specimen Number Method Stage Results Conclusion
175 1995 Rad Pros 40 IHC Tl.2NnMl)=40 9/40 PIN p53+ 
13/40 CaP p53+
Ca P & PIN  from 7 common 
patients  demonstrated 
intense p53 staining.
426 1998 Rad Pros (27) 
TURP (2)
29 PCR-SSCP 3/29 PIN p53 + 
5/29 CaP p53 +
2  patients  had  mutations  in 
both  Ca  P  &  PIN.  but  these 
were distinct mutations.
1 X 7 1998 Rad Pros 
(9  pts  with 
neoadjuvant 
LHRH)
44 IHC T,.,N„M„=26. 
T,.N„M(i  = 18.
0/44 PIN p53 + 
2/43 CaP p53 +
Some  pts  with  LHRH.  low 
incidence of p53.
577 2000 Rad Pros (14 pts 
with
neoadjuvant
LHRH)
27 PCR-SSCP TI.:N„M(I = 1L 
T,.N„M„ = 16.
6/27 PIN had p53 mutations 
8/27 Ca had p53 mutations.
In  only  2  cases  did  both  Ca 
and  PIN have mutations.  Both 
of  these  mutations  were 
different.
Increase  in  p53  mutation 
with  stage.  Different 
mutations in  p53  in  PIN  and 
Ca  imply  PIN  arises  from  a 
different clone.
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Table 14: The relationship between aberrant P53 and metastatic prostate cancer.
Ref. Year Specimen Number Method Stage Results Conclusion
7 X 7 1993 Primary tumours 68 1HC
Flow
Cytometry
9/68 p53+ P53  +  tumours  were  higher  stage  & 
Gleason  score.  +  progressed  more 
rapidly.
107 1994 TURP  (20)  + 
Lymph node( 15)
35 IHC
PCR-SSCP
2/20 TURP p53 +
2/15 Lymph node p53+
Total  concordance  between  PCR-SSCP 
and  IHC.  P53  mutation  is  a  late  and 
infrequent event.
1995 50  hormone 
sensitive  +  34 
hormone 
resistant
84 IHC
PCR-SSCP
6/34 hormone res p53+
19/50 hormone sens p53+
A  significantly  higher  proportion  of 
tumours  with  mutations  were  poorly 
differentiated  compared  with  tumours 
without  mutation  (P  <  0.04).  p53 
mutation  is  a  late  event  in  the 
progression of the disease
1  in 1995 Rad  Pros  (39). 
Rad  Pros/TURP 
+  mets/nodes 
(47)
86 IHC
PCR-SSCP
T,.,N0M(.=  18 
T,.4N0M„ =21 
T ]  _ 4N, M, = 47
0/18 T,.:N0M()  p53+
2/21  Tm N0M„ p53+
4/47  T,.4N,M|  p53+.  & 
11/47 mets/nodes p53+.
4/47 pts with  mets had abnormal  both in 
prostate  and  lymph  nodes.  7/47  had 
mutation  at  mets  only.  P53  mutation 
associated with advanced stage.
174 1995 36  primary 
cases.  17 
positive  lymph 
nodes.  14  bone 
mets
68 IHC 9 10/36  primary  tumours 
positive  9/36  were  Gleason 
score>7,  10/171ymph  nodes 
positive.  6/14  bone  mets 
positive.
Metastatic  tumours  express  more 
aberrant p53 than primary tumours.
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Table 14 (cont): The relationship between aberrant P53 and metastatic prostate cancer.
254 1995 Rad  Pros  (29). 
frozen  section of 
primary  tumour 
(9).  lymph  node 
(12).  and  bone 
marrow (1).
51 IHC.
PCR-SSCP
•> 6/38  primary  tumours  had 
aberrant p53.
3/13  mets/nodes  had 
aberrant p53.
Metastatic  tumours  display  higher  p53 
than primary .
1 (1 1996 Biopsy.  TURP. 
Rad Pros. 
Treatment 
heterogeneous.
77 IHC TI.:N0M0 = 18. 
T,.N()M„ =14. 
T^NiM, =45
23/77 + for p53,
14  of  the  23p53+  patients 
were refractory to hormonal 
manipulation.
37/77 + for bcl2.
23/77 + for p53, 37/77 + for bcl2,
P53  staining  corresponded  to  hormone 
resistance.  In  14/21  (66%)  of cases (p=. 
0012),  increased  p53  +bcl2 
corresponded  to  hormone  resistance  in 
13/16(81.2%) of cases (p<. 0001).
245 1997 Bone  Marrow 
biopsy  in  pts 
treated  with 
LHRH.
43 IHC TmN,mM,=43 22/43 P53+ P53  expression  did  not  correlate  with 
tumour  burden  or  outcome.  Bcl2 
expression was inversely correlated with 
p53 expression.
142 1998 Rad  pros  + 
prostate  fossa 
biopsy (18).
18 IHC T udV .M o.^ll.
Tj_N()_iM(i_|  =6.
T4N(|.|M0.|  =1
Primary  p53 + =  1/18 
Recurrent p53 + = 7/18
Genotype  of  recurrence  is  more 
aggressive than primary lesion.
254 1998 Bone  Marrow 
biopsy  in  pts 
treated  with 
LHRH.
17 IHC
RT-
PCR+SSCP
T.^N.^.M, =17 10/17 P53+ staining
8/10  abnormal  on  RT-
PCR+SSCP
71 %(12)  of  the  bone  marrow  samples 
had  aberrant  p53:  RT-PCR  detected  2 
missed by IHC.
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Table 15:  Miscellaneous papers relating P53 and prostate cancer.
Ref. Year Design  of 
study
Specimen Number Method Stage Results Conclusion
215 1998 Detect
autoantibodies 
for p53 in sera.
Sera 73 ELISA Tm Nm M„=62. 
T|.4NiiM|=I 1.
2/62.  0/11  +  for 
antibodies.
2  patients  with  localised  disease  had 
antibodies:  none  of the  patients  with 
metastatic  disease  had  antibodies. 
Both  of  these  patients  died  in  2-6 
months.
24o 1998 Relationship 
between  p53 
and p21.
Archival
specimens
60 IHC T|.2N„M„ = 16. 
TmN M f IO. 
TmN(HM, 
=34.
TmNoM.f IO/26 
p53 +.
T i_ 4N,,_i M, 
=23/34 p53+
P21wafl  downstream  messenger  of 
wtype  p53  not  activated  by  mutant 
p53,  p53+/p21  -poor  prognosis, 
compared to p53+/p21  +
201 1999 Hormone 
refractory 
tumours  (30) 
versus  matched 
untreated 
primary (24).
Archival
specimens
30 FISH
IHC
T1 _2N0Mi1=6.
Tm N„M,f 24.
T1_4N(|.|M|
= 10.
Primary tumours 
= 4/24 p53+. 
Hormone 
refractory  = 
12/30 p53+
P53  positive  tumours  show  androgen 
receptor  gene  amplification,  which 
may allow these tumours to grow in a 
low androgen milieu.
195 2000 Relationship 
between  p53 
and  15- 
lipoxygenase in 
CaP
Fresh frozen 48 IHC ■ J 36/48  15 
lipoxygenase +. 
19/48 p53 +
Correlation  between  p53,  15- 
lipoxygenase.  and  Gleason  score. 
Mutant  p53  upregulates  15 
lipoxygenase expression.
575 2000 Relationship 
between  p53 
and  VEGF  IN 
CaP
Archival
specimens
55 IHC T1 .2N„M„=31.
TmN(,M,f 24.
12
overexpression 
of P53
No  correlation  between  p53  and 
VEGF
1253.4  BCL2
The  Bcl2  family  of  related  proteins  constitute  important  regulators  in  the 
control  of  apoptosis  (programmed  cell  death)  1.  There  are  over  a  dozen 
members of the  bcl2 family some  suppress and some promote apoptosis.  The 
bcl2  gene  is  highly  conserved.  The  bcl2  gene  was  originally  detected  in  a 
proportion  of  B-cell  follicular  lymphomas  at  the  t  (14:18)  chromosomal 
translocation  breakpoint  202.  The  bcl2  proto-oncogene  is  located  on 
chromosome  18q21  and  codes  for  a  26  kDa,  239  amino-acid  protein  with  a 
hydrophobic  carboxy  terminal.  Bcl2  protein  has  been  located  to  the 
mitochondrial  membrane  l6\   nuclear  envelope,  and  the  endoplasmic 
reticulum388.  Bcl2  may  inhibit  apoptosis  by  regulating  the  mitochondria 
permeability  and  the  release  of  pro  apoptotic  enzymes.  The  pro  apoptotic 
members of this  family are cytosolic,  following the  initiation  of apoptosis the 
pro  apoptotic  members  undergo  a  conformational  change  and  integrate  into 
membranes.  An  additional  characteristic of this family is their frequent ability 
to  form  homo  as  well  as  heterodimers,  suggesting  neutralising  competition 
between these proteins.
In  IL-3  dependent  myeloid  and  lymphoid  cell  lines,  bcl2  inhibited  apoptosis 
induced  by  IL-3  withdrawal  without  stimulating  proliferation  401.  Implying 
therefore,  that  the  malignant  potential  of  bcl2  is  mediated  by  its  ability  to 
promote  cell  survival  rather  than  proliferation.  In  benign  prostatic  tissue,  theProstatic Intraepithelial Neoplasia and Prostate Cancer.
basal cells express bcf  l63.
In prostate cancer, hormone manipulation achieves its effect through activation 
of  apoptosis.  B cf  is  an  inhibitor  of  apoptosis  induced  by  a  number  of 
mechanisms  -   growth  factor  withdrawal,  glucocorticoid  withdrawal,  heat 
shock, and chemotherapeutic agents.
The  initial  evidence  demonstrating  that  bch  imparts  a  growth  advantage 
following androgen ablation was obtained using the hormone sensitive LNCaP 
cell  lines,  the  cell  lines  were  transfected  with  bcf  and  androgen  withdrawn 
from  the  growth  medium.  The  native  cell  lines  did  not  grow  in  the  androgen 
free  medium;  where  as the rate of growth of the  transfected cell  lines was not 
affected  by  androgen  withdrawal  3I3.  This  model  was  further  developed  in 
xenografts  of  these  cell  lines.  The  cells  were  injected  into  nude  mice. 
Following  castration,  the  bcf  expressing  tumours  exhibited  a  significant 
growth  advantage.  Therefore,  bcf  enables  prostate  cancer  cells  to  remain 
viable despite androgen ablation 22.
The relationship between androgen ablation and bcf expression was studied in 
castrated animals at intervals of  1   to  10 days post castration.  Messenger RNA 
for  bcf  was  extracted  from  the  ventral  lobe  of  the  prostate.  This  study 
demonstrated  that  castration  lead  to  an  increase  in  the  levels  of  mRNA  for
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bcb.  The  increase  was greatest at ten  days.  This  effect could  be  negated  with 
subcutaneous  injections  of testosterone246.  Therefore  androgen  ablation  itself 
may lead to the selection of an androgen insensitive phenotype 246.
It  has  been  suggested,  using  gamma  irradiated  LNCaP  cells  that  bcb  protein 
may  inhibit  the  nuclear  import  of P53  protein  and  so  prevent  apoptosis,  the 
exact mechanism by which bcb inhibits the transfer of cytoplasmic p.33 protein 
into the nucleus  is unclear21.  Structural  studies of the bcb protein demonstrate 
similarities  to  the  pore-forming  domains  of bacterial  toxins,  which  suggest  a 
role  in  modulation  of  membrane  function  8\   This  evidence  suggests  a  gate 
keeper role for bcb.
A  set point exists in  most cells for the ratio of bcb  family dimmers, e.g.  bcb: 
bax  and this determines the sensitivity of a cell towards survival and apoptosis 
292.  Internal  and external  messengers can  further regulate  this ratio 335.  Bax 
may be  negatively  selected during progression  of cancer  implying that  it may 
function in a tumour suppresser role independent of P5 3 3I7.
Phosphorylation  of bcb  at  specific  serine  residues can  lead  to  its  inactivation 
and  so  can  inhibit  its  anti-apoptotic  functions  i5°.  P53  can  mediate  bcb
phosphoryaltion and apoptosis via activation of G proteins Cdc42.  Cdc42 is a
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GTPase,  and  p53  promotes  apoptosis  through  activation  of this  G  protein  386. 
Phosphorylation of the bcb protein also leads to decreased binding to bax.
The  anti-cancer  drug  taxol  induces  bcb  phosphorylation  and  subsequent 
apoptosis  of  prostate  cancer  cell  lines149.  Taxol  also  has  an  effect  upon 
microtubule,  it  inhibits  microtubule depolymerisation  during  the cell  cycle329, 
Haidar et al  have  used  this evidence  to suggest that microtubule damage  may
I  4X lead to cell  death  through  a mechanism that  involves bcb phosphorylation 
Taxol  therefore  induces  bcb  phosphorylation  and  cell  death,  whereas  drugs, 
which damage  DNA, do not induce bcb phosphorylation but  induce apoptosis 
through a p ^  dependant pathway.  This has led Haidar et al to suggest that bcb 
is  the  guardian  of  microtubule  integrity  l48.  Microtubules  are  important  in 
chromosome  segregation  and  alteration  could  lead  to  genomic  instability and 
cell death.
Antisence oligodeoxynucleotides  (ODN)  are chemically  modified  stretches of 
single  stranded  DNA  that  are  complimentary  to  mRNA  regions  of  a  target 
gene.  ODNs  inhibit gene expression by forming RNA/DNA duplexes.  Using 
antisence  bcb  ODNs  and  the  agent  paclitaxel  in  LNCaP cell  lines  implanted 
into  nude  mice,  Leung  et  al  demonstrated  that  serum  PSA  levels  mirrored 
tumour  volume.  Mean  serum  PSA  levels  returned  to  or  were  above 
precastration  levels  by  11  weeks  post  castration  in  mice  treated  with  bcb
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ODNs  or  paclitaxel  alone,  but  remained  90%  below  pre-castration  levels  in 
mice  treated  with  combined  antisense  ODNs  and  paclitaxel.  Therefore  the 
combination of antisense bcl2 ODN and paclitaxel  led to a decrease in tumour
99?  «
volume  and  delay  in  androgen  independent  progression  .  Similar  results 
were  obtained  by  Miyake  et  al  except  they  also  demonstrated  using  Shinogi 
tumour cells that antisence bcl2 ODNs could be tumour specific and there was 
no reduction in bcl2 expression in normal tissue  l32-255-256.
Transgenic  mice  have been  used  to  study the  pathogenesis  of prostate cancer. 
The  most extensively used  model  is  the TRAMP (transgenic  adenocarcinoma 
mouse  prostate)  model.  In  this  model  probasin  directed  expression  of SV40 
early genes in the prostate results in progression from hyperplasia to metastatic 
disease by 28 weeks of age.  This model  was used to target bcl2 to the prostate 
and  generate  the  BxT  (bcl2  x  TRAMP)  mouse.  The  BxT  mice  displayed 
increased  prostate  size  associated  with  decreased  apoptosis,  earlier 
development  of PIN  and  invasive  carcinoma.  By  20  weeks  100%  of the BxT 
mice  exhibited  evidence  of  prostate  cancer  compared  to  only  50%  of  the 
TRAMP  mice.  The  rate  and  incidence  of tumour  metastases  was  the  similar 
for the TRAMP and BxT mice.  The transgenic bcl2 did not result in malignant 
transformation of the prostate gland 58.
Transfection  of bcl2  into  LNCap and PC-3  cell  lines  followed  by exposure  to
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ionising  radiation  led  to  the  bcb  transfected cells  having decreased  apoptosis 
although both the controls and the transfected cells did not form colonies after 
exposure  to  radiation  21'.  This  elevation  in  bcb  resulted  in  a  significant 
suppression  of radiation  induced  apoptosis  at 48  hrs,  but  after longer periods 
post  irradiation  even  the  bcb  expressing  cells  underwent  apoptosis.  This 
suggests  that  bcb  over  expression  does  not  provide  a  permanent  protection
against radiation induced apoptosis but rather it delays the onset of the process
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The  angiogenic  switch  stimulates  angiogenesis  at  a  distinct  time  during 
tumorigenesis.  Through  the  stimulation  of angiogenesis  and  the  inhibition  of 
apoptosis  tumour  cells  attempt  to  negate  the  effect  of  hypoxia.  This  was 
investigated  using  prostate  cancer cell  lines  transfected  with  bcb.  These  cell 
lines were subjected to hypoxic conditions in vitro.  Cells with transfected bcb 
expressed  significantly  more  vascular endothelial  growth  factor (VEGF)  than 
the controls  i,A.  The cells were then  injected  subcutaneously  into  nude  mice; 
the  bcl-transfected  tumours  grew  faster,  expressed  more  VEGF  and  a  greater 
micro  vessel  density  ll6.  The  bcb  transfected cells  were  implanted  in  mouse 
corneas,  and  six  of  the  eight  corneas  implanted  with  transfected  cells  had 
evidence of neovascularisation compared to none of the controls.  The authors 
of  his  study  concluded  that  increased  VEGF  expression  and  the  resulting 
increased  vascularisation  associated  with  this  are essential components of theProstatic Intraepithelial Neoplasia and Prostate Cancer.
in vivo growth advantage conferred to tumours expressing bcb  116.
Bcl2  over  expression  occurs  in  colorectal  adenomas,  cervical  intra-epithelial 
neoplasia  and  other  pre-malignant  lesions.  The  basal  cells  of  the  prostatic 
epithelium  probably  house  the  prostatic  stem  cell  population  40.  These  cells 
are resistant to androgen dependant apoptosis, where as secretary luminal cells 
require  androgens  and  undergo  apoptosis  when  deprived  of  androgens.  The 
expression  of  bcl2  is  not  uniform  within  the  prostate,  the  transitional  and 
peripheral  zones exhibit strong expression  for bcb  in the basal cells but not in 
the  secretary  luminal  cells.  The  central  secretory  zone  does  express 
heterogeneous expression of bcb41.  In a series of 216  foci  of high grade PIN 
from 25 radical  prostatectomy specimens, Bcb expression was restricted to the 
basal cells in  169 specimens (78%), and was present in secretory luminal cells 
in  22%.  No  difference  was  detected  in  bcb  expression  with  and  without 
adjacent  cancer.  There  was  a  marked  inverse  relationship  between  the 
expression  of  the  androgen  receptor  and  bcb.  In  the  transition  and  the 
peripheral  zones  the  secretory  luminal  epithelium  strongly  expressed  the 
nuclear  androgen  receptor.  The  basal  cells  were  unreactive  for  androgen 
receptor  staining.  High  grade  PIN  expressing  bcb  in  the  basal  cells  only 
stained for the androgen receptor in the luminal secretory cells.  Where as high 
grade PIN over expressing bcb in the luminal cells showed a marked reduction 
in  expression  of the  androgen  receptor.  The  inverse correlation  between  bcb
132Prostatic Intraepithelial Neoplasia and Prostate Cancer.
and androgen receptor expression was highly significant.  It has therefore been 
postulated that the aberrant expression of bcb  in  sub-sets of PIN may indicate 
resistance  to  androgen  dependent  cell  death,  and  probably  reflect  reduced 
androgen-responsiveness of the dysplastic epithelium 41.
The  development  of  androgen  resistance  can  be  associated  with  bcb 
expression,  it  can  also  occur  independently  of  bcb.  This  has  been 
demonstrated by work carried out on the Dunning AT-3 cell  line that is highly 
malignant but does not express bcb  l22.
3.41  Bcl2 and Prostate Cancer
A  literature  review  was  carried  out  using  the  Medline  database.  The  initial 
keyword  used  was  bcb  and  the  second  was  prostate  neoplasm.  For  the  first 
keyword  a  total  of 6302  references  were  detected  and  for  the  second  33298. 
Theses two searches were combined and the number of references decreased to 
160 references.  The abstracts of these  160 citations were reviewed and a total 
of  50  pertinent  references  were  reviewed  in  detail
10:15:16:20:21:21:22:27:41:43:55:5X:60:66:7476:116:122:125:132:142:148:173:179:185:187:191:204:211:217: 
222:227:235:238;239:245:246:255:256:274:308;315:341:348:364:372:381:382:385:385:394
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3.42  Bcl2 and Radical Prostatectomy.
To  study  the  significance  of  bcl2  a  cohort  of  137  consecutive  radical 
prostatectomy  specimens  obtained  from  patients  who  underwent  radical 
prostatectomy  between  1978  and  1993  at  the  University  of  Bassel  were 
examined for over expression of bcl2 and P53 60.  40 patients were stage pT2, 93 
patients  were  pT3,  no  stage  was  given  for 4  patients,  103  patients  were  pNO 
and  34  were  pNl/2.  Follow  up  data  was  available  from  1  15  patients  with  a 
mean follow up of 5.2 years.  Only eight patients had died,  therefore  survival 
data  was  not  discriminatory,  but  progression  data  was  available.  54  patients 
had  received  adjuvant  local  radiotherapy.  Orchiectomy  was  performed  upon 
six  patients  at the  time of prostatectomy.  Progression  was  documented  in  37 
patients  based  upon  PSA  increase  in  29  patients,  biopsy  in  3  and  a  positive 
bone  scan  in  5.  Bel?  over  expression  was  associated  with  higher  stage, 
shortened  disease  free  survival.  This  study  also  stained  for  Ki-67  and  p .5 3  
expression.  Progression  analysis  showed  that patients  with  bcl2  positive  and 
Ki  67  positive  tumours  had  the  shortest  progression  free  survival,  and  those 
with bcl? and Ki 67 negative tumours had the longest disease free survival60.
The  group  from  the  Walter  Reed  Army  Medical  Centre,  Washington  carried 
out  immunohistochemistry  on  175  radical  prostatectomy  specimens  for  both 
P53  and  bcl2  20.  One  hundred  and  seventy  four  of  the  patients  had  capsule 
confined disease.  Over expression of bcl2 was detected in 47 of 175 (26.9%)
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patients,  these  patients  had  a statistically significant  higher 5  year failure rate 
when compared to bcb negative patients i.e. 67.0% versus 30.7%.  Combining 
the  bcf  positive  and  the  p<?3  positive  patients,  the  failure  rate  was  75.3%, 
compared to  a failure rate  of only 20.4%  if both  bcb  and p.33  were negative"  . 
Similar  results  were  obtained  using  a  consecutive  series  of  208  radical 
prostatectomies  and  a  mean  follow  up  of 4  years.  Twenty-eight cases  (13%) 
expressed  bcb;  bcb  positivity  was  an  independent  prognostic  marker  in  a 
multivariate analysis194.
Specimens  obtained  from  a  heterogeneous  series  of 40  patients  with  prostate 
cancer were used to determine the association between disease progression and 
bcb,  waf-1,  and  p.5 3.  Twelve  patients  over  expressed  bcb,  of  these  ten 
progressed;  twenty-eight patients  did  not express bcb  of these  19  progressed. 
There  was  no correlation  between  the expression  of bcb,  clinical  grade,  stage 
and progression 66.
Apakhama and colleagues  studied  seventy seven patients  with  prostate cancer 
at  various  stages  were  followed  up  for  a  median  of  30  months  and  the 
importance of p.33  and  bcb  assessed.  The age range  was  from 46 to  8 8   years. 
Forty-five  patients  (58.4%)  had  metastases,  37  patients  stained  positively  for 
bcb.  Seventeen  of these  patients  stained  positively  for  both  P53  and  bcb,  of 
these  16  had  had  hormonal  manipulation,  and  13  had  hormone  refractory
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disease.  These workers postulated that the combined detection of p.53 and bcb 
may be useful in detection of hormone refractory disease  l().
A  study of 235  patients,  172  with  no  metastases  which  had  been  treated  by a 
number  of  modalities  including  seven  with  radical  prostatectomy,  4  with 
radical radiotherapy, 22 with oestrogen, 61  with orchiectomy, 33 patients had a 
TURP  and  82  patients  were  treated  conservatively  .  71%  of the  tumours 
were  bcb  negative,  18%  were  weakly  positive,  and  1 1 %  were  strongly 
positive.  The  expression  of  bcb  correlated  with  higher  tumour  stage, 
metastatic  disease,  and  high  grade  and  in  a  univariate  analysis  with  poor 
survival, but in a multivariate analysis the expression of bcb had no prognostic 
significance.  In  a  study  of  41  patients  with  lymph  node  metastases  from  a 
Japanese  centre,  bcb  expression  was  observed  in  both  primary  tumours  and 
metastases  from  14  tumours  "  .  Bcb  expression  was  found  to  be  of  no 
prognostic value.
3.43  Bcb and Radical Radiotherapy.
A  study  of 43  patients  who  had  been  treated  with  definitive  radiotherapy  for 
prostate  cancer  with  a  follow  up  period  of at  least  3  years  showed  increased 
bcb  staining  predicted  relapse173.  A  study  of 54  patients,  who  were  treated 
with  radiotherapy,  showed  that  increased  staining  of  bcb  or  p.33  predicted 
relapse 34 * .
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3.44  Bcl2 and Watchful Waiting.
In  the  Scandinavian  nations prostate  cancer  is  often  treated  conservatively,  a 
study of 221  men diagnosed by TURP chips and treated conservatively with a 
median follow-up of 15 years demonstrated that  114 cases over expressed bcb- 
This correlated with clinical stage and disease specific survival.  If the tumours 
were  further  divided  into  those  that  were  p.33  positive  and  bcb  negative 
compared  to  p.53  positive  and  bcb  positive,  those  in  the  first  group  did  better 
than the second.  But dividing the P53 negative group into those that were bcb 
positive versus those that were bcb negative made no difference to disease free 
survival 4\
3.45  Bcl2 and Recurrence.
The  relationship  between  the  primary  tumour  and  localised  recurrence  after 
definitive  treatment  was  studied  in  a  series  of  recurrent  tumours  after 
definitive surgery (n=18) or radiotherapy (n=13).  There was an increase in the 
expression  of bcb  in  recurrent tumours  when compared  to  the  primary  lesion 
but this did not reach  significance  l42.  This was further studied in  a series of 
32  patients  who  had  failed  radiotherapy  and  had  pre  and  post  radiotherapy 
specimens,  prior  to  radiotherapy  14  patients  expressed  bcb  and  post 
radiotherapy  19  expressed  bcb.  In  the  group  of patients  that  had  no  disease
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recurrence  post  radiotherapy  only  one  out  of the  12  patients  expressed  bcl2. 
This  was  highly  significant.  If  both  p53  and  bcl2  were  examined  together 
significantly  more  patients  had  p33  and  bcl2  immunopositivity  following 
radiation failure, 48%, compared to 8% in those that were successful  m .
3.46  Bcl2 and Prostate biopsies.
The  role  of  prostate  biopsies  at  predicting  outcome  was  studied  in  146 
patients.  Bcl2  positivity  was  detected  in  29  patients.  Bcl2  positvity  was 
detected in 23.7%  (18/76) of patients with  localised disease, and in  15.7%  (11 
of  70)  of  patients  with  metastatic  disease.  Using  multivariate  analysis  bcl2  
positivity was an independent predictor of outcome 239.
The group from  Bristol compared preoperative biopsy assessment of bcl2, p33, 
CD-44  and  e-cadherin  with  the  expression  of these  markers  in  the  respective 
radical  prostatectomy  specimen  55.  Radical  prostatectomy  and  biopsy 
specimens were examined from a total of 76 patients; aberrant staining for bcl2  
was  detected  in  eight  preoperative  biopsies  and  in  15  radical  prostatectomy 
specimens.  Brewster et al  did  not comment if preoperative biopsy staining for 
bcl2 correlated with expression of bcl2 in the radical  prostatectomy specimens. 
Preoperative  bcl?  was  not  a  significant  predictor  of  outcome.  Using  Cox 
regression  no direct  relationship between  bcl2 over expression and p33 protein 
accumulation  could  be  established.  Using  a  multivariate  analysis  post­
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operative  P53  and  bcb  were  independent prognostic  predictors of disease free 
survival55.
Similarly, in a series of 117 preoperative samples from radical prostatectomies 
carried  out  at  the  Walter  Reed  Medical  Centre  the  preoperative  biopsies  did 
not correlate  with  out  come  364.  Forty-nine  patients  had  evidence  of disease 
recurrence, and  18 preoperative samples had evidence of bcb over expression. 
Comparison  between  biopsy  and  prostatectomy  staining  revealed  no 
concordance.  Biopsy samples could not predict outcome  ,64.
Biopsies  have  also  been  used  to  predict  outcome  in-patients  treated  with 
definitive radiotherapy.  In a series of 52 patients with pre radiotherapy biopsy 
material  available for immunostaining, thirteen  stained positively for bcb.  Of 
these,  11  patients  (84.6%) failed radiotherapy,  in  the bcb  negative group only 
16 of the  39  patients  (41.1%)  failed  radiotherapy.  This  result was  significant
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3.47  Androgen deprivation and Bcb
The  role of androgen  ablation  in changing the expression of bcb  and  pS3  was 
studied using radical  prostatectomy specimens obtained from  106 patients was 
compared  with  71  pre  treatment  prostate  biopsies74.  The  patients  prior  to 
surgery  had  3  months  of  LHRH  treatment.  Eleven  of  the  106  radical
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prostatectomy specimens over expressed bcb and nine of the 71  pre treatment 
biopsies expressed bcb.  No correlation  was found between  the expression  of 
bcb  in  the  biopsies  and  prostatectomies,  four  cases  were  positive  in  both 
samples,  four  only  in  the  biopsies  and  three  only  in  the  prostates.  No 
correlation  existed  with  bcb  over  expression  and  clinical  outcome, 
preoperative  PSA,  or accumulation  of aberrant p?3  74.  However the data from 
this  study  must  be  viewed  with  caution  since  in  studies  comparing  biopsies 
and  radical  prostate  specimens,  the  expression  of  bcb  in  material  obtained 
from  biopsies  does  not  correlate  with  the  expression  of  bcb  obtained  from 
radical prostatectomy samples.
An earlier study comparing two groups of radical prostatectomies, one that had 
neoadjuvant  hormonal  therapy  (n=28)  with  ones  that  had  not  (n=51),  found 
increased expression of bcb after neoadjuvant hormonal ablation394.
A  study  of  69  heterogeneous  patients  with  prostate  cancer  demonstrated  a 
trend  towards  increased  bcb  expression  post  androgen  deprivation  l6. 
However  in  this  study  the  authors  could  not  demonstrate  any  correlation 
between the expression of bcb and apoptosis, p.33, or clinical outcome.
This  effect of increased  bcb  with castration  was  further investigated  in  series 
15  responders  and  13  non-responders  of androgen  ablation372.  The  patients
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had biopsies pre androgen ablation and one week after treatment.  Both groups 
had  an  increase  in  bcb  expression  associated  with  androgen  ablation,  but the 
responders had significantly increased bcb expression as compared to the non­
responders 372.
3.48  Bcb and High Grade Prostatic Intra Epithelial Neoplasia (PIN).
High-grade prostatic  intra epithelial  (PIN)  neoplasia  is a putative precursor of 
prostate cancer, and the incidence of bcb expression was studied in PIN using 
43  radical  prostatectomy  specimens.  Bcb  was  over expressed  in  1   of the 43 
cancers (2.3%), and in  15 of the 43 PIN specimens (34.9%)  ls7.  These authors 
suggested  that the foci  of bcb  positive PIN  might not be the  direct precursors 
of invasive cancer.
3.49  Bcb and Metastases.
Prostate  cancer often  metastasises  to  the  bone  marrow.  The  accumulation  of 
bcb  was studied in 43 bone marrow samples obtained from patients with bone 
metastases.  All patients had been treated with at least hormonal ablation.  Bcb 
was detected  in  14 of the 43  cases.  Six of these cases exhibited only positive 
staining for bcb, and eight expressed both p*3 and bcb. The expression of bcb 
protein did not significantly influence patient survival 24\
The relationship between bcb expression and metastasis was in hormone naive
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patients  showed  that  5  of  30  (17%)  patients  with  lymph  node  disease  had 
positive  bcb  staining  and  14  of 27  (52%)  patients  with  bone  metastasis  had
j 7T  .
positive  staining  in  bone  marrow  samples  Therefore  bcb  expression 
increases with increasing stage.
3.50  Bcl2 and Bax.
Prostate  cancer  is  often  managed  with  external  beam  radiotherapy.  The 
prognostic  importance  of  bcb  and  bax  were  investigated  in  a  series  of  41 
patients  who  had  undergone  external  beam  radiotherapy  for  the  management 
of localised carcinoma of the prostate.  21  patients  responded  to  radiotherapy 
and  20  failed  to  respond  as  determined  by  a  PSA  nadir  of  l.Ong/ml.  Bcb 
expression  was  significantly higher  in  the  non-responders  and bax  expression 
was higher in the responders.  The ratio of bcb/bax  was significantly higher in 
the non-responder when compared to the responders’  23\
142Tablel6:  The relationship between bch expression and outcome in patients with radical prostatectomy.
Ref. Year  of 
pub
Type of specimen No
of
case
s
No
localised
No locally 
invasive
No
mets
Method Results/Conclusions
60 1996 Radical
Prostatectomy
137 40 93 34 IHC T2 2/40 (5%) +
T3 29/93 (31%)+
NO 25/104 (2490+
N 1/2 8/34(24%)+
Bcl-2 expression increased with stage.
20 1996 Radical
Prostatectomy
175 Tl=25
T2=149
T3=l 0 IHC 47/175 (21% ) Bcl2 positive. 
Correlated with poor survival
1 0 1996 Heterogeneous 77 45 IHC 37(48%) positive for bcl2. 
20/37 androgen resistant
6 6 1997 Heterogeneous 40 T 1  = 10
T2=5
T3=l 1  
T4=13
21 IHC 12/40(30%) Bel-2 +
10/12 progressed.
No correlation with bcl-2 + and clinical outcome
227 1997 Heterogeneous 235 Tl = 94 
T2 = 56
T3=96
T4=19
63 IHC 18%  weakly positive 
11%   strongly positive.
Bcl-2  correlated  with  poor  survival,  but  of  no  an 
independent prognostic value.
194 1998 Radical 
Prostatectomy 
mean  follow  up 
4yrs.
208 111 97 8 IHC 28/208 (13%) +
Bcl-2  correlated  in  a  multivariate  analysis  with  poor 
outcome.
24S 1998 Biopsies  and 
Radical
Prostatectomies
41 ■ > • ) 41 IHC 14/41  (34%) bcl-2 +.
No correlation with bcl-2 + and clinical outcome.
1 '4 2 1998 Radical
Prostatectomy
18 11 7 5 IHC Increased  expression  of  bcl-2  in  recurrence.  Not 
significant.Prostatic Intraepithelial Neoplasia and Prostate Cancer.
142 1998 Biopsies DXT 13 13 0 0 IHC Increased  expression  of  bcl-2  in  recurrence.  Not 
significant.
74 2000„ Radical
Prostatectomy
106 58 31 17 IHC 11/106 +
No correlation with bcl-2 + and clinical outcome
421 2003 Radical
Prostatectomy
70 70 IHC 3/70 +
Increased expression of bcl2, predicted relapse.
.*14 2005 Radical
Prostatectomy
131 60 71 10 IC 13/131  bcl2+
Increased expression of bc!2, predicted relapse.
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Tablel7: The relationship between bch expression and outcome in patients treated with radical radiotherapy.
Ref. Year  of 
pub
Type of specimen No of 
cases
No localised No  locally 
invasive
No
mets
Method Results/Conclusions
1*5 1998 Pre DXT biopsies 41 41 0 0 IHC Significantly  higher  bcI-2/bax  ratio  in 
radiation failures.
m 1998 Biopsies  and  rad 
prostatectomy
43 43 0 0 IHC 1/12  bcl-2  +  in  the  radiation  success, 
14/31  bcl-2  +  in  the  radiation  failures. 
Bcl-2  was  found  in  significantly  more 
radiation failures.
341 1999 Pre-DXT biopsies 52 52 0 0 IHC 13/52 (25%) bcl-2 +.
11/13  bcl+  cases  failed  treatment  with 
DXT.
32S
2003 Needle biopsy 40 29 11 0 IHC 11/20  patients  with  recurrence 
overexpressed bcl2, 0/20 in the recurrence 
free group.
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Tablel8: The relationship between bcl2 expression in pre operative biopsies and outcome.
Ref. Year  of 
pub
Type of specimen No of 
cases
No localised No  locally 
invasive
No
mels
Method Results/Conclusions
m i Biopsies 146 50 28 68 IHC 29/146  bcl-2  +.  In  multivariate  analysis  an 
independent prognostic indicator.
472
1998 Pre  and  post 
castration  biopsies 
in  15  responding 
patients  and  13 
patients  not 
responding  to 
hormonal therapy.
28 7 21 20 IHC Bcl-2  expression  increased  significantly  with 
androgen  ablation,  significantly  more  so  in  the 
responders.
464 1999 Pre op biopsies 117 IHC 18/117 (15%) bcl-2 +.
No correlation with bcl-2 + and clinical outcome.
55 1999 Pre op biopsies 65 IHC 8/65 bcl-2 (12%) +
Pre-op Bcl-2 did not correlate with outcome.
74 2000 Pre op biopsies 71 9/71  bcl-2 +
No correlation with bcl-2 + and clinical outcome
44 2(K)0 TURP biopsies 221 125 96 60 IHC Patients  treated  with  watchful  waiting.  114  (52%) 
cases  +  for  bcl-2.  Correlated  with  clinical  stage  and 
disease specific survival.
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Tablel9: The relationship between bc^ expression and metastasis.
Ret. Year 
of pub
Type of specimen No of cases No localised No  locally 
invasive
No
mets
Method Results/Conclusions
Oi 19% Lymph  node  (30) 
&  Bone 
marrow(27)
57 0 0 57 IHC 5/30 lymph node bcl-2 +
14/27 bone marrow bcl-2 +
Bcl-2 expression increases with stage.
245 1997 Bone marrow. 43 0 0 43 IHC 14/43 (32%) bcl-2 +.
No  correlation  with  bcl-2  +  and  clinical 
outcome.
1473.60  BAX
Bcl2 associated X protein, or bax  is a proapoptotic molecule,  which dimerises 
with  the  apoptotic  B ek  This  dimerisation  inhibits  the  action  of  bax.  The 
dimerisation takes place at the homology regions and all family members share 
at  least  one  of the  four  regions-  BH1,  BH2,  BH3  and  BH4424.  The  truncated 
form  of  Bax,  expressing  only  BH3,  is  sufficient  to  induce  apoptosis  and 
antagonise the effects of ant-apoptotic members of the family  l< 1 6 .  Induction of 
bax  is promoted by the initiation of apoptosis.  This causes the monomeric bax 
to  translocate  from  the  cytosol  to  the  mitochondrial  membrane;  here  it 
becomes  an  integral  part  of the  membrane  and  cross  link’s  as  a  homodimer, 
resulting in cell death by the release of cytochrome c from the mitochondria141. 
This ability to target the mitochondrial  membrane  is regulated by the terminal 
20 amino acids.  Bcl2 inhibits bax-mediated apoptosis. The bax gene promoter 
is P53 responsive and  so p5 3-binding results  in  transactivation  of the  bax  gene. 
Therefore,  bax  up  regulation  is  one  method  by  which  P53  exerts  its  pro­
apoptotic action  26 *.
A  literature  review  was  carried  out  using  the  Medline  database.  The  initial 
keyword  was  prostate  cancer  and  this  revealed  35234  citations,  the  second 
keyword  was  bax  and  the citation  count was  23802.  When  the  two citations 
were  combined  the  number  decreased  to  194.  The  abstracts  were  reviewedProstatic Intraepithelial Neoplasia and Prostate Cancer.
and  a  total  of  15  citations  were  selected  as  pertinent
9:81:101:117:122:132:187:199:204:226:230:235:235:313:330:422
3.61  Incidence of Bax
The incidence of bax  was studied in 64 radical prostatectomy specimens.  Bax 
was detected in every specimen 204.  In Asians the bax was present in 47 of 62
radical  prostatectomy  specimens  i.e.  76%.  In  a  univariate  analysis  bax
81 expression predicted a significantly poorer survival  .
3.62  Bax and radiotherapy for prostate cancer.
A  retrospective  review  of  41  patients  who  underwent  radiotherapy  with 
curative  intent  showed  that  the  patients  could  be  divided  into  two  groups 
depending  upon  the  PSA  response  and  the  presence  of  tumour  in  the  post 
operative biopsies.  This demonstrated  no difference  in  bax  immunoreactivity 
between  responders  and  nonresponders"  ,  but  the  staining  of  bch  was 
increased  in  non  responders  and  so  the  ratio  of bcf/bax  was  higher  in  non-
"M'S
responders"  .  The  importance  of the  bax:  bcf  ratio  was  further  assessed  by 
using  synthetic  peptide  sequences  from  the  BH3  domain  of bax,  this  resulted 
in  binding  between  the  BH3  peptides  and  bch  and  so  blocking  bcf/bax 
heterodimerisation.  The  excess  of  released  bax  led  to  an  increase  in 
apoptosis117.
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Using adenovirus  vectors,  bax  was over expressed  in  four different cell  lines. 
In  all  the  cell  lines  bax  over  expression  caused  cytochrome  c  release  and 
initiation of the capsase mediated apoptosis pathway.  Bax over expression by 
passed  the  anti  apoptotic  effect  of  bcf,  and  caused  apoptosis  in  cell  lines 
resistant to chemically induced apoptosis 226.  This finding has been confirmed 
by a second group  230  Androgen withdrawal  is known to cause apoptosis; the 
presence  of androgens  in  androgen responsive cell  lines causes  attenuation  in 
the expression of bax  l99.  Using an adeno virus construct, which contained the 
bax  gene,  linked  to  androgen  responsive  elements  and  with  probasin  as  a 
promoter.  Probasin is a prostate specific promoter, so that the molecule can be 
over  expressed  in  prostate  only.  This  model  has  shown  that  bax  expression 
and so apoptosis could be  made to occur in androgen dependant manner, both 
in vitro and in mice9.
3.63  Bax and high grade prostatic intraepithelial neoplasia.
In  a  heterogeneous  group  of  44  radical  prostatectomy  specimens,  Bax 
expression can de detected in all cases of PIN186.
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3.70  Ki 67
The name of the Ki-67 protein is derived from its city of origin -  Kiel, and the 
number of its original clone in a 96 well plate.  The Ki-67 antigen is a nuclear
| -)n
protein  that  is  present  in  proliferating  human  cell  “  .  The  genetic  locus  has 
been assigned to chromosome  10 and consists of 30,000 base pairs127'345. Two 
isoforms  of the  protein  have  detected  with  masses  of 320  and  359kD;  both 
contain  a  large  central  region  with  16  repetitive  elements  345.  Homology 
searches  have  failed  to  detect  regions  of similarity  between  Ki-67  and  other 
proteins.  Although  the functional  role of Ki-67  is  unknown,  it is expressed in 
all  stages  of  the  cell  cycle  (Gl,  S,  G 2,  and  mitosis)  except  for  GO.  Ki-67 
immunoreactivity  appears  to  be  a  valid  method  to  measure  proliferation  346. 
Ki-67  is a part of the nuclear matrix  and of the chromosome scaffold.  Initially 
the  use  of  Ki-67  was  limited  to  frozen  section  material,  however  the 
development  of  antigen  retrieval  systems  has  led  to  newly  developed 
antibodies being applied to formalin fixed material  ,9A.
The  proliferation  rate  is  low  in  prostate  cancer  but  it  may  be  important  in 
determining tumour progression.  Proliferation assessed  by mitotic  rate 402,  S- 
phase  fraction  392 404  and  Ki-67  159,247  has  been  related  to  outcome370. 
However  at  present  the  clinical  significance  is  far  from  established.  Using 
archival  material  and  correlating  this  with  outcome  it  has  been  shown  that 
proliferation  as  assessed  by  Ki-67  immunoreactivity  is  higher  in  prostate
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cancer than in benign tissue  I:84:389. Indeed the grade of the tumour is related to 
the  expression  of Ki-67155:;260:285.  Prostate  hyperplasia  and  well-differentiated 
tumours are negative for the expression of Ki-67"  '.  The Ki-67 expression can 
be  used  as  a  marker  for  predicting  outcome  in  prostate  cancer1155'370.  In 
prostate  biopsies  the  expression  of  Ki-67  can  predict  local  extra  capsular 
spread but not metastasis 229.
The cellular proliferation  index  is  also a predictor of recurrence  after definite
1 local  therapy  i.e.  radiotherapy  or  radical  prostatectomy  ~.  In  patients  with 
lymph node metastasis the Ki-67 labelling index of the primary tumour and the 
lymph nodes had an independent prognostic value where as P53 and bcf had no 
prognostic value142.  Others have not found Ki-67 so useful307.
3.71  Why Study Cell Proliferation?
A  major  stimulus  to  the  study  of  cell  proliferation  is  the  belief  that 
quantification  of this  fundamental  biological  process  would  provide objective 
data with  which  to more effectively categorise tumours, predict prognosis and 
consequently  result  in  tailoring  therapy  to  individual  patients.  In  the  past  a 
number  of  techniques  have  been  used  l52154.  For  example,  mitotic  index 
estimation  by  light  microscopic  examination,  in  vivo  (or  in  vitro) 
incorporation  of  thymidine  analogues  into  DNA  during  S  phase,  flow 
cytometric  assessment  of  DNA  index.  These  methods  have  significant
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disadvantages  such  as  ethical,  methodological  problems  and  loss  of  tissue 
architecture.  An  alternative  method  which  is  simple,  reliable,  reproducible 
and allows retention of normal  histology has been developed  using antibodies 
that  recognise,  by  immunohistochemistry,  molecules  whose  expression  is 
linked to the cell cycle  152-244.
3.72  Cell Cycle
The  cell  cycle  describes  a  co-ordinated  series  of biochemical  alterations  that 
allow  exact  duplication  of  the  DNA  content  in  a  cell  (S  phase)  followed  by 
precise  segregation  of  the  DNA  into  two  sets  and  their  subsequent  partition 
into  two  daughter cells during  mitosis  (M  phase).  After mitosis  the  daughter 
cells  enter  a  quiescent  period  of  varying  duration  before  commitment  to  a 
further cell  cycle.  The  period  between  one  M  phase  and  the  next  S  phase  is 
called  Gl.  During  G1  phase  there  is  growth  and  preperation  of  the 
chromosomes  for  replication.  The  period  between  S  phase  and  the  following 
M phase is called G 2. The cell undergoes preparation for replication during the 
G 2  phase.  Regulated  alteration  in  expression  and  function  of  regulatory  and 
structural  proteins  occurs  during  the  cell  cycle.  This  cyclical  alteration  in 
proteins  permits  the  use  of antibodies  to  define  antigens  expressed  in  a  cell 
cycle related manner.
Potential  antigenic  targets  for the  definition  of cells  within  the  cell  cycle  are
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numerous.  One  of the  most  widely  used  antibody  is  Ki-67  ’“7,  which  reacts
with  a  nuclear  non-histone  protein  of  395  and  345  kD  present  in  all  active
1  *>1' *>08 parts of the cell cycle, i.e., GI, S, G2, and mitosis, but is absent in GO  ~   ~   .
The evidence for the link between the expression of the Ki-67 antigen and the 
cell cycle is overwhelming 57J37.  The molecule begins to be expressed in mid 
GI increasing in level through S and G2 and peaking in M  127.  It is very rapidly 
catabolised  at  the  end  of  M.  There  is  good  relationship  between  detectable 
expression  of  Ki-67  and  growth  fraction  in  several  model  systems  244J46. 
Furthermore,  there  appears  to  be  no  expression  of Ki-67  during  DNA  repair 
processes  unlike  some  other  cell  cycle  associated  molecules  (for  example 
PCNA).  The  function  of  Ki-67  remains  unclear  but  it  may  represent  a 
structural  protein  that maintains the  higher order structure of DNA during the 
important events of mitosis 337. The major drawback of this antibody is that its 
application  is  restricted  to  fresh  or  frozen  tissues  and  the  epitope  does  not 
survive routine histophathological fixation in formaldehyde.
3.73  MIB-1
Recently  monoclonal  antibodies,  MLB  1-3  (MIB  for  Molecular  Immunology 
Borstel),  against recombinant parts of the Ki-67  antigen  have been developed. 
These  antibodies  are  true  Ki-67  equivalents,  as  demonstrated  by 
inimunostaining  of  fresh  specimens,  biochemistry,  and  molecular  biological
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techniques  73:195.  Formerly  immuno-histochemistry  on  formalin-fixed,
paraffin-embedded sections failed to stain for Ki-67.  However, when dewaxed 
microwave  oven-processed  paraffin  sections  of  formalin-fixed  tissues  were 
used,  MIB  1   and  MIB  3  gave  strong  nuclear  staining  of  proliferating  cells 
under  a  variety  of  normal  and  neoplastic  conditions  73-286.  This  method  is 
reproducible,  easy  to  perform  at  low  cost;  no  additional  technical  skill  is 
needed  and allows a much better recognition of cellular details and, therefore, 
a better identification of positive cellular subsets.  This new  method has been 
successfully applied to tissue sections stored for a long time.  The assessment 
of  cell  kinetics  through  the  detection  of  Ki-67  antigen  is  now  possible  on 
archival material.
By  immunostaining  tissue  with  a suitable antibody a  proliferation  index  (P.l.) 
can be calculated as the ratio of nuclear area number positively stained to total 
nuclear area number in a fixed high power field.
3.80  Ki-67 and Prostate Cancer.
A  literature  review  was  carried  out  using  the  Medline  database.  The  initial 
keyword  used  was  prostate  cancer  and  the  second  was  Ki-67.  For  the  first 
keyword  a  total  of 4250  references  were  detected  and  for  the  second  37565. 
Theses two searches were combined and the number of references decreased to 
145 references.  This was further limited to English language abstracts and five
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further  abstracts  were  eliminated.  The  abstracts  of these  140  citations  were 
reviewed  and  a  total  of  43  pertinent  references  were  reviewed  in  detail
1:15:30:43:59:62:63:84:90:109:115:142:155:158-160:187; 194:197:228:229:238:241:260;274:275:285:286;295: 
334:338:345:368:379:379:389:393:394:397:398:403:411:414
3.81  Ki-67  expression  and  outcome  in  patients  with  radical
prostatectomy.
In  a  series  of  180  radical  prostatectomies  with  a  follow  up  of  1   to  9  years, 
MIBl  scoring was high  in  168  specimens and absent or low  in  12 specimens. 
The  five-year  recurrence  free  survival  correlated  with  MIBl  expression.  The 
authors concluded that MIB  1   expression could be used to determine a subset 
of patients who are more likely to relapse 30.
In  a series of 92  radical  prostatectomy patients carried out in  the Netherlands, 
the  expression  of  Ki-67  (MIB  1)  correlated  with  recurrence  but  this  did  not 
reach significance in a multivariate analysis 403.
In a series of  137 consecutive  radical prostatectomies,  with  a  mean  follow  up 
of 5.8 years available for  108 patients, a Ki-67 labelling index above 7.5% was 
predictive  of recurrence  in  a  multivariate  analysis207.  A  similar  study  of 29 
patients  using  a  cut  off  of  1 0 %  also  showed  a  statistically  significant 
association  between  the  proportion  of  Ki-67  cells  labelled  and  biochemical
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relapse15.  A  study of  104 patients focussing on the  Ki-67  staining in the area 
of  highest  tumour  grade  with  a  median  follow  up  of  56  months  showed  a 
median staining of 6.7% (range  1.2 -  42.6).  Using a cut off of 6.7%, the Ki-67 
staining was a predictor of relapse in a multivariate analysis155.
A  recent  study of  122 patients  who  underwent radical  prostatectomy  selected 
22 patients with “metastatic disease” (pT3b-4aN0M0 and pTanyNlMO) and  18 
“nonmetastatic” (<=pT3aN0M0).  At a mean  follow up of 33  (4 -  78)  months, 
the proliferation index predicted relapse in both groups376.
A study of 20 radical  prostatectomy specimens showed that the Ki-67 score is 
greater  for  peripheral  zone  tumours  when  compared  to  transition  zone 
cancer115; this is in concordance with more aggressive behaviour of peripheral 
zone tumours.
3.82  Ki-67  expression  and  outcome  in  patients  with  radical
radiotherapy.
Animal  studies  using  radiated  heterotransplanted  DU-145  cell  lines  and 
comparing the expression of Ki-67  in the radiated and control groups have not 
shown a significant decrease in proliferation activity "  .
Pre-radiotherapy  material  was  stained  from  106  patients  who  had  definitive
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prostate  radiotherapy.  The  mean  Ki-67  labelling  index  was  3.2%,  and 
increased in high grade and high stage disease.  A labelling index greater than 
3.5% predicted early biochemical failure  90
A further study of 42 patients with prostate cancer,  both capsule confined and 
extra capsular, demonstrated that Ki-67 as a measure of cell proliferation could 
predict recurrence  in  both groups  in  a  multivariate  analysis  .A   later study 
confirmed these findings197.
In  a  series  of  55  patients  who  had  received  radical  radiotherapy  and  been 
followed up for a mean of 6 . 8  years, residual cancer was found in 67% (37/55) 
of patients, of these 64%  (23/36) had active tumour cells as determined by Ki- 
67 staining. These authors concluded that the majority of patients with tumour 
on their post radiotherapy biopsies had viable tumour228.
A  study  comparing pre  radiotherapy  biopsies  with  post  radiotherapy  biopsies 
in  13  patients  demonstrated  an  increase  in  Ki-67  score,  between  the  pre  and 
post biopsies. The score increasing from a mean of 5.6 to  10.5 in those patients 
that relapsed  142.
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3.83  Ki-67  expression  and  outcome  in  patients  treated  with  androgen
withdrawal.
A study of  153  unselected patients with prostatic carcinoma demonstrated that 
Ki-67  score  was  related  to  poorly  differentiated  tumour,  and  a  high  Ki-67 
score  was  related  to  metastatic  disease  and  poorer  survival.  In  particular  if 
patients with  metastatic disease were stratified according to their Ki-67 scores 
after androgen withdrawal those with scores >  1% had a poorer outcome  159.
A study of  190 treated patients with  prostate cancer with  a mean  follow  up of 
12.9  years,  demonstrated  that  Ki-67  was  significantly  related  to  stage  and 
grade.  In  a  multivariate  analysis  Ki-67  expression  had  no  independent 
predictive  value  in  organ confined disease  but  was an  independent prognostic 
factor over the entire cohort1.
3.84  The effect of androgen ablation on Ki-67.
A  study  of  18  patients  who  had  biopsies  before  and  after  androgen  ablation 
showed a decrease  in  Ki-67  score after androgen  ablation414.  A further study 
comparing  28  patients  who  had  received  neoadjuvant  androgen  ablation  with 
51  patients  who  had  not,  demonstrated  that  androgen  ablation  leads  to  a 
significant  decrease  in  MIB-1  index  i.e.  7.5%  compared  to  14.4% 
respectively394.
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3.85  Ki-67 and PIN.
In a heterogeneous series of 35 patients the Ki-67  labelling index  increased in 
a stepwise progression when comparing benign tissue, with PIN and cancer l87. 
This has been confirmed by others  160-2 7 x 3 7 9 -393
160Table20: The relationship between Ki-67 (MIBl) expression and outcome in patients with radical prostatectomy.
Ref. Y ear  of 
pub
Type of specimen No of 
cases
No localised No  locally 
invasive
No
mets
Method Results/Conclusions
50 19% Radical 
Prostatectomy 
follow up  1-9 yr.
180 72 107 1 IHC 18  pts  had  low  MIBl  expression. 
Significant  correlation  between  MIB  1  
score  and  nuclear  grade.  Gleason  score, 
pathological  stage.  Low  MIBl  score 
correlated with low chance of recurrence.
207 1996 Radical 
Prostatectomy 
follow up  1-15 yr.
137 44 93 34 IHC Significant correlation  between  recurrence 
and Ki-67>7.5%,
1 5 1999 Radical 
Prostatectomy 
follow up 3yrs
29 39 • y 8 IHC High  MIBl  expression  associated  with 
recurrence, and an  independent prognostic 
factor in a multivariate analysis.
4 1 )5 2000 Radical 
Prostatectomy 
follow up 0-17 yr.
92 65 27 6 IHC High  MIBl  expression  associated  with 
recurrence,  but  was  not  an  independent 
prognostic  factor  in  a  multivariate 
analysis.
155 2001 Radical 
Prostatectomy 
median  follow  up 
56 months.
104 32 72 7 IHC High  MIBl  expression  associated  with 
recurrence, and an  independent prognostic 
factor in a multivariate analysis.
X 4 2002 Radical
Prostatectomy
24 13 1 1 0 IHC High Ki-67 expression in cancer.
177 2005 Radical
Prostatectomy
52 14 38 0 IHC 20/52 progressed.  16 Ki67+ relapsed and 4 
Ki67-, Ki-67 predicted relapse.
576 2005 Radical
Prostatectomy
40 6 12 22 IHC High  Ki-67.  predicted  progression,  and 
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Table21: The relationship between Ki-67 (MIBl) expression and outcome in patients with radical radiotherapy.
Ref. Year  of 
pub
Type of specimen No of 
cases
No localised No  locally 
invasive
No
mets
Method Results/Conclusions
::x 1996 Biopsies 55 9 9 IHC Post  DXT.  there  was  still  active 
proliferation.
44X 1997 Biopsy/TURP 42 30 12 0 IHC 18/23  patients  with  recurrence  had  high 
Ki-67  scores,  compared  to  6/19  with  no 
recurrence.
14; 1998 Biopsy 13 13 0 0 IHC Comparing  pre-treatment  with  post 
treatment  biopsies  in  radiation  failures 
showed  an  increase  in  Ki-67  from  5.6  to 
10.5
19? 1999 TURP 42 35 7 0 IHC The  treatment  failures  had  a  significantly 
higher  Ki-67  score  compared  to  the 
responders.
40 2002 Biopsy/TURP 106 74 32 0 IHC Ki-67>3.5% predicts treatment failure.
225 2004 Biopsy 108 31 77 0 IHC A staining index of greater than  3.5( A   was 
associated  with  a  risk  of developing  local 
progression, and disease specific mortality.
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Table 22:  The relationship of Ki-67 to outcome in patients treated with androgen withdrawal.
Ref. Year of 
pub
Type of specimen No of cases No localised No locally 
invasive
No mets Method
4u 1995 Serial biopsy 18 3 6 9 IHC Androgen  ablation  causes  a  decrease 
in Ki-67.
i 1997 TURP/Biopsy 190 106 84 66 IHC Ki-67 increased with grade and stage. 
In  a  multivariate  analysis  Ki-67 
staining was an  independent predictor 
of outcome.
470 1997 TURP  mean  follow 
up 71  months.
125 89 16 15 IHC Ki-67 increased with grade and stage. 
In  a  multivariate  analysis  Ki-67>3% 
was  an  independent  predictor  of 
outcome.
163Chapter 4: 
Aims
•  To determine  the  relationships  between  the  volume  of  high  grade
prostatic intraepithelial neoplasia, cancer and benign tissue.
•  To determine  the  relationship  between  serum  PSA  and  the  volume of
high grade prostatic intraepithelial neoplasia, cancer and benign tissue.
•  To determine using immunohistochemical techniques the levels of p53,
bcf,  bax,  and  Ki-67  in  formalin  fixed  benign,  malignant  and  tissue 
with PIN.
•  To  determine  using  immunohistochemical  techniques  the  effect  of
androgen ablation on the levels of p53, bcf, bax, and Ki-67 in formalin 
fixed malignant tissue.Prostatic Intraepithelial Neoplasia and Prostate Cancer.
Chapter 5: Materials and Methods.
5.1  Methods
This  study  was  divided  into  two  parts;  the  first  part  was  a  prospective 
assessment of tumour volume,  PIN volume, and total gland volume. This was 
carried  out  in  76  radical  prostatectomy  specimens.  The  second  part  was  a 
retrospective  assessment  of the  expression  of P5 3,  bcf,  bax,  and  Ki-67.  This 
was  carried  out  on  paraffin  fixed  specimens  identified  from  97  radical 
prostatectomy specimens.
All  radical prostate specimens were obtained from patients undergoing radical 
retro  pubic  prostatectomy.  The  patients  preoperatively  were  staged  with 
clinical  examination,  serum  total  PSA  (Hybertech  Assay),  transrectal 
ultrasound  guided  sextant  biopsy,  CT  scan  and  bone  scan.  A  single  surgeon 
(A V Kaisary) carried out the operations and a single pathologist carried out all 
the initial histopathological assessment (M Jarmulowicz).
The specimens were prepared as follows.
165Prostatic Intraepithelial Neoplasia and Prostate Cancer.
5.2  Fixation
Some authors advocate cutting the prostate into slices fresh and then placing in 
fixative344; we have not found this a satisfactory technique.  It is difficult to cut 
the prostate fresh and get consistent slices.  In addition the tissue is friable and 
distorted. This leads to curling of the edges.  Others believe in inking the fresh 
prostate  and  then  fixing  it  whole  343.  We  feel  the  best  results  are  achieved  if 
the  latter  approach  is  adopted.  After  weighing,  the  whole  specimen  is  left  to 
fix  in  10%  buffered  formaldehyde  for at  least  72  hours.  The  specimen  is  not 
incised  to speed  penetration  of the fixative,  as this  will  distort the subsequent 
slices.
After fixation  the specimen  is  measured.  The margins  are painted  with Indian 
ink.  After  painting  the  specimen  is  briefly  immersed  into  Bouin’s  fixative, 
which  instantly fixes  and  hardens the  Indian  ink,  so  minimising the spread of 
ink onto the cut surface on slicing.  The specimen is then cut.
5.3  Cutting the specimen
The specimen is cut with a slicer. The machine setting is calibrated, using any 
available  fixed  tissue,  to  deliver  slices  which  are  3.5  mm  in  thickness.  Our 
experience of these  machines  is  that towards the end  of the cut,  the specimen 
slice  is pulled  away  producing a curved slice  and distorted  surgical  margin  at
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that  point.  To  prevent  this,  the  specimen  is  almost  cut  through,  and  then 
withdrawn  from  the  machine  and  the  cut  completed  using  a  disposable 
microtome blade attached to a disposable handle.
There  are  various  opinions  on  the  best  way  to  tackle  the  apical  slice.  In  our 
laboratory the apical slice is further cut in the saggital plane and then sliced343.
5.4  Scanning the slices
Maintaining the correct orientation, both left / right and apex to base, the slices 
of prostate  are  laid  onto  an  A4  sheet of transparent celluloid.  The  surface  of 
the  slices  to  be  cut to produce  the  microscope  section  is  laid  face  down  onto 
the  celluloid.  The  slices,  together  with  a graduated  rule,  are  then  placed  in  a 
standard  flatbed  scanner.  The  specimen  is covered  with  a  white  A4  sheet of 
paper,  both  to  protect  the  lid  of the  scanner and  to  improve  the  background. 
As the lid will be three millimetres above the glass the background will have a 
green hue due to reflection from the lid.
Select the image size to be scanned as A4. This will  make subsequent printing 
at  real  size easier.  Scan  the  image at  180 dpi  with  printing at 720 dpi  (Figure 
14).
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Fig 14:After fixation the prostate is sliced and scanned.
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5.5  Manipulating the image
Some  centres  use  a  ‘whole  mount’  of the  cut  prostate  slices,  whereas  others 
may not have the facilities and have to use the standard sized cassettes.  Using 
the former method there should be some way of identifying left and right sides 
on the microscope slide. We use standard cassettes and a print out of the image 
forms  a  convenient  template  to  record  the  numbering  of  the  cassettes.  The 
majority of slices need to be cut into four.
The specimen  is then embedded  in paraffin wax and processed as per standard 
protocol  (see  later).  When  examining the  slides  the  areas  of tumour and  high 
grade PIN are marked on the glass slides using a glass marker. Transferring the 
tumour  and  PIN  maps  from  the  microscope  slides  to  the  computer  bitmap 
image  of the  prostate  slices  is  not difficult,  nor is  it a lengthy procedure. The 
quickest  method  is  to  first  transfer  the  map  from  the  microscope  slides  to  a 
printed  image.  If the  image  has  been  printed  at  100%  size  the  tissue  sections 
and  printed  image  will  match  and  slight  variation  to  section 
shrinkage/stretching does not produce any significant difficulties.  The printed 
image can be traced over the slide using a light box; the latter is the easier and 
more accurate (fig  15).
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Fig 15: Areas of PIN and cancer.
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To  achieve  the  final  digitalised  image  the  hand  coloured  printed  hardcopy  is 
re-scanned and overlaid onto the original image. This is straightforward as the 
latest  version  of  software  allows  images  to  be  manipulated  as  a  series  of 
separate  image  layers.  The  re-scanned  image  is  slightly  smaller  than  the 
original,  because  of  the  small  margin  introduced  by  the  printer,  but  this  is 
easily  corrected  using  the  resize  command  of  the  software,  so  that  the  two 
images  are  of the  same  size.  The overlaid  image,  in  a separate  layer,  is  set at 
50% transparency so that it can be moved to perfectly place it over the original 
image.  A digitalised pad with a pen is used to facilitate this stage rather than a 
standard  mouse.  For  clarity  the  marked  tumour  and  PIN  on  the  re-scanned 
layer is traced in  the appropriate colour (Red = cancer,  Blue = PIN), each  in a 
separate  image  layer.  The  final  image  can  then  be  printed  (figure  16).  The 
patient  identification,  slice  labels  and  any  comments  can  readily  be  inserted 
onto  the  image using the text facility of the image software.  For convenience 
it  is  best  to  have  separate  image  layers  for  prostate  slices,  patient/specimen 
identification,  labels  and  comments,  tumour  and  PIN.  Using  Paint  Shop  pro 
(version 6) the image saved as separate layers is approximately.
This technique provides a high quality image of the cut surface of the prostate, 
with an overlaid map of tumour and PIN.
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Fig 16: Composite image of prostate.
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5.6  Calculation of total prostate, PIN and tumour volume
The  acquired  images  of prostate  slices  were  transferred  to  the  image  analysis 
program  using  proprietary  software  (Sigma  Scan  Pro,  version  6.0  by  Jandel 
Scientific,  UK).  In  order  to  make  accurate  measurements  of prostate  gland 
areas;  a  scale  bar  was  included  in  each  image.  The  image  analysis  program 
would use the  scale bar for calibration.  Area measurements  of the regions of 
interest were performed semi-automatically on Kontron KS400 image analysis 
software  (Zeiss,  UK).  A  macro  was  written  to  aid  the  use of this  programme 
(Appendix  1).  The  macro  was  designed  to  interact  with  Paint-Shop-Pro 
images  to convert the  image from  full  colour to grey scale and then allow the 
images  to  be  transported  out  to  the  KS400  environment.  The  regions  of 
interest  where  then  automatically  segmented,  giving  the  operator  a choice  to 
interact if necessary.
Regions measured included:  1)  the  entire  prostate  excluding  the  slices 
containing predominantly seminal vesicles, 2) PIN, and 3) cancer.  The area of 
the apical cone was not included in the calculation, since it was difficult to be 
certain of its exact thickness and so the volume it represented.  After the areas 
had been calculated they were multiplied by the shrinkage factor to correct for 
any changes  in  volume during processing of the  specimen.  All  measurements 
were transferred to Microsoft Excel for statistical analysis.
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5.7  Shrinkage factor
Shrinkage  factors  have  been  calculated  by  a  number  of authorities,  and  vary 
from  1   to  1.5301’344.  It  is  important  to  calculate  it  for  your  specific  lab.  In 
addition different labs use different techniques to fix the prostate with different 
fixatives  and  different  protocols  for  the  processing  of the  prostate343.  Some 
labs cut the fresh  prostate  into slices and then  fix  the  gland  in  slices343  where 
as others, ours included, fix the whole gland and then cut it into slices.
In our lab we do not have the resources to process the prostate slices as whole 
mount  so  as  described  previously  we  cut  them  into  portions  that  will  fit  into 
our  cassettes.  Taking  all  this  into  account  we  decided  to  calculate  the 
shrinkage fraction for our lab rather than accept one that may not be applicable 
to our institution.
The first problem  is how to accurately the measure the volume of the prostate. 
Since  prostates  are  an  irregular  shape  and often compressible  it  is difficult to 
get  reproducible  measurements  with  a  ruler.  Therefore,  the  fresh  prostates 
were taken from the operating theatre, loose tissue was removed and they were 
weighed  and  immersed  in  water and  the  volume of water displaced  weighed. 
The measurement of the volume was repeated. The prostates are then placed in 
the fixative,  10% buffered formaldehyde for at least 72 hours.
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Just prior to slicing the prostates, the measurement of volume and weight was 
repeated.  This gave us the shrinkage factor for the first stage. This method of 
measuring  changes  in  the  volume  takes  into  account  any  contraction  that 
occurs  in  the  urethral  cavity  whereas  if  simply  the  maximal  linear 
measurement  was  taken  before  and  after  fixation  this  would  not  have  been 
taken into account343.  However the volume obtained also includes the seminal 
vesicles which may have different tissue characteristics with respect to fixation 
and processing.  We did consider removing the vesicles prior to measuring the 
volumes,  but  this  would  have  meant considerable  dissection  of the  specimen 
prior  to  histopathological  assessment  of  the  specimen,  and  it  was  felt  this 
would  not  be  in  the  best  interest  of the  patient.  In  addition  other authorities 
have included the seminal vesicles when calculating the shrinkage fraction301.
Since  the  slices  are  now  scanned,  this  factor can  be used  for determining  the 
total  volume  of the  gland  from  the  images.  Then  the  slices  are  divided  into 
convenient  sections  for placing  in  the cassettes;  initially  we  attempted  to  use 
linear  measurements  with  a  vernier  calliper.  However  this  was  not 
reproducible  and  there  was  considerable  inter  and  intra  user  variation. 
Therefore  this  part  of the  procedure  evolved,  and  now  we  scan  the  prostate 
slices whole after the fixation in formalin and then the processed slides stained 
with haematoxylin and eosin were scanned (fig  16).
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Fig 16:H&E stained slices for comparison with slices from fig 14.
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Thus using the KS-400 software we could calculate the area of these slices and 
so  the  second  correction  factor.  This  can  be  multiplied  with  the  previously 
calculated correction  factor can  provide  an  accurate  result for prostate cancer 
and PIN.  See appendix2.
5.8  Slice thickness.
The  thickness  of the  prostate  slices  after  fixation  in  formalin  was  measured 
with  a  pair  of  Venier  callipers.  Consecutive  slices  from  six  prostates  were 
measured  and  the  average  thickness  calculated.  This  was  multiplied  by  the 
shrinkage fraction. See Appendix 3.
5.9  Preparation of specimens
The  paraffin  blocks  were  cooled  in  an  ice  bath  before  using  a  standard 
microtome  to  cut  3-4  micron  thick  serial  sections  of  all  specimens.  The 
sections  were floated on  water heated to 45° C  in a water bath.  In some cases 
they  needed  to  be  straightened  out  with  the  aid  of  methyl  alcohol  covered 
slides  before  floating.  Sections  were  examined  with  the  naked  eye  to  ensure 
that  a  cross  section  of  the  whole  block  was  obtained.  Each  slide  usually 
contained one piece of serial  section from, the same block.  The sections were 
then mounted on to APES coated microscopic glass slides (Appendix No. 4) to 
avoid tissue  loss  during  micro waving.  The  slides  were  immediately labelled
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using, a lead pencil,  with their respective pathology number which consists of 
a  7  digit  code  (identical  to  number  on  block).  The  upper  left  corner  of the 
frosted  part  of  the  slide  was  consistently  used  to  ensure  correct  orientation 
when  handling them.  Slides  were then transferred  into racks and  left for 24 - 
48 hours in a warn room at 37° C to dry.
5.10Dewaxing.
Prior  to  staining  the  slides  had  to  dewaxed.  This  was  carried  out  as  per 
appendix  5.  Then  the  specimens could be  stained  with  haematoxin and eosin 
or with the appropriate antibodies.
5.11  Staining methods
There  are  four  main  methods  of immunoperoxidase  staining that can  be used 
to localise cellular antigens.  The direct, indirect, PAP, and streptavidin-biotin 
methods.  Each  may  have  certain  advantages  and  disadvantages  which  have 
been  evaluated  in  our  laboratory;  we  use  the  streptavidin-biotin  method.  The 
streptavidin-biotin  technique  lends  itself  to  the  localisation  of  numerous 
antigens  in  a  variety  of  specimens  including  paraffin  sections,  cryostat 
sections,  smears,  imprints  and  cytospins.  For  a  specific  antigen  it  can  be 
determined what type of cells produce this substance in normal  and neoplastic 
tissue,  levels of the  substance produced,  and the determination of tumour cell
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differentiation.
Immunoperoxidase  staining  involves  the  use  of  antibodies  and  the  enzyme 
peroxidase.  Peroxidase is commonly used for several reasons:
1.  Its small size will not hinder the binding of antibodies to adjacent sites.
2.  It  is  easily  obtainable  in  highly  purified  form  so  that  the  chance  of 
contamination is minimised.
3.  It  is  very  stable,  and  therefore  will  remain  unchanged  during 
manufacture, storage and application.
4.  Only small amounts are present in tissue specimens, and this endogenous 
peroxidase activity is easily quenched.
5.  There is a wide  availability of chromogens,  which can  be acted upon by 
peroxidase to form a coloured end product that will precipitate at the site 
of the antigen to be localised.
5.12  Streptavidin-biotin Method
This  method  is  based  on  the  ability  of the  egg  white  glycoprotein  avidin  to 
immunologically bind four molecules of the vitamin biotin.  Three reagents are 
used.  The  first  is  a primary  antibody specific  for the  antigen  to  be  localised. 
The  secondary  antibody,  capable  of  binding  to  that  first,  is  conjugated  to 
biotin.  The  third  reagent  is  a  complex  of peroxidase  conjugated  biotin  and
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avidin.  The free sites of the avidin molecule allow binding to the biotin on the 
secondary  antibody.  The  peroxidase  enzyme,  and  therefore  the  original 
antigen, is visualised with an appropriate chromagen.
Even though conjugated antibodies are used in this method, the strong affinity 
of avidin for biotin gives this method greater sensitivity than other conjugated 
antibody techniques such as the direct and indirect methods.  Excellent results 
can be achieved on fixed, paraffin embedded specimens.
5.13  Staining Procedure
The details of the exact staining procedure are summarised in Appendix No.6 .
5.14  Endogenous Peroxidase Activity (Appendix No. 7)
The  substrate  chromagen  reaction  used  to  visualise  peroxidase  cannot 
distinguish  between  the  enzyme  immunologically  localising  the  cellular 
antigen, and similar enzymatic activity present in the specimen before staining. 
This endogenous peroxidase activity is confined mostly to red and white blood 
cells.
If it  is  not removed  before  adding the  marking enzyme, positive  staining will 
be  observed  that  is  due  not  to  the  specific  antigen  alone,  but  also  due  to 
peroxidase  activity already present in  the specimen.  Removal  of endogenous
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peroxidase  is  essential  to  correct  interpretation.  This  was  achieved  by 
quenching the  mounted specimens in a solution of 0.5%  hydrogen peroxide in 
methanol.
5.15  Antibodies
The Dako D07 was used for the detection of aberrant P53 because this has been 
shown  to be an  effective antibody in comparative studies  of six  antibodies  L \  
and  has  been  used  in our laboratory routinely and by others  with good  results 
l0.  Dako  M887  was  used  for  bcf,  SantaCruz  Bax  N20  for  bax  alpha,  Dako 
M722 for Ki-67, and Dako A562 for PSA.
5.16  Dilution of antibodies.
Optimally diluted antibodies must be used to achieve meaningful  results.  The 
dilution of any one antibody is dependent upon several factors:
-  Concentration  of  specific  antibody  in  the  solution  as  provided  by  the 
manufacturer  (antibody  titre).  The  more  specific  antibody  molecules  per 
millilitre, the higher the titre and the lower the working concentration.
A  number  of substances  other than  specific  antibody  are  often  present  in 
the  solution;  high  levels  of  contaminating  proteins  necessitate  high 
dilutions to prevent non-specific background staining.
181Prostatic Intraepithelial Neoplasia and Prostate Cancer.
Generally the  longer the incubation  time,  the  more  dilute  the  antibody can be 
used.  In  this  study,  antibody  incubation  times  were  held  constant  after 
experimental determination of optimal time.
Other considerations  such  as  the  choice  of dilution  buffer,  use  of a  humidity 
chamber,  the  specimen  fixation  and  processing  protocol,  will  all  affect  the 
dilution  used.  Optimal  dilutions  for  our  laboratory  conditions  were 
ascertained for each individual antibody.
When  interpreting  dilution  results,  two  criteria  were  evaluated:  Specific 
staining  and  non-specific  background  staining.  The  goal  was  to  achieve  the 
greatest  intensity  of  specific  staining  with  the  least  amount  of  background 
interference.  The  higher  the  antibody  dilution,  the  lower  the  background 
staining due to undesired protein binding.
5.17  Incubation times
Incubation  times,  antibody  dilutions,  non-specific  background  staining  and 
specific staining intensity are all  interrelated.  The  longer the incubation times 
the  higher the  antibody dilution.  The  more dilute  the  antibody,  the  lower the 
non-specific  background  stain.  The  lower  the  non-specific  stain,  the  greater 
the contrast with the specific stain, making interpretation easier.
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Incubations  with  antibody  solutions  were  for 60  minutes  to  16  hours.  When 
processing several  slides at once, there will  be a one or two minute difference 
between  the  first  slide  and  the  last.  To  achieve  consistency  processing  of 
slides was staggered so that all  specimens undergo identical  incubations.  The 
temperature  of  incubation  will  also  affect  antibody  dilutions.  The  optimal 
temperature is calculated for each antibody.
Haematoxylin  and  eosin  stains  were  carried  out  on  all  the  sections.  This 
determined  the  presence  of carcinoma,  PIN,  and  benign  prostate  tissue.  The 
areas  of  tumour  and  PIN  were  demarcated  and  then  transferred  to  the 
computer-generated images.
5.19  Antigen retrieval (micro waving) (Appendix No.9)
The  use of formalin  fixed paraffin  blocks  was unreliable  before  the advent of 
antigen  retrieval  techniques  such  as  microwave  irradiation  or  a  pressure 
cooking  to  reverse  some  of  the  effects  of  fixation  (un-fixation).  Studies 
indicate that antigen  retrieval  provides an extremely successful  method for the 
demonstration  of  nuclear  antigens  with  formalin  fixed,  paraffin  embedded 
tissues  351'335-383"384?   even  after  fixation  in  formalin  for  as  long  as  7  days  383. 
The use of an antigen retrieval system provided excellent results with minimal 
background staining, and high contrast between positively stained and negative
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cells.  Studies  for  p.33  using  single  strand  conformational  polymorphism 
analysis  of  RNA/PCR  products  and  sequencing  have  shown  that  using 
microwave irradiation as an antigen retrieval system detects 93% of mutations 
between exons 5-8 4I3.
For the immunohistochemical  studies the slides were microwaved or placed in 
a  pressure  cooker  as  part  of  an  antigen  retrieval  system.  The  microwave 
incubation times had been predetermined (PSA = 5mins, p.<>3 =  10 minutes, and 
bcf =20 minutes).  For Ki-67  pressure-cooking has been  used successfully in 
our  laboratory  as  an  antigen  retrieval  system,  the  time  used  was  90seconds. 
For bax no antigen retrieval is required.
5.19  Controls
Certain procedural  and reagent controls are essential for the validation of the 
results  of immunoperoxidase  staining.  Most of these controls centre on  the 
primary  antibody  to  ascertain  that  positive  staining  is  the  result  of specific 
binding  to  the  antigen.  After  determining  the  optimal  dilution  of  a  new 
primary  antibody,  several  known  positive  and  negative  specimens  were 
stained to certify the antibody’s specificity.
Positive  control:  A  specimen,  processed  identically  to  the  unknown  that 
contains the antigen in question.
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Two  negative  controls:  One  specimen  processed  in  an  identical  way  except 
that  non-immune serum  is used instead of the primary antibody. This serves 
as  a  specimen  blank  since  any  staining  observed  is  due  not  to  antibody 
localisation  of the  antigen  but  to  non-specific  protein  binding,  endogenous 
peroxidase activity, or non-specific binding of the other antibody reagents. 
The second specimen processed in an  identical  way except that non-immune 
serum  is used in place of both primary and secondary antibodies. This serves 
to  exclude  staining  that  may  be  due  to  interaction  between  the  chromogen 
used 3, 3 Diaminobenzidine Tetrachloride (DAB) and processed tissue (DAB 
negative control).
All  controls  underwent  the  same  fixation  and  processing  schedule  as  the 
unknown specimen and were processed along with the unknown to assure the 
accuracy of the results.
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Antigen Clone Supplier Antigen
retrieval.
Ab
Dilution
Incubatio 
n time.
Controls
P 5 3 D07 Dako 1 0  mins 
microwave
1:50 60  mins  @ 
room temp.
Vulval
cancer
Bcl2 M887 Dako 2 0 mins
microwave
1:25 60  mins  @ 
room temp.
Tonsil
Bax-
alpha
Bax
N 2 0
SantaCruz 0 1:800 16hrs
@4°C
Breast
Ki-67 M722 Dako 90s in 21 
Citrate 
buffer in a 
pressure 
cooker.
1:500 60  mins  @ 
room temp.
Tonsil
PSA A562 Dako 5 mins 
microwave
1:800 60  mins  @  
room temp.
Benign
prostate
Table23: A summary of the antibodies used the incubation times, and the 
controls.
5.20  Principles of Interpretation of immunostaining
The most difficult aspect of immuno-staining is in the correct evaluation of the 
finished  product.  The  amount  of chromagen  precipitated,  and  therefore  the 
intensity  of the  reaction  has  been  found  to  be  proportional  to  the  amount  of 
antigen  present.  Not  all  cells  contain  the  same  amount  of  antigen,  and 
therefore  stain  with  varying  intensity.  Non-antigen  containing  cells  and  cell 
components  are  contrasted  by  a  counter  stain  (methylene  blue)  which  makes 
distinguishing the two easier.
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Specific  staining  is  localised  in  cells,  non-specific  background  staining  is 
usually  found  in  collagen  and connective  tissue.  Interpretation  is  basically  a 
comparison  of the  specific  and  non-specific  staining  pattern  and  intensity,  if 
any, of the specimen with that of the control.  The source of the tissue, antigen 
characteristics  and  the  procedure  used  must  be  taken  into  account  for proper 
evaluation.
Several  artefacts  maybe  found in  specimens,  which  may produce staining and 
interfere  with  correct  interpretation.  They  are  mostly  not  confined  within 
cells, but are spread randomly across the specimen.  Any staining that occurred 
on the very edge or along knife marks is often non-specific and can be ignored. 
Positive staining of necrotic crushed or cells that have undergone autolysis and 
haemorrhagic  tissue,  is  always  regarded  as  non-specific.  Only  the  staining 
pattern of viable cells is considered for interpretation.
5.21  Non-specific Background Staining
Positive staining of a specimen that is not a result of antigen  antibody binding 
is  termed  non-specific  background  staining.  The  most  common  cause  is 
attachment  of  protein  to  highly  charged  collagen  and  connective  tissue 
elements of the specimen.  Antibodies are proteins.  If the first protein solution 
applied  to  the  tissue  is  the  primary  antibody,  it  can  be  non-specifically 
adsorbed  to  these charged  sites.  The  secondary antibody can  still  bind  to  the
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primary  and  the  peroxidase  colour  reaction  will  occur.  Positive  staining  of 
these  sites  is  due  not  to  localisation  of the  tissue  antigen,  but  to  non-specific 
antibody  attachment  to  collagen  and  connective  tissue,  and  neurones  and 
ganglion cells for bch.
Other  causes  of  non-specific  background  staining  such  as  inappropriate 
antibody  dilutions  incomplete  removal  of paraffin,  improper  rinsing  of slides 
and  incorrect  substrate  incubation  can  be  minimised  by  careful  and  accurate 
technique.
5.22  Scoring of immunostaining
All  samples  were  scored  firstly  as  positive  or  negative  staining,  secondly  by 
assessing the intensity of staining,  thirdly by  assessing the proportion of cells 
stained.  In  carcinoma  and  PIN  this  grading  was  confined  to  only  regions  of 
interest  within  the  specimen.  The  areas  of  PIN  and  cancer  within  each 
specimen were initially identified with H&E.
Cases  were  considered  positive  if  any  of  the  tumour  cells  manifested 
positivity.  Intensity  was  scored  on  a four point  scale:  no  staining  = 0;  weak 
staining  =  1;  moderate  staining  =  2  and  intense  staining  =  3.  Assessment  of 
intensity  of  staining  was  always  referenced  to  a  standard  positive  control, 
stained at the time and under the same conditions as the test case.
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The  proportions  of  cells  staining,  for  KI-67  in  particular,  were  scored  as  a 
percentage  of  cells  staining  positive  against  total  number  of  cells  per  high 
power  microscopic  field  (x  400).  All  histopathological  assessment  was 
confirmed  two  histopathologists,  Dr  Michael  Jarmulowicz,  Consultant 
Histopathologist  at the  Royal  Free  Hospital,  and  Dr Tara Walker,  Consultant 
Histopathologist  at  Queen  Alexandra  Hospital,  Portsmouth.  There  was 
agreement in  most (>90%) of cases with regard to the  intensity and pattern of 
staining  between  the  two  pathologists.  In  the  sections  in  which  the  scores 
differed, we agreed a common result.  The percentage of positive cells within a 
section was estimated by 'eye-brain' co-ordination.
5.23  Background staining
Background  staining  was  minimal  or  absent  in  most  sections  and  did  not 
therefore  interfere  with  assessment.  The  P5 3,  bcf  and  MIB-1  antibodies 
achieved particularly specific staining with an absence of background staining. 
The bax had some diffuse background staining.
5.24  Staining patterns
The criterion for a positive reaction was nuclear staining for p .33 and Ki-67 and 
cytoplasmic staining for bcf, bax alpha.
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5.30  Statistics.
The data obtained  from  this  study  was tabulated  in  an  excel  spreadsheet. The 
raw  data  is  presented  in  Appendix  10  and  11.  The  data  was  assumed  not  to 
follow  a  normal  Gaussian  pattern,  and  therefore  treated  as  a  non-parametric 
data  set.  Analysis  designed  for  parametric  data  can  not  be  applied  to  non- 
parametric data, but non-parametric  analysis can  be  applied to parametric  and 
non-parametric data to give valid results.  Therefore the use of non-parametric 
tests would maintain the statistical stringency of the analysis.
The  stastical  package  for  social  science  (SPSS)  10.1  was  used  for  data 
analysis.  The  analysis  of  variance  (ANOVA)  was  used  calculate  the 
relationship  between  tumour,  PIN,  and benign  tissue volume  and  serum  PSA. 
The data obtained from  the  staining of the slides was also assumed to be non- 
parametric, so the Mann-Whitney U test was used to compare the relationship 
between the slides stained.
Assistance  and  guidance  about  statistical  method  was  sought  from  Richard 
Morris  (Department  of Statistics, The Royal  Free  Hospital),  David  St George 
(Department  of  Statistics,  The  Royal  Free  Hospital)  and  Roger  A’Hern 
(Department of Statistics, The Royal Marsden Hospital).
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Chapter 6: Results
The  results  obtained  during  this  piece  of  work  have  been  divided  into  two 
sections. The first set of data was obtained from the morphometric analysis of 
76  radical  prostatectomy  specimens.  This  was  carried  out  prospectively.  In 
summary  the  whole  radical  prostatectomy  was  fixed  in  10%  buffered 
formaldehyde for 72 hours. The specimen is then weighed and inked, slices are 
prepared at intervals of 3.46mm, the slices are scanned and the image obtained 
is used as a template. The slices are then cut into four and placed in a standard 
cassette.  Slides  are  prepared  from  the  cassettes  and  haemotoxylin  and  eosin 
stain  is  used  to  determine  the  areas  of  interest.  This  is  transcribed  onto  the 
initial template.  A shrinkage fraction for the template is  1.03, and for the areas 
of cancer, and PIN is  1.22.
The  data  is  presented  in  graphical  form  wherever  possible.  The  raw  data  is 
available in appendix  10.
191Prostatic Intraepithelial Neoplasia and Prostate Cancer.
6.1:  Results 1: Morphometric Studies.
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Fig 18:The age of the patients.
This  graph  represents  the  age  distribution  of  the  76  patients  whose 
prostatectomy  specimens  were  used  to  investigate  the  relationship  between 
serum  PSA, cancer volume and  PIN volume.  The mean age of the patients at 
the time of surgery is 63.07 +/- 7.4 (SD), with a range of 46 to 78 years.
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Fig 19:Stage of radical prostatectomy specimens.
This  graph  represents  the  stage  distribution  of  the  radical  prostatectomy 
specimens obtained from the 76 patients whose prostatectomy specimens were 
used  to  investigate  the  relationship  between  serum  PSA,  cancer  volume  and 
PIN  volume.  The  stage  of  specimens  was  assigned  using  the  International 
Union  against Cancer  (UICC) TNM  Classification  of malignant  tumours,  6th 
edition, published in 2002.
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Fig 20:Distribution of weight of gland.
The specimens were obtained fresh from the operating theatre. All loose tissue 
was  removed.  The  specimens  were  then  directly  taken  fresh  to  the 
histopathology department and weighed.  The mean  fresh weight is 61.3 g +/-
21.6  (SD) with a range of 26 to  173 g.
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Fig 21:Distribution of volume of glands.
Prostatectomy  specimens  are  an  irregular  shape  and  therefore  linear 
instruments can  not be used to calculate their dimensions.  The volume of the 
prostatectomy  specimen  was  calculated  by  obtaining  the  fresh  specimen, 
removing any  loose tissue,  and fixing  it in formaldehyde. The  slices were cut 
at  3.5mm  intervals.  They  were  then  scanned  using  Paint  Shop  Pro  (version 
6.0).  The scanned images were transferred using Sigma Scan Pro (version 6.0 
by Jandel  Scientific,  UK).  This  made  the  images  into  a  format  accessible  to 
image analysis software. The software used was Kontron KS400.
The  regions  of  interest  could  then  be  identified  and  measured.  In  order  to 
measure  the  volume  of the  gland,  the  area of all  the  slices  except  the  apical 
slices  were  measured.  This  was  multiplied by  the  thickness  of the  slices  and 
the  shrinkage  fraction,  to  obtain  the  volume  of the  entire gland.  There  is  an
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assumption  made  that  the  prostate  specimen  is  of uniform  density.  The  mean 
calculated  volume  of the  prostatectomy  specimens  is  50.9  mis  +/-20.6  (SD), 
with a range of 19.4 to  155.5 mis.
196Prostatic Intraepithelial Neoplasia and Prostate Cancer.
180'
160'
140'
120
100
80
W t  60 
gms
40
20
0 20 40 60 80 100 120 140 160
Total calculated  vol/mls
Fig 22: Correlation between calculated volume and weight of gland (Rsq = 
0.985).
The  data  obtained  from  the  weight  and  the  volume  of the  specimens  was  used  to 
calculate a correlation coefficient.  SPSS software was used and analysis of variance 
(ANOVA) was used to calculate the correlation coefficient.
There is good correlation between the volume of the specimens and the weight of the 
gland. This is reassuring and further supports using the scanned images to accurately 
calculate  the  volume  of  the  gland.  The  majority  of human  tissue  is  composed  of 
water so the density obtained from this calculation is close to  lg/ml.
The line does not cross the 0 on the x and y-axis simultaneously. This could be due to 
the volume of the apical slices not being included in the volume calculations.
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Fig 23: Distribution of Gleason score
The  Gleason  score  is the  sum  of the two most common Gleason grades. The 
Gleason  grade  is  determined  by  the  architecture  of the  prostate  cancer131230. 
The Gleason score will affect the management options available to the patient, 
for example patients with a Gleason score of seven or above are rarely offered 
surveillance. The Gleason score also has prognostic significance, in this series 
the  mean Gleason  score is 6.2 +/-  1.2 (SD) with a range of 2 to 9.  This is in 
keeping with the results from other published series.
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Fig 24:The  distribution  of  PSA  (ng/ml)  in  the  76  patients  studied  for 
morphometric analysis.
The  blood sample  for the  PSA was  taken  the  night before the operation.  The 
hybertech assay was used for PSA. The range of PSA was 3 to 45 ng/ml, with 
a mean of 9.1+/- 5.9 (SD), and a median of 5.5 ng/ml.
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Fig 25:The distribution of cancer volume.
The fresh prostate was fixed for 72 hours in formaldehyde.  The specimen was 
then  sliced at 3.5-mm  intervals;  the  slices  were  then  scanned using  Scan  Pro 
(version  6.0).  Thus  preparing  a  template.  The  prostate  slices  were  placed  in 
cassettes  and embedded.  Slides  were prepared and stained with  haematoxylin 
and eosin. The areas of cancer were  identified. This was transcribed on to the 
template  in  red.  The  scanned  images  were  transferred  using  Sigma Scan  Pro 
(version  6.0  by  Jandel  Scientific,  UK).  This  made  the  images  into  a  format 
accessible to image analysis software. The software used was Kontron KS400. 
The  regions  of  prostate  cancer  were  identified  and  measured.  In  order  to 
measure  the volume of the prostate cancer,  the area of all  the areas of cancer 
except the apical slices were measured. This was multiplied by the thickness of 
the  slices  and  the  shrinkage  fraction,  to obtain  the volume of the cancer. The 
range of the prostate cancer was .09 to 15 mis with a mean of 2.5 +/-2.7 (SD).
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Fig 26:The distribution of PIN volume in the 76 prostates studied.
The fresh prostate was fixed for 72 hours in formaldehyde.  The specimen was 
then sliced at 3.5-mm  intervals; the slices were then scanned using Scan Pro 
(version  6.0).  Thus  preparing a template.  The  prostate slices  were  placed  in 
cassettes and embedded.  Slides were prepared and stained with haematoxylin 
and eosin.  The  areas of PIN  were  identified.  This  was  transcribed on  to the 
template in blue. The scanned images were transferred using Sigma Scan Pro 
(version  6.0  by Jandel  Scientific,  UK).  This  made  the  images  into  a format 
accessible to image analysis software. The software used was Kontron KS400. 
The  regions  of PIN  were  identified  and  measured.  In  order  to  measure  the 
volume of PIN, the area of all  the areas of PIN except the apical  slices were 
measured. This was multiplied by the thickness of the slices and the shrinkage 
fraction, to obtain the total volume of PIN.
The range of PIN measured was 0 to 2.7 mis with a mean of 0.53 +/-0.6 (SD) 
mis.  The  area of the  prostate  taken  up  by  benign tissue  was calculated  by
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subtracting  the  volume  occupied  by  PIN  and  prostate  cancer  from  the 
calculated volume of the whole gland. The range of volume for benign gland 
was 47.5 mis with a range of 13.3 -  153.4 mis.
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Fig 27: Relationship between serum PSA and benign volume of prostate.
The  volumes  were  calculated  using  the  scanned  images,  multiplying  by  the 
slice thickness and making a correction for the shrinkage fraction. The benign 
volume of the gland was calculated by subtracting both the volume of PIN and 
cancer from the total  volume of the gland i.e. total prostate volume -  (volume 
of PIN  +  volume  of prostate  cancer).  The  volume  of the  benign  tissue  was 
plotted against the  serum  PSA  (ng/ml) using SPSS 10.1  software. The scatter 
chart generated correlation (spearman rho=0.24). The correlation between the 
serum PSA and the volume of benign prostate is significant (p=0.05).
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Fig 28:  Relationship between serum PSA and volume of prostate cancer.
The volume of cancer was calculated from the scanned images; the area of the 
cancer was measured from the scanned images and multiplied by the thickness 
of the slices.  The volume so calculated for each specimen was multiplied by a 
correction  factor  for  shrinkage  of  l .22.  The  volume  of prostate  cancer  was 
plotted against the serum PSA. There is a correlation between the serum PSA 
and  the  volume  of  prostate  cancer,  spearman  rho  =  0.36,  this  is  highly 
significant with a p value of 0.01).
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Fig  29:  Relationship  between  serum  PSA  and  volume  of  prostatic 
intraepithelial neoplasia.
The  volume  of PIN  was  calculated  from  the  scanned  images  using  Kontron 
KS400  software  to  determine  the  area  of  the  regions  of  interest.  This  was 
multiplied  by  the  slice  thickness  (3.46mm)  and  the  shrinkage  factor  (1.22). 
The  volume of PIN  was plotted against serum  PSA  (in  ng/ml). There was no 
correlation between  the volume of PIN and serum PSA. Therefore, PIN using 
the  model  developed  in  this  piece  of  work  does  not  appear  to  contribute 
significantly to PSA.
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Fig 30:  Relationship between PIN volume and cancer volume.
The  volume  of PIN  was  compared  to  the  volume  of cancer.  Some  uuthours 
have  suggested  there  is  a strong and significant  inverse  relationship between 
the volume of PIN and cancer. Hypothesising that this may be further evidence 
to support the  view that PIN develops into prostate cancer99.  A weak inverse 
relationship  was  detected  between  the  volume  of  PIN  and  prostate  cancer 
(correlation  coefficient  =  -0.155),  but  this  does  not  reach  significance  (p  = 
0.183). Therefore this data does not support the work of de la Torre et al 99.Prostatic Intraepithelial Neoplasia and Prostate Cancer.
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Fig 31:  Relationship between PIN volume versus total calculated volume.
The total volume of the gland was calculated using the prostate maps, and this 
was  compared  with  the  volume  of PIN.  There  was  a  significant  correlation 
with  a  coefficient  of  0.4(p=0.03).  This  may  imply  that  both  conditions 
respond to common stimuli, e.g. testosterone.
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Fig32: Cancer volume versus reciprocal of total volume.
The  volume  of cancer  was  compared  to  the  volume  of the  gland  measured 
from  the  templates.  The  volume  of cancer  is  inversely  related  to  the  total 
volume of the gland with a correlation coefficient of 0.3, and a p value of 0.01.
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This may be due to the fact that in the majority of patients in this data set, the 
trigger for a biopsy is PSA, and if the PSA reaches a critical threshold then the 
patient  is  offered  a  biopsy.  Since  both  benign  and  malignant  tissue  can 
produce  PSA,  therefore  a  patient  may  be  offered  a  biopsy  if he  has  a  large 
benign gland with minimal  tumour - the majority of the PSA being generated 
by benign tissue; or a small  gland with a high  volume of tumour - the rise in 
serum PSA being due to prostate cancer.
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Fig 33: Cancer volume versus Gleason score.
The  Gleason  score  is  a  predictor  of  outcome  in  patients  with  prostate 
cancer131'250.  Tumour  volume correlates  with  stage  and  is  also  a prognostic 
factor.  Therefore  there  may  be  a  relationship  between  Gleason  score  and 
cancer volume.  We  investigated this.  No relationship could  be demonstrated 
between tumour volume and Gleason score.
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Fig 34: PIN volume versus Gleason score.
The volume of PIN was calculated using the templates, and this was compared 
to the Gleason score of the prostate specimens. There is no correlation between 
these two variables.
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6.2:  Results 2: 
Immuno-histochemical determination of p5 3, bcl2, bax- 
alpha,  and  PSA  in  benign  prostate  tissue,  PIN,  and 
prostate cancer.
Areas  of  cancer,  and  PIN  were  identified  on  H&E  sections  of  microscope 
slides obtained  from radical  prostatectomy specimens from 92 hormone naive 
patients,  and  areas  of  cancer  were  identified  from  radical  prostatectomy 
specimens  obtained  from  14  patients  treated  with  three  months  of androgen 
ablation.  It  is difficult to  identify areas of PIN  after androgen  ablation.  Low 
power views were used to identify the areas of interest.
The  mean  age  of the  patients  was  64.1  (range  46-71)  years,  mean  PSA  9.6 
(range  1.9-32.40)  ng/ml,  77  patients had organ  and capsule confined disease, 
and  29  patients  had  extracapsular disease.  The  mean  Gleason  score  was  6.1 
(range 2 to 9). All patients were fully staged and were NOMO.
Specimens  obtained  from  19  patients  who  had  a  TURP  for  benign  disease 
were used as controls
For  ps3  the  D07  antibody  was  used,  and  nuclear  positivity  was  sought,  the 
presence of positive staining was regarded as positive. The presence of ps^ was 
sufficient for a specimen to be labelled as positive regardless of the percent of
212Prostatic Intraepithelial Neoplasia and Prostate Cancer.
cells being stained positive 312 421.  in addition the intensity of the staining was 
compared  (Table  25).  There  was  no  significant difference  in  the  intensity of 
staining between the groups studied.
For  Ki-67  staining,  the  MIB-1  antibody  was  used,  in  order  to  obtain  a 
proliferation  index.  1000  cells  were  examined  at  high  power  and  the 
proliferation index was the percentage of cells staining tumours positively with 
MIB-1.  Brown granular nuclear staining was considered positive for Ki-67.
For bch and bax cytoplasmic staining was used to determine a positive result. 
For bcf the  Dako  M887  antibody was  used,  and  for bax  the Santa Cruz bax 
N20 antibody  was  used.  The  presence of positive  staining cytoplasmic cells 
was  regarded  as  positive;  in  addition  for  bcf  the  proportion  of  positive 
staining  cells  in  the  region  of  interest  was  noted.  The  intensity  was  also 
measured for both of the antibodies.
The crude data is available in Appendix  11.
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Table 24
Percentage of P53 positive cells per slide.
N Minimum Maximum Mean Std. Deviation
Benign 19 0 0 .00 .000
PIN 91 0 100 3.46 15.859
Ca 92 0 100 6.96 23.334
LHRH Treated 12 0 100 25.83 39.648
Table 25
Intensity of Staining of P53 Staining.
N Minimum Maximum Mean Std.  Deviation
Benign 19 0 0 .00 .000
PIN 92 0 3 .10 .446
CA 92 0 2 .14 .459
LHRH 14 0 3 .43 .852
Table 26
Percentage of Bcl2 positive staining cells
N Minimum Maximum Mean Std.  Deviation
Benign 19 0 0 .00 .000
PIN 92 0 100 47.93 36.736
Ca 92 0 100 15.98 29.800
LHRH 14 0 100 55.71 46.029
Table 27
Intensity of Staining of BCL-2 Staining.
N Minimum Maximum Mean Std.  Deviation
Benign 19 0 0 .00 .000
PIN 92 0 5 1.39 .889
CA 92 0 2 .35 .563
LHRH 14 0 3 1.00 .961
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Table 28
Percentage of Ki 67 positive staining cells
N Minimum Maximum Mean Std.  Deviation
Benign 19 0 0 .00 .000
PIN 92 0 40 4.50 6.010
CA 92 0 35 5.68 6.304
LHRH 14 1 25 2.79 6.399
Table 29
Intensity of Staining of Bax Staining.
N Minimum Maximum Mean Std. Deviation
Benign 19 0 2 1.38 .650
PIN 84 0 3 1.80 .741
CA 84 0 3 1.88 .735
LHRH 14 .00 2.00 1.40 .986
Table 30
Intensity of Staining of PSA Staining.
N Minimum Maximum Mean Std. Deviation
Benign 19 3 3 3.00 .000
PIN 92 1 3 2.59 .577
CA 92 0 2 .14 .459
215Total Number  No. +  Mean no of +ve cells +/- SO
P53 BPH 19 0 0
PIN 92 5 3.46+/-15.86
CaP 92 9 6.96+/- 23.33
LHRH 14 4 25.83+/-39.65
Bcl2 BPH 19 0 0
PIN 92 75 47.93 +/- 36.74
CaP 92 27 15.98+/-29.8
LHRH 14 9 55.71 +/- 46.03
Baxalpha  BPH 13 13 100
PIN 84 78 100
CaP 84 80 100
LHRH 10 10 100
Ki-67 BPH 19 0 0
PIN 92 91 4.5+/-6.01
CaP 92 92 5.68+/- 6.3
LHRH 14 14 2.79 +/- 6.4
PSA BPH 19 19 100
PIN 92 92 100
CaP 92 92 100
Table 31: Summary of results obtained by immunohistochemisty
Staining intensity +/- SD
0
0.1 +/- 0.45 
0.14+/- 0.46 
0.43 +/- 0.85
0
1.39+/-0.89 
0.35 +/- 0.56 
1+/- 0.96
1.38+/-0.65 
1.8+/-0.74 
1.88+/-0.74 
1.4+/-0.96
3+/-0 
2.6 +/- 0.56 
2.15 +/-0.76Number of + specimens Number of cells Staining intensity
Comparisons P53 Bel 2 Bax Ki-67 PSA P53 Bcl2 Ki-67 P53 Bcl2 Bax
alpha
PSA
PIN and BPH NS <.001 NS <.001 NS 0.71 <0.001 <0.001 0.71 <0.001 0.06 0.0116
CaP and PIN NS < . 0 0 1 NS NS NS 0.61 <0 . 0 0 1 0.16 0.62 <0 . 0 0 1 0.57 0.0002
CaP and BPH NS <.006 NS <.001 NS 0.51 0.04 <0.001 0.51 0.04 0.03 <0 . 0 0 1
LHRH and CaP .07 0.015 NS NS NS 0.19 0.006 0.006 0.27 0.016 0.04
Table 32: Comparison of the benign, PIN, and cancer using the Mann Whitney U Test and the difference of the means for 
the number of cells and staining intensity. P-values in bold denote negative differences, i.e. the second factor is higher than 
the first. Otherwise the first factor is higher.Chapter 7: Discussion
The volume of the prostate glands was calculated using digital  images of the 
slices, which were corrected for the shrinkage factor.  This calculated volume 
was  compared  to  the  weight  of  the  gland.  There  was  good  correlation 
(correlation coefficient of 0.967). This would support this technique as a valid 
method of calculating prostate volumes.
7.1  Relationship between total volume of gland, volume of PIN, benign 
volume of gland, and volume of cancer.
Tumour  volume  as  assessed  in  total  prostatectomy  specimen  correlates  with 
prognosis,  especially  tumour  volumes  greater  than  4.0cm3   even  in  patients 
who have relapsed 93 367.  When comparing the tumour volume as a marker for 
recurrence, some have suggested that it is a better predictor of recurrence after 
radical prostatectomy than either Gleason score or preoperative PSA"  .
Tumour differentiation decreases and  DNA patterns deteriorate as the tumour 
volume  increases.  Some  groups  have  shown  that  tumour  volume  correlates
with  histological  grade301365  and  although  it  did  predict  progression,  in  a
^01
multivariate analysis  it was  not an  independent predictor of recurrence  .  InProstatic Intraepithelial Neoplasia and Prostate Cancer.
our series tumour volume did not correlate with Gleason grade.
In  this  study  the  volume  of cancer was  related  to  the  stage  (p<0.001).  The 
cancer  volume  also  had  an  inverse  correlation  with  the  benign  and  the  total 
volume of the gland (p<. 001).  This  may be due to the fact that to trigger a 
biopsy  and  so  the  possible  diagnosis  of prostate  cancer  the  patient  needs  to 
reach a threshold PSA.  PSA can either be produced by the benign tissue, i.e. a 
patient will have a large gland with a small volume of cancer; or by malignant 
tissue and  so a patient will  have a small gland with a large  volume of cancer 
sufficient to produce the PSA which leads to serum levels that trigger a biopsy.
Additionally  this  work  has demonstrated that  the  size of the gland correlates 
with  the  volume  of PIN.  Both  BPH  and  PIN  increase  with  age  and  require 
androgens.  Therefore, the stimulus for these lesions is probably identical, with 
PIN  developing  in  the  peripheral  zone  and  BPH developing  in  the  transition 
zone.  If we accept that PIN is a premalignant lesion, then large glands have a 
corresponding  increased  volume  of PIN,  which  would  predispose  to  cancer. 
Therefore  gland  volume  is  a  predictive  factor  for  prostate  cancer.  The 
European  Randomised  Study  of  Screening  for  Prostate  Cancer  (ERSPC) 
screened  a  total  of 8,621  men.  Using  a  logistic  regression  model  this  group 
determined  the  most  important  predictors  for  prostate  cancer  was  PSA, 
followed by prostate volume, DRE, and TRUS findings, in that order205.  Thus
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a large gland irrespective of the PSA may be indicative of prostate cancer, due 
to the increased volume of PIN.
No  significant correlation  was  detected  between  the  volume  of PIN  and  the 
volume of cancer in this study. This is in contrast to other studies. De la Torre 
et al  did demonstrate an  inverse relationship between  volume of PIN and the 
volume  of cancer.  Implying  that  as  PIN  transforms  into  prostate  cancer,  the 
volume of PIN decreases as the volume of cancer increases, however they did 
not  differentiate  between  high  and  low  grade  PIN  Alexander  et  al 
demonstrated a significant correlation between PIN volume and the weight of 
the gland and the cancer volume 6.
7.2  Relationship  between  volume  of  PIN,  volume  of  benign  tissue, 
volume of cancer and serum PSA.
In this study it has been shown using a regression  model  that the serum PSA 
significantly  correlates  with  the  volume  of  the  gland  and  the  volume  of 
prostate  cancer.  In  a  multivariate  analysis  this  correlation  appears  to  be 
independent.  Using  SPSS  ANOVA  software,  we  have  calculated  one  gm  of 
benign prostate tissue correlates with 0.07ng/ml of serum PSA, and one gm of 
malignant tissue to 0.8 ng/ml of serum PSA.
Stamey et al  in their seminal paper calculated that the serum PSA was related
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to  tumour volume,  and that prostate cancer produced  more  PSA than  benign 
tissue  366.  In  the  cohort  of  patients  with  prostate  cancer  no  significant 
correlation was calculated between the volume of benign tissue and the serum 
PSA.  In  seven  separate  patients  undergoing  a  Millen’s  retro  pubic 
prostatectomy for benign disease they calculated that on average one gram of 
benign tissue corresponded to 0.29 ng/ml of PSA  in the serum366. This group 
further studied the relationship between cancer and serum PSA and concluded 
that prostate cancer elevates serum PSA twelve fold compared to BPH and so 
one gram of cancer increases serum PSA by 3.5ng/ml365.  However, of the  102 
radical  prostatectomy  specimens  used  to  calculate  this  figure  only  48  were 
completely confined to the prostate, and therefore the total tumour volume was 
only  measured  with  any  degree  of accuracy  in  less  than  half of this cohort. 
Stamey  also  detected  a correlation  between  serum  PSA  and  prostate  weight, 
but not with the volume of benign tissue365. Partin et al studied the relationship 
between  tumour volume, benign gland volume and serum  PSA in 350 radical 
prostatectomy  specimens  and  72  men  with  benign  prostatic  hyperplasia.  A 
correlation was found between the cancer volume and PSA, no correlation was 
detected  between  serum  PSA  and  the  volume of benign  tissue300.  Later,  the 
same  group  in  a  series  of  47  radical  prostatectomy  specimens  detected  a 
significant  correlation  between  serum  PSA  and  the  weight  of the  gland  and 
volume of malignant tissue 412.  This has been confirmed in this study and by 
others6.  Ronnett et al demonstrated that in small volume tumours i.e. 0.5cc or
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less, the weight of the gland correlates with the PSA, and the tumour volume 
does not326.
In a series of 159 cases with a clinically benign diagnosis and using TRUS to 
calculate  the  volume  of the  gland,  and  of the  transition  zone.  Aarnich  et  al 
calculated  that one-gram  of the  transition  zone contributed  to 0.150ng/ml  of 
serum  PSA  and  the  remainder  of  the  prostate  contributed  0.077ng/ml  per 
gram.  The mean contribution for one gram of prostate was 0.092ng/ml 2.  An 
earlier study of 472 men calculated a value of 0.72 ng/ml  per gram of benign 
prostate tissueK < s .  The relationship between prostate volume and free PSA has 
also  been  studied.  Using  a  multiple  linear  regression  analysis  in  a  model 
containing both  free  and  total  PSA  values obtained from  681  men,  free PSA 
was  the  only  significant  predictive  variable  of  prostate  volume271.  Studies 
have examined not only the effect of prostate volume on serum PSA but also 
age, it has been shown that serum PSA increases with age86102'325.
In  this study  we  have  demonstrated  that there  is  no  relationship  between  the 
volume of PIN and serum PSA.
Brawer postulated  that  for PSA  to enter the serum  it  must traverse  the basal 
cell  layer,  epithelial  basement  membrane,  stroma,  capillary  basement 
membrane and the endothelial cells. In PIN there maybe disruption in the basal
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cell  layer  and  so  it  was  postulated  that  serum  PSA  might  be  increased  in 
patients  with  PIN50.  In  a  series  of  81  patients,  treated  for  bladder  outlet 
obstruction by retro pubic Millen’s prostatectomy and TURP, which included 
25  men  with  PIN  and  26  with  BPH.  The  median  serum  PSA  levels  were 
significantly  higher  in  the group  with  PIN  (4.0 ng/ml)  compared  to the  men 
with BPH (2.1 ng/ml)53.  Using needle biopsies Morote et al identified 321  men 
with  benign  prostatic  hyperplasia,  17  had  PIN  present  and  304  had  no  PIN, 
there was a small  but insignificantly higher total  PSA in patients with benign 
tissue  and  associated  PIN  than  those  with  no  PIN  (7.7ng/ml  vs.  7.2ng/ml, 
p>0.05)270.  Fowler  et  al  carried  out  TRUS  guided  biopsies  on  1961 
consecutive  men  with  suspected  prostate  cancer  as  part  of  a  screening 
protocol.  93  patients  had  PIN  diagnosed  in  the  absence  of cancer,  and  957 
patients had a benign diagnosis without PIN.  The mean total PSA was 5.6 and 
4.6  ng/ml,  and  the  percentage  free  was  20.6  and  21.5  respectively.  The 
difference in the percentage of free PSA was not significant, but the total PSA 
was significantly higher in the group with PIN (p=0.02)l2°.  Bostwick et al also 
detected  an  increased  PSA  in  patients  with  PIN  diagnosed  on  needle  biopsy
48 compared to a benign diagnosis
A study of 15 patients with BPH, 46 with PIN, and  16 with localised prostate 
cancer,  the  total  mean  PSA  was  significantly  different  between  the  three 
groups  i.e.  2.78ng/ml  for  BPH,  4.89ng/ml  for low grade  PIN,  8.21 ng/ml  for
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high grade PIN, and  12.70ng/ml  for cancer.  The mean free to total  ratio was 
lower  in  patients  with  low  grade  PIN  (25%)  or  high  grade  PIN  (21%) 
compared to cancer (14%) but this did not reach significance198.  Minardi et al 
carried out a retrospective study of 87 patients, 30 patients with BPH, and 24 
with  high  grade  PIN,  8  with  low  grade  PIN  and  25  with  carcinoma  of the 
prostate2^8.  The mean free to total ratio was 24.2% in those with BPH,  17.6% 
in the high grade PIN, and  13% in the prostate cancer group. These differences 
were  significant.  The  mean  values  for  the  total  PSA  i.e.  6.17  ng/ml,  6.89 
ng/ml, and 8.02 g/ml  respectively, were not statistically significant2^8.  Ramos 
et  al  similarly  followed  up  48  men  who  were  diagnosed  with  PIN  without 
prostate cancer.  This cohort was compared to a group diagnosed with prostate 
cancer and  a group  with  benign  prostatic  hyperplasia  in  the  absence of PIN. 
The  percentage  free  PSA  was  significantly  lower  in  patients  with  prostate 
cancer, but there was no difference in the percentage free PSA in the men with 
PIN and those with BPH (20.8+/- 7.1% and 20. l+/-7.3%, respectively)3I6. In a 
study of 81  consecutive patients  undergoing radical  prostatectomy,  Morote et 
al  found  no  significant  difference  in  the  total  serum  PSA  between  the 
specimens that contained PIN and cancer compared to those with cancer alone. 
But the free to total serum PSA was significantly lower in the group with PIN, 
but in a multivariate analysis PIN did not contribute to free serum PSA 269.  In 
the  large  Austrian  screening  study  of  1474  patients,  the  mean  total  PSA  of 
patients  with  BPH,  PIN  and  cancer  was  6.0,  5.9,  and  8.7ng/ml,  with  the
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percentage free ratio being 21.9,  15.0 and  12.1% respectively.  With regard to 
total PSA there was no significant difference between BPH and PIN, but with 
regard to the percentage free PSA there was a significant difference between 
the  BPH  group  and  all  the  other groups,  and  the  PEN  and  cancer groups170. 
This  study  could  not  identify  a  clear  cut  off  between  the  groups  due  to  a 
significant overlap170.
Alexander et al  have shown  that PIN volume does correlate with  serum  PSA 
concentration6.  This group studied  194 whole  mounted radical  prostatectomy 
specimens and used a grid counting technique to determine the volume of PIN, 
and  prostate  cancer.  They,  however,  concluded  that  the  relationship  between 
serum PSA and PIN was an artefact, in a multiple regression analysis adjusting 
for cancer volume, gland weight, Gleason  score, and extraprostatic extension, 
log PIN volume did not contribute to log serum PSA 6.
Ronnet et al using 65 whole mount radical prostatectomy specimens weighing 
less  than  65  gm  and  with  small  tumour  volumes  of  <0.5mls,  found  no 
correlation  between  PSA  and  tumour  and  PIN  volume,  but  did  find  a 
correlation between serum PSA and total gland weight326.
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Fig35:  PIN stained with PSA x 40
Fig36: Cancer stained with PSA x 40
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7.3  P 5 3  in benign, PIN and malignant prostate tissue.
Expression  of  p.33  increased  in  a  stepwise  manner  from  benign  to  intra 
epithelial  neoplasia  to  malignancy.  0/19  benign,  5/92  PIN,  and  9/92  cancer 
specimens were positive for P5 3.  This increase was not significant. Loss of p.33
974
was  thought  to  be  a common  event  in  localised  prostate  cancer  ,  however 
more  recent  studies  have  not supported  this  view273.  In only  two out of the 
five PIN specimens expressing P53 was there also concurrent expression of P53 
in the cancer specimens implying aberrant expression of P53 is not required for 
progression.  Furthermore sequencing studies of aberrant  p .3 3   in both  PIN and 
cancer in the same specimen have revealed that the sites of the point mutations 
are  not  identical  and  therefore  PIN  and  prostate  cancer  may  arise  from  a 
different clone  with  in  the same  specimen377'426.  In  addition  we  have  shown 
that progression to cancer from  PIN can occur in spite of the loss of aberrant 
P5 3.  Loss of P53 is probably a late change in prostate cancer369, and not related 
to the early genesis of this disease.
Androgen  ablation  led  to  proportionally  increased  expression  of  P5 3;  this 
however  did  not  reach  significance  (p=0.07).  There  may  be  a  number  of 
explanations  for  the  increase  in  p.3 3.  Androgen  ablation  leads  to  the 
withdrawal  of  a  necessary  stimulus  for  the  prostate,  the  cells  of  the  gland 
involutes, and a p.33 dependant pathway may cause this.  In addition increased
-)  I
bcL inhibits the nuclear translocation of p .5 3 "  and so may increase the amount
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of  free  wild  type  p.53  antigenically  available  for  the  immunohistochemistry 
antibody to react with.
Increased  P53  after androgen  ablation  may  also  be  a predictor of relapse.  An 
analysis of 39 patients,  who had received neoadjuvant LHRH treatment prior 
to definitive surgery, demonstrated 21  patients that were positive for P5 3.  90% 
(19 patients) of these patients relapsed. Therefore the  increased expression of 
P53 associated with androgen ablation may predict relapse 3I2.
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F i g37:  P I N   s t a i n e d   w i t h   P 53  x  40
F i g38:  C a n c e r   s t a i n e d   w i t h   P 53  x  40
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7.4  Bcl2 in benign, PIN and malignant prostate tissue.
Bch  is  always  present  in  the  stem  cells  of the  prostate;  therefore  we  only 
measured the expression of bch the luminal cells.  The expression of bch was 
significantly different between the three groups studied. The expression of bch 
in  the prostate cancer was comparable with  the results of others20'74'238'239.  It 
was greatest in the PIN slides, and least in the benign tissue.  In 22 specimens 
bch  staining  was  detected  concomitantly  in  PIN  and  cancer.  Bch  infers  a 
degree of immortality and  resistance  to the cells  from  cytotoxic  treatment,  if 
PIN  is  a  pre  malignant  lesion  and  not an  epi  phenomenon,  this  would  imply 
that  PIN  luminal  cells  have  a  survival  advantage.  Others  also  share  this
41:1X7 view
Expression of bch  allows cells to remain viable despite androgen ablation 
In this study androgen ablation led to an up regulation of bch and therefore it 
may  be  postulated  that  androgen  ablation  selects  out  clones  with  a  survival 
advantage246.  Others have also supported this finding394. Up regulation of bch 
may  also  play  a  role  in  the  development  of  radio  resistant  clones "  and 
increased expression of VEGF resulting in higher microvessel density 116.
An  interrelationship  exists  between  p.53 and  bch.  Up  regulation  of bch  can
-) 1
inhibit the action of the pro apoptotic p.s 3~   and conversely p.33 can up regulate 
bax and down regulates bch261.
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7.5  Bax in benign, PIN and malignant prostate tissue.
A predetermined set point is thought to exist in cells for the ratio of bch and 
bax, and this is thought to play a critical role in the response of malignant cells 
to therapies,  which  lead to apoptosis" ".  Bax  inactivation  abolishes induction 
of apoptosis by chemopreventitive drugs178.  The expression of bax was almost 
uniform  in  all  the  groups.  However,  the  staining  intensity  increased 
significantly  from  BPH  to  cancer  and  there  was  inactivation  of  bax  with 
androgen  ablation.  This  would  imply  up  regulation  of bax  from  benign  to 
malignant  tissue,  so  cancer  cells  are  selectively  more  susceptible  to 
chemotherapeutic/hormonal  intervention.  When  comparing  the  specimens, 
which have been treated with androgen ablation there is a decrease in staining 
intensity, this  may be because the susceptible cells have undergone apoptosis 
and only the resistant clones are left.  The ratio of bax to bch is important and 
in  the  group  treated  with  androgen  ablation  there  is  an  increase  in  the 
expression  of bch,  and  so  further adding weight to the  argument  that  in  this 
group  androgen  ablation  is  selecting  resistant  clones.  Bax  inactivation  is 
important  in  human  carcinogenesis,  and  contributes  to  tumour  progression. 
Although  the  number  of  positive  staining  specimens  does  not  show  a 
significant change, but the staining intensity does, and therefore a quantitative 
method  for  determining  the  expression  of  bax  is  required  to  confirm  its 
importance.  If one  measures  expression  of bax  exclusively  in  terms  of the 
number  of  specimens  staining  positive,  then  its  loss  does  not  appear  to  be
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important in the initiation of prostate cancer.  Others share this view187,204.
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7.6  Ki-67 in benign, PIN and malignant prostate tissue.
In this study there is a significant increase in the expression of Ki-67 between 
benign  tissue,  and  PIN or cancer.  However, the difference between PIN and 
cancer is not significant.  Others have also detected low expression of Ki-67 in 
benign tissue 2 X \   Ki-67 positive cells shift from basal to luminal as one moves 
from  benign,  to  PIN  and cancer.  This  would  imply,  that not only  is  there  a 
decrease  in  the  level  of apoptosis  in  cancer,  but  there  is  also  increased  cell 
production  from  benign  to PIN or cancer and  this  is  localised to the areas of 
malignant tissue.
The  prostate  is  a  hormone  responsive organ  and cell  production  is decreased 
by androgen ablation. Therefore this explains the decrease in Ki-67 expression 
associated with androgen ablation.
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Chapter 8: Conclusion.
In  the  third  month  of gestation  the  mesenchyme  surrounding  the  urethra,  in 
response to androgens, begins to differentiate into the capsule and the smooth 
muscle  of the  prostate.  This  along  with  the  primitive  lining  of  the  urethra, 
which  develops  into  ducts  and  the  acini,  forms  the  basic  structures  of  the 
prostate.  By the  end  of the  15th   week  of gestation,  development  of the  basic 
prostate  is  complete.  The  dependence  upon  androgens  that  is  so  necessary 
early on will be hallmark of the development of this gland.
The  prostate  in  response  to  androgens  grows  through  out  adult  life.  This 
results  in  a  number  of  pathological  conditions,  both  benign  and  malignant, 
which  are  major health  issues.  Yet,  any intervention on  the prostate gland is 
fraught,  due  to  the close  proximity of this gland  to the urinary sphincter and 
the  neurovascular  bundles  responsible  for  potency.  Lowsley  traditionally 
described  the  prostate  as  having  five  lobes,  but  a  more  useful  zonal
"M S classification  was  proposed  by  McNeal"  .  The  majority  of prostate  cancer 
develops in the peripheral zone.
Prostate  cancer  is  the  second  commonest  cause  of  cancer  related  death  in 
males,  yet  the  optimal  management  of  localised  carcinoma  of  the  prostate 
represents  a paradigm  of uncertainty333.  A  number of risk  factors  have  been 
implicated; these include age, race, family history, diet and androgens.
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In  this thesis,  the  various  options  have  been  outlined for the  management of 
prostate  cancer.  The  rational  for  these  treatment  modalities,  whether  it  be 
watchful  waiting, active surveillance, radiotherapy- external  beam, conformal 
external  beam,  brachytherapy,  or  radiotherapy  with  adjuvant  androgen 
ablation,  surgery  -  open  retro  pubic,  perineal,  laparoscopic  (extra  or 
transperitoneal) has been discussed.  Yet, despite the mushrooming options for 
the  management of localised carcinoma only  relatively recently  has evidence 
been available that intervention does have any positive impact33.
The increased interest in prostate cancer, has led to the discovery of a number 
of  lesions  which  were  thought  to  be  premalignant,  one  of these  is  prostatic 
intraepithelial  neoplasia46,  a  lesion  which  exhibits  the cytological  changes of 
prostate  cancer,  but  the  basal  cell  layer  is  retained.  Prostatic  intra  epithelial 
neoplasia  has  to  be  distinguished  from  atypia,  transitional  cell  metaplasia, 
basal  cell  hyperplasia,  clear  cell  cribriform  hyperplasia,  normal  ejaculatory 
ducts,  and  seminal  vesicle  epithelium,  high  grade  transitional  cell  carcinoma 
involving the ducts and acini, cribriform acinar and cribriform ductal prostatic 
carcinoma.
Initially  prostatic  intra  epithelial  neoplasia  was  thought  to  exist  in  three 
distinct forms, but this has been distilled to two, and then only one type, high-
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grade  prostatic  intraepithelial  neoplasia.  Studies  have  shown that this  lesion 
may precede prostate cancer, and can be detected in men as early as their third 
decade.  The  incidence  of  PIN  in  screening  studies  is  between  0.7%  and 
16.5%,  in  TURP  specemens  it  is  between  2.8  and  3.2%.  The  discrepancy  is 
probably due to the TRUS  biopsies sampling the peripheral  zone, and TURP 
chips being obtained from the transition zone.
PSA is a 240 amino acid glycoprotein serine protease with a molecular weight 
of  33,000.  Initially  used  in  forensic  medicine  it  has  evolved  into  one  most 
important  tumour  markers  used  in  medicine.  The  relationship  between  PIN 
and serum PSA had not been clearly defined, and it is hoped that this work has 
helped to elucidate this better.
To investigate the relationship between  PIN,  prostate cancer and  serum  PSA, 
this  prospective  study  was  undertaken.  Prostate  maps  of  fresh  specimens 
obtained from radical prostatectomy specimens were constructed.  The prostate 
was initially placed in  10% formaldehyde for 72 hours. The specimen was then 
sliced.  The  slices  were  scanned,  and  then  fixed.  Slides  were  prepared  of the 
slices and areas of tumour and PIN identified and transcribed onto the prostate 
maps.  The  volume  of cancer,  PIN  and  of the  total  specimen  was  calculated 
from  the scanned images,  by measuring the area of interest from  the scanned 
images and then multiplying it by the thickness of the slices.  The volume so
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calculated  for  each  specimen  was  multiplied  by  a  correction  factor  for 
shrinkage. The resulting volumes were compared to the serum PSA.
The  volume  of PIN  is  proportional  to  the total  volume  of the gland  and  the 
volume of benign tissue with in the gland.  The volume of cancer is inversely 
proportional to the benign and total volume of the gland, and directly related to 
the stage of the cancer.
PSA  increases with the volume of benign and malignant tissue.  One gram of 
benign  tissue  correlates  with  0.07  ng/ml  of  serum  PSA,  and  one  gram  of 
malignant  tissue  correlates  with  0.8  ng/ml  of serum  PSA.  Serum  PSA does 
not correlate with the volume of PIN.  The intensity of PSA staining decreases 
from benign, to PIN, to malignant tissue in a stepwise manner.
The importance of PIN  is due to its predictive value  for prostate cancer in up 
to 50% of patients with an initial diagnosis of PIN on biopsy. The relationship 
between  PIN  and  prostate cancer was  investigated  at a molecular level  using 
p< ; 3, bcl-2, baxaipha and Ki-67.
P53 protein  is the product of a gene located on  the short arm of chromosome
17.  The product of the P53 gene has a molecular weight of 53 Kda, and the wild 
type P53 by binding to DNA as a transcription factor inhibits the advancement
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of cells from the G1  to the S phase, and so initiates apoptosis in defective cells 
- the Guardian of the genome. A mutant p<n gene produces a defective protein, 
which can  not regulate cell  proliferation, and  so cells  may become immortal. 
Transfection of wild type P53 into immortal cell lines can lead to growth arrest 
and  apoptosis.  Lack  of  a  functioning  p<n  confers  an  elevated  risk  of 
developing cancer -  Li Fraumeni Syndrome400.  The aberrant P53 gene product 
has  a  longer  half-life  than  the  wild  type  and  so  is  detected  by 
imunohistochemical analysis.
Initially  P53  was  thought  to  be  an  important  prerequisite  in  localised 
carcinoma,  and  was  used to predict outcome in  patients at different stages of 
the  disease  with  different  Gleason  scores.  In  patients  who  had  undergone 
radical  prostatectomy  psi  was  thought to  be able  to  predict outcome,  but the 
weight  of  evidence  at  present  points  to  its  role  being  greater  in  metastatic 
disease, and causing extra prostatic spread.
In  our experiments,  p<n expression  was detected  using  immunohistochemical 
staining.  The  level  of staining  for  p.53  did  not  increase  significantly  as  one 
progressed from benign, to FIN, and to cancer.  P 5 3  therefore does not appear to 
be important in the early genesis of prostate cancer. The presence of positive 
staining for P53 appears to be a relatively infrequent event. There are some who 
agree with this 421 and others who do not356.
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The discrepancy between our data and others  may be due to the  stage of the 
disease in patients. Even a recent study of 98 radical prostatectomy specimens, 
identified 57% of specimens were positive for pS 3, but at a median follow up 
of 7.42  years (2.6 -12.9),  9  patients died  from  prostate cancer and  32 others 
progressed, implying relatively advanced disease at the time of surgery3'" 1 6.
There appears to be an increase in P53 staining in the specimens obtained from 
patients  who  have  received  androgen  ablation  therapy  prior  to  radical 
prostatectomy.  However,  this  did  not  reach  significance.  The  increase  in 
expression  may  be  due  to  androgen  ablation  causing  apoptosis  via  a  psr 
mediated pathway.
The  bch gene  was  initially detected  in  B-cell  follicular lymphomas.  The  bch 
proto-oncogene is located on the long arm of chromosome  18 and codes for a 
26  kDa  membrane  protein.  The  bch  protein  inhibits  apoptosis,  possibly  by 
limiting  the  release  of pro-apoptotic  enzymes  from  the  mitochondria and  so 
promotes survival.
Bch expression can  allow prostate cancer cell  lines to  survive in the absence 
of androgens, and so can negate the therapeutic effect of androgen ablation in 
the  management  of prostate  cancer313.  Further  more  in  animal  experiments
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androgen ablation  led to an  increase  in  the  mRNA for bch,  this  may support 
the  hypothesis  that  trigger  for  the  development  of  androgen  insensitive 
controls is the withdrawal of androgens246.
Bch  expression  in  radical  prostaectomy  specimens  is  associated  with  higher 
stage  and  shorter  progression  free  survival61.  In  patients  being  treated  with 
radiotherapy,  the  expression  of  bch  is  associated  with  shorter  time  to 
relapse173.
Bch expression  increases  from  benign  to  PIN  and  then  decreases  in  cancer. 
The  high  levels  of expression  of  bch  in  PIN,  would  allow  PIN  to  become 
relatively  resistant  to  androgen  ablation  and  chemotherapeutic  intervention. 
The relative survival advantage conferred on PIN, could allow it to become the 
source  for androgen insensitive clones.  This is further supported by evidence 
that  shows  that  bch expression  appears  to  have  an  inverse  relationship  with 
androgen receptor expression41.
Androgen  ablation  led  to  an  up  regulation  in  the  expression  of  bch.  This
^  I  ^
allows  the  cells  to  become  androgen  independent  and  also  inhibits  P53 
mediated  apoptosis  by preventing  the  wild  type  P53 from  translocating  to  the 
nucleus  and  triggering  apoptosis21.  Increased  bcl2  also  causes  increased 
expression  of VEGF,  and  so  increased  microvessel  density,  allowing cells to
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survive in hostile environments116.
Bel  associated  x  protein  or  bax  is  a  proapototic  molecule.  It  is  a  cytosolic 
protein which forms a heterodimer with bch. This causes the bax molecule to 
translocate to the  mitochondrial  membrane and  bind to the  membrane bound 
bch protein.  This binding results in inactivation of bch and cell death.
The  expression  of bax  was  ubiquitous,  in  benign,  PIN,  and  prostate  cancer. 
The  staining  intensity  was  however  greater  in  prostate  cancer  (p=0.03)  and 
PIN  (p=0.06)  than  in  benign  tissue,  implying  that  there  may  be  increased 
production  of  bax  on  a  cellular  basis  leading  to  increased  turnover  of 
malignant and pre-malignant cells.  Androgen ablation decreased the staining 
of cells expressing bax and so this may lead to decreased cell turnover via the 
bch/bax axis, especially since there is increased expression of bch.
The  gene  coding  for  the  Ki-67  protein  is  on  chromosome  10.  Ki-67  is  a
nuclear protein expressed in the Gl, S, G2, and M phases of the cell cycle, but 
not  in  GO  -   the  resting  phase  of the  cell  cycle.  Therefore  MIB-1  antibody 
staining can be used in formalin fixed tissue to determine the proliferation rate. 
The  alternative  is  thymidine  incorporation  assays,  but  for this  fresh  tissue  is 
required  and  this  is  a  very  demanding  technique.  The  proliferation  rate  as
H i)
measured  by  Ki-67  can  be  used  to  predict  extra-capsular  spread" ,
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recurrence1 4 2   and  outcome  after surgery or  radiotherapy1 .  The  proliferation 
rate may also increase with Gleason grade
In our series the proliferation index increases from benign, to PIN, and cancer. 
The increase from benign to PIN and from benign to cancer is significant.  If 
the  proliferation  rate  as  measured  by  Ki-67  is  a  predictor  of the  malignant 
potential of tissue, then PIN may be part of the way there.
Others  smaller  studies  have  supported  this  stepwise  increase  in  MIB-1 
expression  when  comparing  benign  tissue,  with  PIN  and  cancer
160; 187 ;275;379:393
Prostate  cancer  is  an  androgen  responsive  tumour,  and  by  removing  the 
stimulus for proliferation by chemical androgen ablation, the proliferation rate 
declines  to a level  significantly less than cancer,  but still  higher than benign 
tissue.  This would support the view that androgens are not the only regulator 
of proliferation, and that these cells are displaying some autonomy from their 
endocrine regulators even at this early stage.
Bcb staining increases from benign to malignant tissue, and so allowing the 
cancer  cells  to  be  resistant  to  intervention  with  androgen  ablation  or 
chemotherapy.  Ki-67  increases  from  BPH  to  PIN  and  from  BPH  to  cancer.
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Implying that there is increased cell production in malignant and pre-malignant 
tissue compared to benign tissue.
Androgen  ablation  led  to  a  decrease  in  Ki-67  staining,  an  increase  in  the 
number of specimens expressing bch and a decrease  in  the staining intensity 
for bax, implying LHRH not only leads to a decrease in the production of new 
cells but also to the selection of androgen resistant clones.
In summary in this thesis, it has been shown that the volume of cancer is proportioi 
to  the  local  stage  of the  disease;  it  is  inversely proportional  to  the  volume  of beni 
and  PIN  tissue.  The  total  gland  volume  is  proportional  to  the  volume  of PIN.  O 
gram  of benign  tissue  correlates  with  0.07  ng/ml  of serum  PSA,  and  one  gram 
malignant tissue correlates with 0.8 ng/ml of serum PSA, the volume of PIN does r 
correlate with serum PSA.
With  respect  to  the  immunohistochemical  studies,  p53  is  a  rare  event  in  localis 
disease;  bcb  is  significantly  over  expressed  in  PIN  compared  to  cancer  or  beni 
tissue,  and  the  intensity  of  bax  staining  significantly  increases  when  compari 
benign tissue with PIN or malignant tissue, as does the expression of Ki-67.
Androgen ablation causes a significant increase in the expression of bcl2, and decrea 
in the expression of Ki-67 and staining intensity of bax.
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Appendix
Appendix 1: Area Calculation.
# Area measurements from micrographs for Sarb
# Chris Thras 4.01.2O O O  
MSsetprop "FRAMEMODE",0
# showwindow "Editor", 1
while 1
loops = 1   # reset loop number 
# imgsetpath "d:\sarb"
MSload "sarb"
# MSsetfeat "FIELDFEAT"
DBsetpath "c:\ks400\data\sarb" 
dbnamef= "databases"
#specimen loop to allow data from several fields to be appended 
while
read dbnamef,  "Input the field data base name you want to use" 
n = DBexist (dbnamef) 
if n == 0 : break
MBok "Database name exists - try again" 
endwhile
while  1  
imgdelete 
Gclear 0
imgnew  1,768,1024,1,"Grey" 
imgdisplay  1
MBok " Copy and past total image from PSP into image  1" 
imgnew 2,768,1024,1 ,"Grey"
MBok " Copy and past PIN image from PSP into image 2" 
imgnew 3,768,1024,1,"Grey"
MBok " Copy and past CANCER image from PSP into image 3"
imgdisplay  1
greytran  1,4,"invers.col"
disaut 4,7,0,1
binfill 7,10
imgdisplay 2
greytran 2,5,"invers.col"
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disaut 5,8,0,1 
imgdisplay 3 
greytran 3,6,"invers.col" 
disaut 6,9,0,1
if loops ==  1  
imgdisplay  1  
MSsetgeom
!  MSmeasmask 10,1,dbnamef,0,0,10 
imgdisplay 8
!  MSmeasmask 8,1,dbnamef, 1,0,10 
imgdisplay 9
!  MSmeasmask 9,1,dbnamef, 1,0,10 
datalist dbnamef,0,0
else
imgdisplay  1  
MSsetgeom
!  MSmeasmask  10,1,dbnamef,0,0,10 
imgdisplay 8
!  MSmeasmask 8,1,dbnamef, 1,0,10 
imgdisplay 9
!  MSmeasmask 9,1,dbnamef, 1,0,10 
datalist dbnamef,0,0
endif
loops = loops + 1
# MByesno "Do you have another section in this group?" 
if .STATUS ==0: break
endwhile
MByesno "Another sample/specimen?"
if .STATUS == 0 :break 
endwhile 
beep  100,880
stop
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Pt Id Fresh Wt Fresh Vol Fresh Density Fx Wt Fx Vol Fixed  Density % Change in Wt % Change in Vol
D 71.57 67.75 1.06 71.61 66.90 1.07 -0.05 1.25
G 61.20 56.70 1.08 60.90 55.80 1.09 0.49 1.59
H 44.01 43.60 1.01 42.86 41.61 1.03 2.61 4.57
M 42.70 40.97 1.04 41.96 39.65 1.06 1.73 3.21
To 60.12 57.24 1.05 59.70 56.72 1.05 0.69 0.91
Tu 70.79 69.95 1.01 70.30 66.45 1.06 0.69 5.00
Average 58.40 56.03 1.04 57.89 54.52 1.06 1.03 2.76
Therefore if the true volume is x, the volume measured should be multiplied by 100/(100-% Change in volume) ie.
1.03
Pt Id  Fx Slice Area  Mounted Slice Area H+E  Change in Area
D 1753.00 1560.62 10.97
G 1228.00 1027.30 16.34
H 1437.00 1165.50 18.89
M 1114.00 941.47 15.49
To 1842.50 1421.69 22.84
Tu 1535.60 1364.44 11.15
15.95
Therefore if the fixed slice area  is y, the area measured should be multiplied by 100/(100-% Change in area) ie.
1.19  and this will give the area of the H+E slides prior to being embedded in wax, and this should be multiplied by
1.03  and this will give the fresh area ie 1.22348Prostatic Intraepithelial Neoplasia and Prostate Cancer.
Appendix 3: Slice thickness
Pt Id Slice 2 Slice 3 Slice 4 Slice 5 Slice 6 Slice 7 Slice 8 Total Slice Thickness Av Slice thickness
D 3.17 3.38 3.39 3.31 3.52 3.3 3.77 23.84 3.41
G 2.77 2.92 3.08 3.01 3.06 2.7 3.62 21.16 3.02
H 3.02 3.36 3.32 3.42 3.75 4.28 3.28 24.43 3.49
M 3.19 3.26 3.41 3.79 3.61 4.21 4.33 25.80 3.69
To 2.42 2.63 3.04 3.38 3.58 3.23 3.29 21.57 3.08
Tu 3.88 3.62 3.19 3.24 3.36 3.41 3.63 24.33 3.48
To get the volume one should multiply the area by the thickness of the slices multiplied by the shrinkage fraction for the fixation 
in formalin i.e.  1.028335. i.e. 3.46.  This has been corrected to one decimal place as 3.5mm.Appendix 4:
Preparation of 3-Aminopropyltriethoxysilane (APES) coated slides.
Royal  Free Hospital School of Medicine -  Standard Operating Procedure 
No.5
METHOD  (van  Prooijen-Knegt  ACet  al.  1983;  MaddoxPH  and  Jenkins, 
1987).
1.  Degrease  slides  in  hot  detergent  solution,  rinse  in  distilled  water  then 
alcohol (740 P) and air dry for 1  0 minutes.
2.  Immerse  slides  in  a  freshly  prepared  2  %  solution  of APES  in  acetone- 
minimum  1   minute.
3. Drain slides briefly and wash in distilled water -  2 quick dips.
4.  Drain  slides on paper towels  and dry at 40°C over night  in oven on  paper 
towels.
5.Store at room temperature in empty slide boxes.Prostatic Intraepithelial Neoplasia and Prostate Cancer.
Appendix No.5
Preparation Paraffin Sections for immunohistochemistry
Royal Free Hospital School of Medicine -  Standard Operating Procedure
No.2
1.  Cool paraffin blocks.
2.  Cut paraffin sections at 3 micro m.
3.  Float sections on 20% alcohol then 45°C water bath.
4.  Pick up sections on APES coated glass slides as appropriate.
5.  Place slides in 37°C oven over night
6.  De-parafinise sections and take them to alcohol.
a) Xylene  1 5 minutes
b) Xylene 2 5 minutes
c) Xylene 3 5 minutes
d) Absolute Alcohol 2 minutes
e) Absolute Alcohol 2 minutes
0 Absolute Alcohol 2 minutes
g) Double distilled water 2 minutes
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Appendix No.6: Staining procedure.
Royal Free Hospital School of Medicine -  Standard Operating Procedure 
No.13
1.  Deparafinise sections and take to alcohol.
2.  Transfer  sections  to  humidity  chamber  and  block  endogenous 
peroxidase activity.
3.  Wash in 3 times changes of de-ionised or distilled water for 2 minutes 
each.
4.  Use antigen retrieval  system.
5.  Transfer  slides  to  a  humidity  chamber  and  cover  sections  with  two
changes of Tris buffered saline (TBS) for 5 minutes each.
6.  Block non specific binding by covering with normal goat serum  1/10 in 
TBS for 15 minutes at room temperature.
7.  Drain  and  cover  sections  with  optimally  diluted  primary  antibody
diluted  in  TBS.  Leave  sections  in  humidity  chamber  for  the
appropriate time and temperature for the  antibody.
8.  Rinse in TBS twice for 3 minutes.
9.  Drain  and  cover  sections  with  biotinylated  goat  anti  rabbit/mouse 
antisera  1/200 in 4% normal  human sera for 30 minutes in a humidity 
chamber at room temperature.
10.  Repeat step 8.
11.  Drain  and  cover  sections  with  STR-ABC  1/200  for  30  minutes  in  a 
humidity chamber.
12.  Repeat step 8.
13.  Develop  sections  with  freshly  prepared  Diaminobenzidine (DAB)
solution.
14.  Wash in distilled water for 5-10 minutes.
15.  Counter stain with Mayer’s haemotoxylin for 2 minutes.
16.  Rinse in distilled water.  Differentiate in 0.5% acid alcohol and blue  for
5 minutes.
17.  Dehydrate, clear, and mount.
18.  Sites of immunoperoxidase activity  =  Brown,
Nuclei  =  Blue.
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Appendix  No.  7  :  Blocking  endogenous  peroxidase  activity  and  alkaline
phosphatase activity.
Royal Free Hospital School of Medicine -  Standard Operating Procedure
No.3
Hydrogen Peroxide/Water Method
1.  De-paraffinise sections and take to water
2.  Transfer slides to a humidity chamber at  room  temperature and cover
the sections  with freshly prepared 0.  5  %  H2O2 in  distilled  water  for
10-15 minutes.  This solution contains:  0.2  mis  H2O2  (30%
W/Vol.) and  11.8 mis water (enough for approx, 20 slides).
3.  Wash  sections  in  distilled  water  3  times  and  proceed  with
immunostaining method.
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Appendix No. 8
Buffers for Immuno-histochemistry
EQUIPMENT 
Magnetic stirrer 
pH meter 
Balance 
Conical flask 
1   0 Litre plastic vat 
Magnetic flea
A.  Tris buffered saline (TBS) pH 7.6.
REAGENTS
Sodium chloride  80  gm
Tris (Tris hydroxymethylamine)  6.6  gm
1   M Hydrochloric Acid  44  mis
Double distilled water  10  litres
METHODS
1.  Mix  reagents  with  2  litres  of distilled  water on  a magnetic  stirrer with  a 
magnetic flea.
2.  When components are dissolved transfer solution to a plastic  10-litre vat.
3.  Add 8 litres of water and mix thoroughly.
4.  Take an aliquot and pH to 7.6 (+/-0.05) using buffer components.
5.  Buffers must be as fresh as possible in order to prevent adverse affects on 
staining.  If storing, keep at 4 'C ready for use.
B.  Phosphate.buffered saline  (PBS) pH 7.4
REAGENTS
PBS tablets (Oxoid)  1
Double distilled water  lOOmls
METHODS
1  .Mix  reagents and check pH is 7.4 (+/- 0.05).  If not correct ph check water 
pH and/or quality of tablets.
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Appendix No. 9
Microwave technique for immuno-histochemistry 355 3:> 2 354 353 383 384
EQUIPMENT
pH meter
Microwave (700W) oven with rotation plate.
Balance
Plastic coplin jars 
1   L conical flask
Citric acid buffer
REAGENTS 
Citric Acid Monohydrate 
Double distilled water.
2M NAOH
pH to 6.0 with buffer components 
METHOD
1.  De-paraffinise  sections  (appendix  2)  sections  must  be  mounted  on  APES 
slides (see appendix  1) or there will be section loss.
2. Block endogenous peroxidase activity (appendix 4)
3. Wash slides with PB S.
4. Fill plastic coplin jar 4/5 with citric acid buffer 0.01  m Citric acid buffer 
solution and submerge sections.
2-lg 
10 litres 
13 mis
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Appendix 10 Raw Morphimetric data
Pt Id PSA Total  vol Ca Vol PIN Vol Benign
vol
Pros
Weight
1 7 39605.6 2467.9 544.6 36593.1 42.03
2 5 37719.8 1922.2 250.9 35546.8 50.70
3 13.5 80401.6 8947.7 44.6 71409.3 93.00
4 14 64846.7 2656.1 307.5 61883.1 75.00
5 4.5 42495.4 2984.7 875.4 38635.3 52.30
6 9.6 59843.0 901.5 45.7 58895.7 67.80
7 9.6 42027.8 3774.7 836.9 37416.2 57.00
8 9.2 60964.2 612.5 243.0 60108.7 79.00
9 4.9 67633.6 8.9 12.5 67612.2 67.00
10 8.4 67063.1 22.2 1157.2 65883.7 77.80
11 5.6 80449.2 5089.8 234.5 75124.8 90.00
12 7.2 60497.7 2243.0 2300.2 55954.4 74.20
13 10 57438.6 957.8 117.9 56362.9 70.00
14 6.1 35346.4 1965.9 117.3 33263.2 47.60
15 9.7 89791.2 130.8 1132.1 88528.3 91.30
16 5.9 37108.8 3632.7 153.0 33323.1 44.00
17 5.5 70380.8 652.7 775.1 68952.9 75.50
18 6.2 39543.2 3265.3 487.2 35790.8 55.00
19 6.9 31638.0 1880.8 278.5 29478.7 46.00
20 5 40453.1 1543.9 510.0 38399.3 54.00
21 5.4 56137.8 430.2 462.9 55244.7 59.80
22 13.7 74299.1 2024.0 2728.5 69546.5 82.70
23 6.1 36654.9 1793.4 397.5 34464.0 42.00
24 13.2 39420.7 857.8 1514.2 37048.6 41.86
25 32.4 62789.4 15150.6 249.9 47388.9 88.40
26 5.3 41864.9 2519.3 180.8 39164.8 50.00
27 16.1 64089.7 293.3 479.5 63316.8 63.29
28 8.1 84674.2 4073.2 465.4 80135.7 99.00
29 10.3 55855.5 113.5 220.4 55521.6 71.00
30 9.6 83056.3 3704.6 400.0 78951.8 89.00
31 7.5 40394.0 1507.8 509.3 38376.9 43.01
32 4.1 46648.7 382.6 411.0 45855.1 57.80
33 5.2 29175.3 2767.0 64.9 26343.4 35.00
34 3.6 24503.2 1934.3 78.6 22490.3 32.20
35 5.7 69594.5 5324.7 343.3 63926.5 87.50
36 8.3 50470.0 3074.4 0.0 47395.6 59.00
37 6.2 28633.4 1564.1 283.5 26785.8 39.50
38 10.1 40458.6 1254.1 266.7 38937.8 48.00
39 11 39406.3 656.2 29.7 38720.4 61.60
40 7.3 43101.7 903.4 296.2 41902.1 52.30
41 5 62086.4 393.9 70.4 61622.1 81.00
42 15 23074.0 1427.0 132.2 21514.7 37.00
43 7.9 37088.2 1638.8 174.2 35275.2 42.40
44 12.4 34313.5 2153.4 207.1 31953.0 51.10
45 7.2 72421.6 694.0 1558.4 70169.2 67.80
46 8.2 70390.9 664.0 358.6 69368.3 71.00
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4.2 19359.9 5839.4
3 71721.5 139.1
11.5 68491.4 3170.7
7.4 41647.8 8847.8
3.6 43831.8 946.1
10.7 51745.4 209.9
12.6 30462.3 2778.9
7 34510.7 520.9
5.3 32558.9 1874.2
12.1 52898.0 12286.9
5.3 35251.5 4213.2
7.1 38953.1 3436.1
8.1 67732.9 160.6
8.3 45525.4 1550.7
45 59354.2 4282.1
6.2 60233.1 854.2
9.9 32028.5 5823.5
14.4 31259.8 4905.4
6.3 48891.0 57.2
6 35443.7 2725.4
11.5 56645.0 761.9
14 51785.8 2094.0
4.8 29300.4 1186.6
9 24580.4 5062.5
13 155519.0 142.2
6.2 47481.5 665.3
6.7 34677.6 3283.6
6.2 41129.4 2284.5
7.5 48382.7 507.7
13.4 64003.2 466.7
222.6 13298.0 31.80
985.9 70596.5 79.00
392.2 64928.5 73.80
328.5 32471.5 59.10
2259.3 40626.3 54.00
2406.5 49129.1 67.00
32.9 27650.5 42.00
887.3 33102.4 52.00
605.9 30078.8 44.00
438.5 40172.5 57.35
156.8 30881.5 46.50
152.0 35365.0 42.00
354.4 67217.9 49.75
1535.8 42438.9 65.00
635.8 54436.2 62.90
255.9 59123.0 74.60
572.9 25632.1 34.67
449.5 25904.9 43.00
23.5 48810.3 59.00
304.1 32414.2 41.00
933.8 54949.3 70.00
21.6 49670.3 68.40
18.4 28095.4 39.00
26.5 19491.4 26.00
1939.8 153437.0 173.00
125.1 46691.1 55.70
378.7 31015.2 43.50
400.7 38444.3 48.22
1151.6 46723.4 58.00
2.9 63533.6 68.60
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Appendix 11:  Raw Immunohistochemical data.
Data obtained from regions of prostate cancer.
Number of + cells P53 Ca  P53 Ca  PSA Ca  Number of + cells Bcl2 Ca  BCI2 Ca  Ki67 Ca  Bax Ca
1 0 0 2 0 0 1 1
2 0 0 2 0 0 1 1
3 0 0 3 0 0 1 2
4 0 0 3 0 0 1 0
5 0 0 2 60 1 1 2
6 0 0 3 0 0 1 3
7 100 2 1 40 1 1 1
8 0 0 2 0 0 1 0
9 0 0 3 50 1 1 3
10 0 0 1 0 0 1 2
11 0 0 2 0 0 1 3
12 0 0 2 0 0 1 1
13 0 0 3 0 0 1 2
14 0 0 2 10 1 1 2
15 100 2 3 100 2 1 3
16 0 0 3 0 0 1 3
17 0 0 3 0 0 1 1
18 0 0 3 20 1 1 3
19 0 0 2 10 1 1 2
20 0 0 2 0 0 1 2
21 0 0 2 0 0 1 1
22 100 1 2 0 0 1 1
23 0 0 1 0 0 1 1
24 0 0 2 80 2 1 2
25 0 0 3 0 0 35 1
26 0 0 3 0 0 8 1
27 0 0 3 0 0 5 2
28 0 0 3 0 0 4 2
29 0 0 2 0 0 10 2
30 0 0 2 0 0 3 1
31 0 0 2 0 0 3 2
32 0 0 3 100 1 5 1
33 0 0 2 0 0 1 2
34 0 0 3 0 0 1 2
35 50 1 1 50 1 7 3
36 0 0 1 0 0 0 2
37 80 2 1 0 0 7 2
38 0 0 3 0 0 10 2
39 0 0 2 0 0 3 1
40 0 0 2 0 0 2 2
41 0 0 3 0 0 3 3
42 0 0 2 0 0 5 2
43 0 0 1 0 0 3 2
44 0 0 2 0 0 10 2
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0 0 3 0 0 1 1
0 0 3 50 1 10 2
0 0 3 30 1 3 2
0 0 2 0 0 15 2
0 0 2 0 0 5 2
0 0 3 0 0 5 1
0 0 3 40 1 10 2
0 0 1 0 0 15 2
0 0 3 0 0 1 1
0 0 2 0 0 12 3
0 0 2 0 0 1 1
0 0 2 10 1 30 1
0 0 3 0 0 20 3
0 0 1 100 1 10 2
10 1 2 0 0 5 1
0 0 2 0 0 6 1
0 0 2 0 0 10 2
0 0 1 50 1 4 2
0 0 1 0 0 8 1
50 1 3 50 2 1 1
0 0 1 30 1 20 2
50 2 2 0 0 5 2
0 0 3 0 0 1 1
0 0 1 10 1 5 2
0 0 2 80 1 5 2
0 0 3 0 0 10 2
0 0 3 100 1 5 2
0 0 0 0 0 0 1
100 1 3 50 1 1 3
0 0 0 100 2 3 1
0 0 2 0 0 10 2
0 0 1 0 0 5 2
0 0 2 0 0 10 3
0 0 1 50 1 5 2
0 0 3 0 0 1 1
0 0 2 60 1 5 2
0 0 2 100 1 15 3
0 0 3 0 0 7 2
0 0 2 0 0 3 2
0 0 2 0 0 1 2
0 0 1 0 0 10 1
0 0 3 10 1 10 3
0 0 1 0 0 4 2
0 0 2 0 0 10 2
0 0 2 0 0 15 1
0 0 3 0 0 1 1
0 0 2 0 0 20 2
0 0 2 0 0 10 1
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Data obtained from regions of PIN.
Number of + cells P53  PIN  P53 PIN  PSA  PIN  Number of + cells  Bcl2  PIN  BCI2  PIN  Ki67  PIN  Bax PIN
1 0 0 3 60 2 1 1
2 0 0 2 0 0 1 0
3 0 0 3 80 1 1 1
4 0 0 3 0 0 1 2
5 0 0 3 0 0 1 2
6 0 0 3 60 2 1 2
7 0 0 3 20 1 1 1
8 0 0 3 100 2 1 1
9 0 0 2 80 2 1 1
10 0 0 3 100 2 1 1
11 0 0 3 50 2 1 1
12 0 0 3 30 2 1 2
13 0 0 3 25 2 1 1
14 0 0 3 40 1 1 2
15 0 0 3 100 2 1 1
16 0 0 3 100 2 1 1
17 100 3 3 10 2 1 1
18 0 0 3 80 2 1 2
19 0 0 3 60 2 1 3
20 0 0 3 5 1 1 2
21 0 0 3 25 2 1 2
22 0 0 2 0 0 1 2
23 0 0 3 0 0 0 2
24 0 0 2 60 1 5 2
25 0 0 2 100 1 1 2
26 25 2 3 80 2 5 1
27 0 0 2 60 2 2 3
28 0 0 3 0 0 5 2
29 0 0 2 20 1 5 2
30 0 0 2 100 1 3 2
31 0 0 2 0 3 5 2
32 0 0 3 10 2 5 2
33 0 0 3 10 2 1 2
34 0 0 3 60 1 2 1
35 50 2 3 100 1 5 3
36 0 0 2 100 5 4 2
37 50 1 2 0 0 7 2
38 0 0 3 30 1 5 2
39 0 0 2 70 3 5 1
40 0 0 3 60 2 4 2
41 0 0 3 50 2 3 3
42s 0 0 1 80 2 1 1
43 0 0 1 0 0 3 2
44 90 1 3 50 1 3 2
45 0 0 3 100 2 2 2
46 0 0 3 30 2 3 2
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0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
3 80
2 0
2 70
3 70
3 0
2 30
3 10
2 30
3 100
2 5
3 30
2 80
2 0
0 0
3 50
3 50
2 40
0 0
1 10
3 100
3 0
2 10
3 100
3 0
3 70
3 10
2 100
0 0
3 0
2 80
3 30
3 30
1 100
3 50
2 100
3 0
3 60
3 10
2 50
3 60
3 100
2 100
2 40
2 80
2 30
3 100
2  20  2
0  15  2
2  2  2
2  1  2
0  5  2
2  3  2
1  1  1
2  5  3
2  1  1
1  40  1
1  3  3
2  5  2
0  5  0
0  0  0
1  15  2
2  1   2
2  5  1
0  0  0
2  15  2
2  10  2
0  1  1
2  2  2
1  8  2
0  10  2
1   5  0
1   5  2
2  1   0
0  0  1
0  10  2
1  1  2
1   25  3
1  3  2
3  1   1
2  5  2
1   15  3
0  5  2
2  3  2
1  1   2
1  2  0
2  3  3
1  2  2
2  5  2
1  5  1
1  1   1
1  20  2
1   10  1
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Data obtained from specimens with 3 months of androgen ablation.
Number of + cells  P53 LHRH  Number of + cells  BCI2 LHRH  Ki67 LHRH  Bax LHRH
1 0 0 100 3 1  1
2 0 0 70 1 1  1
3 0 0 0 0 1   1
4 0 0 50 1 1   1
5 0 0 100 2 1   2
6 0 0 100 2 1  2
7 0 0 0 0 25  1
8 0 0 60 1 1  2
9 50 3 0 0 1   2
10 80 1 100 2 1   1
11 0 0 0 0 2  2
12 100 1 0 0 1   1
13 0 0 100 1 1  2
14 80 1 100 1 1   1
Data obtained from benign (control specimens)
P53  Benign PSA  Benign Number of + cells BCI2  Benign Ki67 Bax
1 0 3 0 0 0 1
2 0 3 0 0 0 2
3 0 3 0 0 0 1
4 0 3 0 0 0 2
5 0 3 0 0 0 1
6 0 3 0 0 0 2
7 0 3 0 0 0 0
8 0 3 0 0 0 2
9 0 3 0 0 0 2
10 0 3 0 0 0 1
11 0 3 0 0 0 2
12 0 3 0 0 0 1
13 0 3 0 0 0 1
14 0 3 0 0 0 2
15 0 3 0 0 0 1
16 0 3 0 0 0 2
17 0 3 0 0 0 1
18 0 3 0 0 0 1
19 0 3 0 0 0 1
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